
<html lang="en"     class="pb-page"  data-request-id="875bac53-69b8-4a1b-91b6-95a6f976e87e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.7b01529;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2018.61.issue-9;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of N2-(4-Amino-cyclohexyl)-9-cyclopentyl-N6-(4-morpholin-4-ylmethyl-phenyl)-9H-purine-2,6-diamine as a Potent FLT3 Kinase Inhibitor for Acute Myeloid Leukemia with FLT3 Mutations" /></meta><meta name="dc.Creator" content="Tomáš  Gucký" /></meta><meta name="dc.Creator" content="Eva  Řezníčková" /></meta><meta name="dc.Creator" content="Tereza  Radošová Muchová" /></meta><meta name="dc.Creator" content="Radek  Jorda" /></meta><meta name="dc.Creator" content="Zuzana  Klejová" /></meta><meta name="dc.Creator" content="Veronika  Malínková" /></meta><meta name="dc.Creator" content="Karel  Berka" /></meta><meta name="dc.Creator" content="Václav  Bazgier" /></meta><meta name="dc.Creator" content="Haresh  Ajani" /></meta><meta name="dc.Creator" content="Martin  Lepšík" /></meta><meta name="dc.Creator" content="Vladimír  Divoký" /></meta><meta name="dc.Creator" content="Vladimír  Kryštof" /></meta><meta name="dc.Description" content="FLT3 tyrosine kinase is a potential drug target in acute myeloid leukemia (AML) because patients with FLT3-ITD mutations respond poorly to standard cytotoxic agents and there is a clear link betwee..." /></meta><meta name="Description" content="FLT3 tyrosine kinase is a potential drug target in acute myeloid leukemia (AML) because patients with FLT3-ITD mutations respond poorly to standard cytotoxic agents and there is a clear link betwee..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 19, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01529" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01529" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01529" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01529" /></link>
        
    
    

<title>Discovery of N2-(4-Amino-cyclohexyl)-9-cyclopentyl-N6-(4-morpholin-4-ylmethyl-phenyl)-9H-purine-2,6-diamine as a Potent FLT3 Kinase Inhibitor for Acute Myeloid Leukemia with FLT3 Mutations | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01529" /></meta><meta property="og:title" content="Discovery of N2-(4-Amino-cyclohexyl)-9-cyclopentyl-N6-(4-morpholin-4-ylmethyl-phenyl)-9H-purine-2,6-diamine as a Potent FLT3 Kinase Inhibitor for Acute Myeloid Leukemia with FLT3 Mutations" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0010.jpeg" /></meta><meta property="og:description" content="FLT3 tyrosine kinase is a potential drug target in acute myeloid leukemia (AML) because patients with FLT3-ITD mutations respond poorly to standard cytotoxic agents and there is a clear link between the disease and the oncogenic properties of FLT3. We present novel 2,6,9-trisubstituted purine derivatives with potent FLT3 inhibitory activity. The lead compound 7d displays nanomolar activity in biochemical assays and selectively blocks proliferation of AML cell lines harboring FLT3-ITD mutations, whereas other transformed and normal human cells are several orders of magnitude less sensitive. The MV4-11 cells treated with 7d suppressed the phosphorylation of FLT3 and its downstream signaling pathways, with subsequent G1 cell cycle arrest and apoptosis. Additionally, a single dose of 7d in mice with subcutaneous MV4-11 xenografts caused sustained inhibition of FLT3 and STAT5 phosphorylation over 48 h, in contrast to the shorter effect observed after administration of the reference FLT3 inhibitor quizartinib." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="FLT3 tyrosine kinase is a potential drug target in acute myeloid leukemia (AML) because patients with FLT3-ITD mutations respond poorly to standard cytotoxic agents and there is a clear link between the disease and the oncogenic properties of FLT3. We present novel 2,6,9-trisubstituted purine derivatives with potent FLT3 inhibitory activity. The lead compound 7d displays nanomolar activity in biochemical assays and selectively blocks proliferation of AML cell lines harboring FLT3-ITD mutations, whereas other transformed and normal human cells are several orders of magnitude less sensitive. The MV4-11 cells treated with 7d suppressed the phosphorylation of FLT3 and its downstream signaling pathways, with subsequent G1 cell cycle arrest and apoptosis. Additionally, a single dose of 7d in mice with subcutaneous MV4-11 xenografts caused sustained inhibition of FLT3 and STAT5 phosphorylation over 48 h, in contrast to the shorter effect observed after administration of the reference FLT3 inhibitor quizartinib." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0010.jpeg" /></meta><meta name="twitter:title" content="Discovery of N2-(4-Amino-cyclohexyl)-9-cyclopentyl-N6-(4-morpholin-4-ylmethyl-phenyl)-9H-purine-2,6-diamine as a Potent FLT3 Kinase Inhibitor for Acute Myeloid Leukemia with FLT3 Mutations" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01529"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01529">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01529&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01529&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01529&amp;href=/doi/10.1021/acs.jmedchem.7b01529" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 9</span><span class="cit-fg-pageRange">, 3855-3869</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/9" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00218" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b01670" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of <i>N</i><sup>2</sup>-(4-Amino-cyclohexyl)-9-cyclopentyl-<i>N</i><sup>6</sup>-(4-morpholin-4-ylmethyl-phenyl)-<i>9H</i>-purine-2,6-diamine as a Potent FLT3 Kinase Inhibitor for Acute Myeloid Leukemia with FLT3 Mutations</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Tomáš Gucký</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tomáš Gucký</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical Biology and Genetics, Centre of the Region Haná for Biotechnological and Agricultural Research, Faculty of Science, Palacký University, Šlechtitelů 27, 783 71 Olomouc, Czech Republic</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tom%C3%A1%C5%A1++Guck%C3%BD">Tomáš Gucký</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eva Řezníčková</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eva Řezníčková</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Palacký University and Institute of Experimental Botany AS CR, Šlechtitelů 27, 783 71 Olomouc, Czech Republic</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eva++%C5%98ezn%C3%AD%C4%8Dkov%C3%A1">Eva Řezníčková</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tereza Radošová Muchová</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tereza Radošová Muchová</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biology, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 3, 775 15 Olomouc, Czech Republic</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tereza++Rado%C5%A1ov%C3%A1+Muchov%C3%A1">Tereza Radošová Muchová</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Radek Jorda</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Radek Jorda</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Palacký University and Institute of Experimental Botany AS CR, Šlechtitelů 27, 783 71 Olomouc, Czech Republic</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Radek++Jorda">Radek Jorda</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zuzana Klejová</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zuzana Klejová</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biology, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 3, 775 15 Olomouc, Czech Republic</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zuzana++Klejov%C3%A1">Zuzana Klejová</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Veronika Malínková</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Veronika Malínková</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical Biology and Genetics, Centre of the Region Haná for Biotechnological and Agricultural Research, Faculty of Science, Palacký University, Šlechtitelů 27, 783 71 Olomouc, Czech Republic</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Veronika++Mal%C3%ADnkov%C3%A1">Veronika Malínková</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Karel Berka</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Karel Berka</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Physical Chemistry, Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacky University, 17. listopadu 12, 771 46 Olomouc, Czech Republic</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Karel++Berka">Karel Berka</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9472-2589" title="Orcid link">http://orcid.org/0000-0001-9472-2589</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Václav Bazgier</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Václav Bazgier</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Physical Chemistry, Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacky University, 17. listopadu 12, 771 46 Olomouc, Czech Republic</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=V%C3%A1clav++Bazgier">Václav Bazgier</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Haresh Ajani</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haresh Ajani</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Physical Chemistry, Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacky University, 17. listopadu 12, 771 46 Olomouc, Czech Republic</div><div class="loa-info-affiliations-info">Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 166 10 Prague 6, Czech Republic</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haresh++Ajani">Haresh Ajani</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1223-3819" title="Orcid link">http://orcid.org/0000-0002-1223-3819</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Martin Lepšík</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Martin Lepšík</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 166 10 Prague 6, Czech Republic</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Martin++Lep%C5%A1%C3%ADk">Martin Lepšík</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vladimír Divoký</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vladimír Divoký</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biology, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 3, 775 15 Olomouc, Czech Republic</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vladim%C3%ADr++Divok%C3%BD">Vladimír Divoký</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Vladimír Kryštof</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vladimír Kryštof</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Palacký University and Institute of Experimental Botany AS CR, Šlechtitelů 27, 783 71 Olomouc, Czech Republic</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +420585634854. Fax: +420585634870. E-mail: <a href="/cdn-cgi/l/email-protection#c8bea4a9aca1a5a1bae6a3bab1bbbca7ae88bdb8a7a4e6abb2"><span class="__cf_email__" data-cfemail="11677d7075787c78633f7a636862657e775164617e7d3f726b">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vladim%C3%ADr++Kry%C5%A1tof">Vladimír Kryštof</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5838-2118" title="Orcid link">http://orcid.org/0000-0001-5838-2118</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01529&amp;href=/doi/10.1021%2Facs.jmedchem.7b01529" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 9</span><span class="cit-pageRange">, 3855–3869</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 19, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>13 October 2017</li><li><span class="item_label"><b>Published</b> online</span>19 April 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 May 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01529" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01529</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3855%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DTom%25C3%25A1%25C5%25A1%2BGuck%25C3%25BD%252C%2BEva%2B%25C5%2598ezn%25C3%25AD%25C4%258Dkov%25C3%25A1%252C%2BTereza%2BRado%25C5%25A1ov%25C3%25A1%2BMuchov%25C3%25A1%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D9%26contentID%3Dacs.jmedchem.7b01529%26title%3DDiscovery%2Bof%2BN2-%25284-Amino-cyclohexyl%2529-9-cyclopentyl-N6-%25284-morpholin-4-ylmethyl-phenyl%2529-9H-purine-2%252C6-diamine%2Bas%2Ba%2BPotent%2BFLT3%2BKinase%2BInhibitor%2Bfor%2BAcute%2BMyeloid%2BLeukemia%2Bwith%2BFLT3%2BMutations%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3869%26publicationDate%3DMay%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01529"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2187</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">15</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01529" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of N2-(4-Amino-cyclohexyl)-9-cyclopentyl-N6-(4-morpholin-4-ylmethyl-phenyl)-9H-purine-2,6-diamine as a Potent FLT3 Kinase Inhibitor for Acute Myeloid Leukemia with FLT3 Mutations&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Tomáš&quot;,&quot;last_name&quot;:&quot;Gucký&quot;},{&quot;first_name&quot;:&quot;Eva&quot;,&quot;last_name&quot;:&quot;Řezníčková&quot;},{&quot;first_name&quot;:&quot;Tereza&quot;,&quot;last_name&quot;:&quot;Radošová Muchová&quot;},{&quot;first_name&quot;:&quot;Radek&quot;,&quot;last_name&quot;:&quot;Jorda&quot;},{&quot;first_name&quot;:&quot;Zuzana&quot;,&quot;last_name&quot;:&quot;Klejová&quot;},{&quot;first_name&quot;:&quot;Veronika&quot;,&quot;last_name&quot;:&quot;Malínková&quot;},{&quot;first_name&quot;:&quot;Karel&quot;,&quot;last_name&quot;:&quot;Berka&quot;},{&quot;first_name&quot;:&quot;Václav&quot;,&quot;last_name&quot;:&quot;Bazgier&quot;},{&quot;first_name&quot;:&quot;Haresh&quot;,&quot;last_name&quot;:&quot;Ajani&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;Lepšík&quot;},{&quot;first_name&quot;:&quot;Vladimír&quot;,&quot;last_name&quot;:&quot;Divoký&quot;},{&quot;first_name&quot;:&quot;Vladimír&quot;,&quot;last_name&quot;:&quot;Kryštof&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;19&quot;,&quot;issue&quot;:&quot;9&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;3855-3869&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01529&quot;},&quot;abstract&quot;:&quot;FLT3 tyrosine kinase is a potential drug target in acute myeloid leukemia (AML) because patients with FLT3-ITD mutations respond poorly to standard cytotoxic agents and there is a clear link between the disease and the oncogenic properties of FLT3. We present novel 2,6,9-trisubstituted purine derivatives with potent FLT3 inhibitory activity. The lead compound 7d displays nanomolar activity in biochemical assays and selectively blocks proliferation of AML cell lines harboring FLT3-ITD mutations, whereas other transformed and normal human cells are several orders of magnitude less sensitive. The MV4-11 cells treated with 7d suppressed the phosphorylation of FLT3 and its downstream signaling pathways, with subsequent G1 cell cycle arrest and apoptosis. Additionally, a single dose of 7d in mice with subcutaneous MV4-11 xenografts caused sustained inhibition of FLT3 and STAT5 phosphorylation over 48 h, in contrast to the shorter effect observed after administration of the reference FLT3 inhibitor quizartinib.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01529&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01529" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01529&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01529" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01529&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01529" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01529&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01529&amp;href=/doi/10.1021/acs.jmedchem.7b01529" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01529" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01529" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01529%26sid%3Dliteratum%253Aachs%26pmid%3D29672049%26genre%3Darticle%26aulast%3DGuck%25C3%25BD%26date%3D2018%26atitle%3DDiscovery%2Bof%2BN2-%25284-Amino-cyclohexyl%2529-9-cyclopentyl-N6-%25284-morpholin-4-ylmethyl-phenyl%2529-9H-purine-2%252C6-diamine%2Bas%2Ba%2BPotent%2BFLT3%2BKinase%2BInhibitor%2Bfor%2BAcute%2BMyeloid%2BLeukemia%2Bwith%2BFLT3%2BMutations%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D9%26spage%3D3855%26epage%3D3869%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=290969" title="Cell and molecular biology">Cell and molecular biology</a>,</li><li><a href="/action/doSearch?ConceptID=290682" title="Post-translational modification">Post-translational modification</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/9" title="Go to Volume 61, Issue 9"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/jmcmar.2018.61.issue-9/20180510/jmcmar.2018.61.issue-9.largecover.jpg" alt="Go to Volume 61, Issue 9"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/medium/jm-2017-015295_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01529&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">FLT3 tyrosine kinase is a potential drug target in acute myeloid leukemia (AML) because patients with FLT3-ITD mutations respond poorly to standard cytotoxic agents and there is a clear link between the disease and the oncogenic properties of FLT3. We present novel 2,6,9-trisubstituted purine derivatives with potent FLT3 inhibitory activity. The lead compound <b>7d</b> displays nanomolar activity in biochemical assays and selectively blocks proliferation of AML cell lines harboring FLT3-ITD mutations, whereas other transformed and normal human cells are several orders of magnitude less sensitive. The MV4-11 cells treated with <b>7d</b> suppressed the phosphorylation of FLT3 and its downstream signaling pathways, with subsequent G1 cell cycle arrest and apoptosis. Additionally, a single dose of <b>7d</b> in mice with subcutaneous MV4-11 xenografts caused sustained inhibition of FLT3 and STAT5 phosphorylation over 48 h, in contrast to the shorter effect observed after administration of the reference FLT3 inhibitor quizartinib.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08623" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08623" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Acute myeloid leukemia (AML) is a cancer for which current therapies are inadequate. Recent advances in molecular cancer biology have enhanced our understanding of AML biology and led to the discovery of many cancer-related genes, including potential targets for treatment.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The most common mutations in AML occur in the <i>FLT3</i> gene; the mutations are observed in approximately 30% of AML patients and are tightly linked to poor prognosis.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The <i>FLT3</i> gene encodes the membrane-bound receptor tyrosine kinase FLT3, which is closely related to KIT, FMS, and PDGFR.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Upon binding to an extracellular ligand, FLT3 dimerizes, gets autophosphorylated, and activates downstream signaling pathways including RAS/MAPK, JAK/STAT5, and PI3K/AKT. These pathways collectively promote growth, proliferation, survival, and differentiation of myeloid cells.</div><div class="NLM_p">The most common group of <i>FLT3</i> mutations (found in 23% of all AML patients) are internal tandem duplications (ITD) of variable length and position that promote ligand-independent dimerization.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The length of ITD mutations influences prognosis: Patients with longer ITDs have worse outcomes and lower overall survival.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Point mutations within the activation loop of FLT3 are also somewhat common, occurring in approximately 7% of all AML cases. These mutations stabilize the kinase in its active conformation and promote constitutive activation.</div><div class="NLM_p">FLT3 is regarded as a potential drug target because patients with FLT3-ITD mutations respond poorly to standard cytotoxic agents and there is a clear link between AML and the oncogenic properties of FLT3.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Consequently, many groups have attempted to develop specific FLT3 inhibitors for AML therapy, and a variety of drugs have entered clinical trials.<a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6−8)</a> Early trials used general receptor tyrosine kinase inhibitors such as sunitinib, sorafenib, or lestaurtinib that exhibit activity against FLT3 but were originally developed for other indications.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> These compounds were quite potent in preclinical experiments, but generally failed in phase I/II clinical trials with AML patients.</div><div class="NLM_p">The toxicity problems and limited efficacy of these drugs are probably due to their broad specificity toward receptor tyrosine kinases.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> Therefore, new and more specific FLT3 inhibitors have been developed. These so-called second-generation compounds include quizartinib, crenolanib, pexidartinib (PLX3397), tandutinib (MLN518), and gilteritinib (ASP2215). These compounds demonstrated significant numbers of complete and partial responses in AML patients<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> and are often also active in quizartinib-resistant AML cells with secondary FLT3 point mutations.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a></div><div class="NLM_p">Some of the developed compounds are multitargeted anti-FLT3 drugs effective against both AML and other indications. For example, the doubly selective JAK2/FLT3 inhibitor pacritinib was successful in phase 2 clinical trials against myelofibrosis and lymphoma.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Similarly, the clinically tested compound gilteritinib targets FLT3 and AXL,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> while TG02 (SB1317) inhibits FLT3, JAK2, and all cyclin-dependent kinases (CDKs).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The effectiveness of simultaneously targeting FLT3 and CDKs is further demonstrated by the example of AMG 925 (FLX925), which selectively targets FLT3 and CDK4.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> Despite these promising results, acquired resistance to specific FLT3 inhibitors continues to present a major challenge in drug development.</div><div class="NLM_p last">We have previously prepared nanomolar CDK inhibitors with a 6-benzylaminopurine scaffold,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> but we found that modified analogs (in which the 6-benzylaminopurine core was replaced with a 6-anilinopurine) exhibited substantially reduced cytotoxic activity in most cancer cell lines other than MV4-11 bearing FLT3-ITD mutation. Cells from this line rapidly stopped proliferating and entered G1 phase arrest upon treatment with nanomolar concentrations, whereas the other tested cell lines did not respond to submicromolar concentrations. Here we report the preparation of a new set of compounds in this series and demonstrate that their target in the MV4-11 cell line is FLT3.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01880" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01880" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">The synthesis started from commercially available 2,6-dichloropurine, which was initially alkylated with isopropanol, cyclopentanol, or benzyl alcohol via the Mitsunobu reaction to obtain 9-substituted-2,6-dichloro-9<i>H</i>-purines <b>1a</b>,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a><b>1b</b>,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and <b>1c</b><a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> with good regioselectivity. 2,6-Dichloro-9-(2-tetrahydropyranyl)-9H-purine (<b>1d</b>) was prepared using the previously described reaction of 2,6-dichloro-9<i>H</i>-purine with 3,4-dihydro-2H-pyran.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p">Most of the used 4-substituted-phenylamines were commercially available, but 6-morpholin-4-ylpyridin-3-amine (<b>4a</b>) and 4-(2-oxa-6-azaspiro[3.3]hept-6-yl)aniline (<b>4b</b>) were prepared by the reaction of 4-bromonitrobenzene (<b>2a</b>) or 2-bromo-5-nitropyridine (<b>2b</b>) with the corresponding cyclic secondary amine to yield nitro derivatives (<b>3a</b>, <b>3b</b>) that were reduced with hydrogen on palladium at atmospheric pressure (see <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/medium/jm-2017-015295_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0005.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01529&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reaction conditions: (a) Appropriate secondary amine, K<sub>2</sub>CO<sub>3</sub>, ethanol, reflux; (b) H<sub>2</sub>/Pd–C 5%, rt, atmospheric pressure.</p></p></figure><div class="NLM_p">The nucleophilic substitution at position 6 of the purine moiety with appropriate 4-substituted-aniline or 2-substituted-5-aminopyridine derivatives was performed in the presence of Hünig’s base to obtain compounds (<b>5a</b>–<b>5m</b>). The substitution of the chlorine at position 2 with a primary or secondary amine was performed with a large excess of the appropriate amine in 1,2-ethandiol at 160 °C. These reactions proceeded smoothly, providing the desired compounds with good yields and high purities (see <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). We used <i>trans</i>-1,4-diaminocyclohexane for the synthesis of compounds <b>6a</b>, <b>6c</b>, <b>6d</b>, <b>6h</b>, <b>6l</b>, <b>7a</b>–<b>7f</b>, and <b>8l</b>. The 2-aminopropan-1-ol used for the synthesis of compounds <b>6b</b>, <b>6e</b>, <b>6f</b>, <b>6i</b>, and <b>6m</b> was racemic, and for the synthesis of compound <b>8l</b>, 2-aminobutan-1-ol of R-configuration was used. The collection of newly synthesized compounds (<b>6a</b>–<b>6o</b>, <b>7a</b>–<b>7f</b>, and <b>8a</b>–<b>8o</b>) is presented in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>.</div><figure id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/medium/jm-2017-015295_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0006.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01529&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reaction conditions: (a) Appropriate 4-substituted aniline or 6-substituted-pyridine-3-amine, DIPEA, <i>n</i>-propanol, 120 °C, 4–20 h, sealed tube; (b) appropriate primary or secondary amine, 1,2-ethandiol, 160 °C, 4–20 h, sealed tube.</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. 2-Substituted-amino-6-(4-halogenophenyl)amino-9-substituted-9<i>H</i>-purines <b>6a</b>–<b>6o</b> and Their Biochemical (Recombinant FLT3-ITD) and Cellular Activities</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/medium/jm-2017-015295_0007.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">For SD values see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01529/suppl_file/jm7b01529_si_003.pdf" class="ext-link">Table S1</a>.</p></div></div><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> In Vitro Structure–Activity Relationships</h3><div class="NLM_p">The newly prepared 6-(4-substituted-anilino)purine (<b>6a</b>–<b>6o</b>, <b>7a</b>–<b>7f</b>, and <b>8a</b>–<b>8o</b>) and 6-(5-substituted-3-aminopyridine)purine (<b>8l</b>, <b>8m</b>) compounds were tested to determine their ability to inhibit the recombinant FLT3-ITD kinase and to evaluate their antiproliferative activity in the myeloid leukemia MV4-11 (acute; FLT3-ITD-positive) and K562 (chronic; FLT3-negative) cell lines. <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> summarize the results obtained.</div><div class="NLM_p">We began our investigation into the compounds’ structure–activity relationships using molecules <b>6c</b> and <b>6d</b>, which exhibited high selectivity toward FLT3-ITD-positive cells and only weak activity in K562 cancer cell line. Both these compounds have 4-aminocyclohexylamino and 4-halogenophenylamine groups at positions 2 and 6, respectively, with a cyclopentyl group at position 9. To study the impact of substituting position 9 of the purine ring, we compared these initial compounds to a series of analogs with the same substituents at positions 2 and 6 but isopropyl, tetrahydropyran-2-yl, or benzyl groups at position 9. The lowest GI<sub>50</sub> values in MV4-11 cells were obtained with compounds bearing isopropyl (<b>6a</b>) and cyclopentyl (<b>6c</b>, <b>6d</b>) substituents (7, 10, and 21 nM, respectively); these compounds were also very potent inhibitors of FLT3-ITD. Introducing the tetrahydropyran-2-yl group (<b>6l</b>) reduced both the cellular and kinase-inhibitory activities of the compounds, but the lowest activities were observed for compound <b>6h</b>, which has a benzyl group in position 9. To verify the positive impact of substituent 9, we also modified position 2 by replacing the 4-aminocyclohexylamino group with various branched alkylamines (<b>6e</b>–<b>g</b>) or bulky morpholino (<b>6j</b>) or 4-methyl-piperazin-1-yl (<b>6k</b>) moieties. All the analogs substituted in this way had weaker antiproliferative and FLT3-inhibitory activities than the 4-aminocyclohexylamine-substituted compounds and substantially higher IC<sub>50</sub> and GI<sub>50</sub> values (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_p">We next explored the effect of extended substituents at position 6. All the compounds tested in these experiments had a cyclopentyl group at position 9 and an aminocyclohexylamino group at position 2 (<b>7a</b>–<b>7f</b>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The halogen in the phenylamine substituent of the lead molecule was replaced with pyrrolidin-1-yl (<b>7a</b>), morpholin-4-yl (<b>7b</b>), 4-ethyl-piperazin-1-yl (<b>7c</b>), morpholin-4-ylmethyl (<b>7d</b>), 2-oxa-6-aza-spiro[3.3]hept-6-yl (<b>7e</b>), or <i>N</i>-4-benzyl-piperazin-1-yl (<b>7f</b>) moieties. These compounds were among the most active in the entire series: Their GI<sub>50</sub> values in FLT3-ITD-positive MV4-11 cells were in the single-digit nanomolar range and approximately 100 times lower than the corresponding values for K562 cells. They also strongly inhibited the enzymatic activity of FLT3-ITD at low nanomolar concentrations. These results indicate that position 6 can host various substitutions without significant loss of in vitro activity (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. 2-(4-Aminocyclohexylamino)-6-(4-substituted-phenyl)amino-9-cyclopentyl-9<i>H</i>-purines <b>7a</b>–<b>7f</b> and Their Biochemical (Recombinant FLT3-ITD) and Cellular Activities</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/medium/jm-2017-015295_0008.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">For SD values see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01529/suppl_file/jm7b01529_si_003.pdf" class="ext-link">Table S1</a>.</p></div></div><div></div></div><div class="NLM_p">Since the most active compounds of the series (<b>7b</b>–<b>7d</b>) have a cyclopentyl group in position 9 and extended 6-(4-substituted-phenylamino) groups, we investigated analogs of these compounds with modifications at position 2 to determine whether the 4-aminocyclohexylamine moiety is the optimal substituent with respect to in vitro activity. We investigated linear aminoalkylamines (<b>8a</b>–<b>8c</b>, <b>8n</b>, <b>8o</b>), hydroxyalkylamines (<b>8i</b>–<b>8k</b>), bulky saturated heterocyclic moieties (<b>8f</b>–<b>8h</b>, <b>8m</b>) or aromatic substituents (<b>8d</b>, <b>8e</b>). Compounds with an 4-aminobutylamine group in position 2 (<b>8a</b>, <b>8n</b>, <b>8o</b>) showed comparable potency against FLT3-ITD to starting molecules <b>7d</b>, <b>7b</b>, <b>7c</b> and inhibited MV4-11 proliferation at low nanomolar concentrations, with GI<sub>50</sub> values of about 11 nM. Longer aminoalkyl side chains yielded weaker antiproliferative and kinase-inhibitory activities: The FLT3-ITD IC<sub>50</sub> values for the butyl- (<b>8a</b>), pentyl- (<b>8b</b>), and hexyl- (<b>8c</b>) substituted compounds were 1, 5, and 10 nM, respectively, and the corresponding MV4-11 GI<sub>50</sub> values were 11, 35, and 86 nM, respectively. Compounds with hydroxyalkylamines in position 2 (<b>8i</b>–<b>8k</b>) exhibited weaker biological activity: The most potent of these derivatives (<b>8k</b>) was 6 times less potent than <b>7d</b> with respect to FLT3-ITD inhibition and had a 40-fold higher GI<sub>50</sub> value in MV4-11 cells. Shortening of the hydroxyalkyl chain of <b>8k</b> (hydroxyethylamine <b>8i</b> and hydroxypropylamine <b>8j</b>) further reduced their in vitro activity. Similarly low activities were achieved with compounds bearing bulky morpholine (<b>8f</b>) or methylpiperazine (<b>8g</b>) substituents in position 2. The least active compounds in the group were those bearing piperidine (<b>8h</b>), benzylamine (<b>8d</b>), or 4-methoxybenzylamine (<b>8e</b>) moieties (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. 9-Cyclopentyl-2-substituted-amino-6-arylamino-9<i>H</i>-purines <b>7d</b>, <b>8a</b>–<b>8o</b> and Their Biochemical (Recombinant FLT3-ITD) and Cellular Activities</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/medium/jm-2017-015295_0009.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">For SD values see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01529/suppl_file/jm7b01529_si_003.pdf" class="ext-link">Table S1</a>.</p></div></div><div></div></div><div class="NLM_p">Our synthetic approach allowed us to further modify the first aromatic ring in position 6; we replaced the phenylamine with pyridinamine and extended it with morpholine (<b>8l</b>, <b>8m</b>). This modification did not improve the molecules’ biological activity, for example, compound <b>8l</b> displayed similar activity to its phenylamine counterpart <b>7b</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>).</div><div class="NLM_p">To investigate the cellular selectivity of the new compounds, the antiproliferative activities of the most potent derivatives were tested in cancer cell lines with different histological origins (MOLM-13, Kasumi-1, THP-1, U937, MCF-7, HCC-827) and in noncancerous cells (MRC-5, HUVEC, BJ; <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). The compounds exhibited nanomolar activity in the MOLM-13 line (which is FLT3-ITD-positive, like MV4-11), but their GI<sub>50</sub> values in other cancer cell lines were in the micromolar range, confirming their high selectivity toward FLT3-ITD-positive cells. Notably, Kasumi-1 and HCC-827 cells bearing an activating mutation in c-KIT (Asn822Lys) and an activating deletion in EGFR, respectively, displayed submicromolar sensitivity to compounds <b>7a</b>–<b>7e</b>, and compounds from series <b>8</b> (<b>8a</b>–<b>8d</b>, <b>8o</b>, <b>8n</b>) seemed to be even more selective for FLT3-ITD-positive cell lines. Importantly, nontransformed human MRC-5 and HUVEC cells, as well as nonproliferating BJ cells, were not affected by these compounds even when treated with concentrations 1000-fold higher than those toxic against the FLT3-ITD-positive MV4-11 and MOLM-13 cell lines.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Biochemical (Recombinant Enzymes) and Cellular Activities of the Most Potent Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="9" align="center" char=".">GI<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char=".">FLT3 WT</th><th class="colsep0 rowsep0" align="center" char=".">FLT3 D835Y</th><th class="colsep0 rowsep0" align="center" char=".">MOLM-13</th><th class="colsep0 rowsep0" align="center" char=".">Kasumi-1</th><th class="colsep0 rowsep0" align="center" char=".">THP-1</th><th class="colsep0 rowsep0" align="center" char=".">U937</th><th class="colsep0 rowsep0" align="center" char=".">MCF-7</th><th class="colsep0 rowsep0" align="center" char=".">HCC-827</th><th class="colsep0 rowsep0" align="center" char=".">MRC-5</th><th class="colsep0 rowsep0" align="center" char=".">HUVEC</th><th class="colsep0 rowsep0" align="center" char=".">BJ</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>6c</b></td><td class="colsep0 rowsep0" align="char" char=".">0.016</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="char" char=".">0.015</td><td class="colsep0 rowsep0" align="char" char=".">0.481</td><td class="colsep0 rowsep0" align="char" char=".">2.280</td><td class="colsep0 rowsep0" align="char" char=".">1.797</td><td class="colsep0 rowsep0" align="char" char=".">0.520</td><td class="colsep0 rowsep0" align="char" char=".">1.275</td><td class="colsep0 rowsep0" align="char" char=".">20.628</td><td class="colsep0 rowsep0" align="char" char=".">10.062</td><td class="colsep0 rowsep0" align="char" char=".">14.688</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>7a</b></td><td class="colsep0 rowsep0" align="char" char=".">0.021</td><td class="colsep0 rowsep0" align="char" char=".">0.011</td><td class="colsep0 rowsep0" align="char" char=".">0.024</td><td class="colsep0 rowsep0" align="char" char=".">0.569</td><td class="colsep0 rowsep0" align="char" char=".">3.114</td><td class="colsep0 rowsep0" align="char" char=".">3.171</td><td class="colsep0 rowsep0" align="char" char=".">0.487</td><td class="colsep0 rowsep0" align="char" char=".">1.068</td><td class="colsep0 rowsep0" align="char" char=".">14.046</td><td class="colsep0 rowsep0" align="char" char=".">12.077</td><td class="colsep0 rowsep0" align="char" char=".">15.894</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>7b</b></td><td class="colsep0 rowsep0" align="char" char=".">0.021</td><td class="colsep0 rowsep0" align="char" char=".">0.007</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="char" char=".">0.816</td><td class="colsep0 rowsep0" align="char" char=".">1.159</td><td class="colsep0 rowsep0" align="char" char=".">1.572</td><td class="colsep0 rowsep0" align="char" char=".">0.320</td><td class="colsep0 rowsep0" align="char" char=".">0.521</td><td class="colsep0 rowsep0" align="char" char=".">23.265</td><td class="colsep0 rowsep0" align="char" char=".">4.531</td><td class="colsep0 rowsep0" align="char" char=".">12.249</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>7c</b></td><td class="colsep0 rowsep0" align="char" char=".">0.010</td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="char" char=".">0.839</td><td class="colsep0 rowsep0" align="char" char=".">0.514</td><td class="colsep0 rowsep0" align="char" char=".">0.605</td><td class="colsep0 rowsep0" align="char" char=".">1.050</td><td class="colsep0 rowsep0" align="char" char=".">0.592</td><td class="colsep0 rowsep0" align="char" char=".">21.964</td><td class="colsep0 rowsep0" align="char" char=".">4.439</td><td class="colsep0 rowsep0" align="char" char=".">12.932</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>7d</b></td><td class="colsep0 rowsep0" align="char" char=".">0.013</td><td class="colsep0 rowsep0" align="char" char=".">0.008</td><td class="colsep0 rowsep0" align="char" char=".">0.001</td><td class="colsep0 rowsep0" align="char" char=".">0.513</td><td class="colsep0 rowsep0" align="char" char=".">0.713</td><td class="colsep0 rowsep0" align="char" char=".">0.664</td><td class="colsep0 rowsep0" align="char" char=".">0.197</td><td class="colsep0 rowsep0" align="char" char=".">0.327</td><td class="colsep0 rowsep0" align="char" char=".">20.565</td><td class="colsep0 rowsep0" align="char" char=".">5.866</td><td class="colsep0 rowsep0" align="char" char=".">12.663</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>7e</b></td><td class="colsep0 rowsep0" align="char" char=".">0.013</td><td class="colsep0 rowsep0" align="char" char=".">0.028</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="char" char=".">0.734</td><td class="colsep0 rowsep0" align="char" char=".">0.693</td><td class="colsep0 rowsep0" align="char" char=".">0.638</td><td class="colsep0 rowsep0" align="char" char=".">1.063</td><td class="colsep0 rowsep0" align="char" char=".">0.456</td><td class="colsep0 rowsep0" align="char" char=".">9.797</td><td class="colsep0 rowsep0" align="char" char=".">5.947</td><td class="colsep0 rowsep0" align="char" char=".">14.580</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>8a</b></td><td class="colsep0 rowsep0" align="char" char=".">0.006</td><td class="colsep0 rowsep0" align="char" char=".">0.005</td><td class="colsep0 rowsep0" align="char" char=".">0.019</td><td class="colsep0 rowsep0" align="char" char=".">2.241</td><td class="colsep0 rowsep0" align="char" char=".">3.739</td><td class="colsep0 rowsep0" align="char" char=".">1.341</td><td class="colsep0 rowsep0" align="char" char=".">2.105</td><td class="colsep0 rowsep0" align="char" char=".">1.664</td><td class="colsep0 rowsep0" align="char" char=".">3.878</td><td class="colsep0 rowsep0" align="char" char=".">6.265</td><td class="colsep0 rowsep0" align="char" char=".">10.351</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>8b</b></td><td class="colsep0 rowsep0" align="char" char=".">0.025</td><td class="colsep0 rowsep0" align="char" char=".">0.065</td><td class="colsep0 rowsep0" align="char" char=".">0.020</td><td class="colsep0 rowsep0" align="char" char=".">1.283</td><td class="colsep0 rowsep0" align="char" char=".">2.418</td><td class="colsep0 rowsep0" align="char" char=".">3.629</td><td class="colsep0 rowsep0" align="char" char=".">2.120</td><td class="colsep0 rowsep0" align="char" char=".">1.120</td><td class="colsep0 rowsep0" align="char" char=".">5.883</td><td class="colsep0 rowsep0" align="char" char=".">14.165</td><td class="colsep0 rowsep0" align="char" char=".">11.174</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>8c</b></td><td class="colsep0 rowsep0" align="char" char=".">0.021</td><td class="colsep0 rowsep0" align="char" char=".">0.069</td><td class="colsep0 rowsep0" align="char" char=".">0.054</td><td class="colsep0 rowsep0" align="char" char=".">1.024</td><td class="colsep0 rowsep0" align="char" char=".">3.590</td><td class="colsep0 rowsep0" align="char" char=".">2.920</td><td class="colsep0 rowsep0" align="char" char=".">5.004</td><td class="colsep0 rowsep0" align="char" char=".">2.248</td><td class="colsep0 rowsep0" align="char" char=".">4.095</td><td class="colsep0 rowsep0" align="char" char=".">10.321</td><td class="colsep0 rowsep0" align="char" char=".">7.265</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>8d</b></td><td class="colsep0 rowsep0" align="char" char=".">0.083</td><td class="colsep0 rowsep0" align="char" char=".">0.624</td><td class="colsep0 rowsep0" align="char" char=".">0.122</td><td class="colsep0 rowsep0" align="char" char=".">4.757</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">9.793</td><td class="colsep0 rowsep0" align="char" char=".">8.600</td><td class="colsep0 rowsep0" align="char" char=".">>5</td><td class="colsep0 rowsep0" align="char" char=".">23.932</td><td class="colsep0 rowsep0" align="char" char=".">10.105</td><td class="colsep0 rowsep0" align="char" char=".">>25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>8n</b></td><td class="colsep0 rowsep0" align="char" char=".">0.023</td><td class="colsep0 rowsep0" align="char" char=".">0.007</td><td class="colsep0 rowsep0" align="char" char=".">0.017</td><td class="colsep0 rowsep0" align="char" char=".">2.016</td><td class="colsep0 rowsep0" align="char" char=".">6.906</td><td class="colsep0 rowsep0" align="char" char=".">4.070</td><td class="colsep0 rowsep0" align="char" char=".">3.255</td><td class="colsep0 rowsep0" align="char" char=".">1.408</td><td class="colsep0 rowsep0" align="char" char=".">7.559</td><td class="colsep0 rowsep0" align="char" char=".">8.058</td><td class="colsep0 rowsep0" align="char" char=".">12.976</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>8o</b></td><td class="colsep0 rowsep0" align="char" char=".">0.013</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="char" char=".">2.071</td><td class="colsep0 rowsep0" align="char" char=".">4.355</td><td class="colsep0 rowsep0" align="char" char=".">3.419</td><td class="colsep0 rowsep0" align="char" char=".">2.150</td><td class="colsep0 rowsep0" align="char" char=".">0.976</td><td class="colsep0 rowsep0" align="char" char=".">10.312</td><td class="colsep0 rowsep0" align="char" char=".">11.421</td><td class="colsep0 rowsep0" align="char" char=".">15.389</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>quiz</b></td><td class="colsep0 rowsep0" align="char" char=".">0.036</td><td class="colsep0 rowsep0" align="char" char=".">0.136</td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="char" char=".">0.064</td><td class="colsep0 rowsep0" align="char" char=".">>20</td><td class="colsep0 rowsep0" align="char" char=".">>20</td><td class="colsep0 rowsep0" align="char" char=".">>20</td><td class="colsep0 rowsep0" align="char" char=".">>5</td><td class="colsep0 rowsep0" align="char" char=".">n.t.</td><td class="colsep0 rowsep0" align="char" char=".">n.t.</td><td class="colsep0 rowsep0" align="char" char=".">n.t.</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">For SD values see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01529/suppl_file/jm7b01529_si_003.pdf" class="ext-link">Table S2</a>, and n.t. indicates not tested.</p></div></div></div><div class="NLM_p last">To further confirm the FLT3-inhibitory effects of our compounds, we evaluated the antiproliferative activity of <b>7d</b> in murine Ba/F3 pro-B cells stably transfected with FLT3-ITD. While the Ba/F3 FLT3-ITD cells were highly sensitive to the <b>7d</b> treatment and the GI<sub>50</sub> values reached low nanomolar concentrations (GI<sub>50</sub> = 0.034 ± 0.015 μM), in parental Ba/F3 cells the GI<sub>50</sub> values were higher than 1 μM (GI<sub>50</sub> = 1.136 ± 0.389). The similar results were obtained using quizartinib as a control (GI<sub>50</sub> = 0.007 ± 0.003 μM in Ba/F3 FLT3-ITD and 1.452 ± 0.166 μM in parental Ba/F3 cells). Experiments were performed at least in triplicates; for representative graphs see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01529/suppl_file/jm7b01529_si_003.pdf" class="ext-link">Figure S1</a>.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Binding Mode in FLT3 Active Site</h3><div class="NLM_p">Kinase inhibitors bind via several types of binding modes, and type I and II inhibitors were described for FLT3.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> Type I inhibitors bind to the ATP binding site, forming hydrogen bonds with the hinge region and presenting substituents in the hydrophobic region near the gatekeeper residue in the active kinase conformation (activation loop-out; DFG-in). In contrast, type II inhibitors bind to the allosteric site in the inactive kinase conformation (DFG-out). Type II FLT3 kinase inhibitors (e.g., quizartinib) were previously structurally characterized in complex with the inactive state of FLT3.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The inhibitors in the present study, however, are suggested to have type I binding because of their similar inhibition of WT and D835Y-mutated FLT3 enzymes (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Due to the unavailability of the structure of the active conformation of FLT3 kinase, we prepared its homology model and docked the lead compound <b>7d</b> (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01529/suppl_file/jm7b01529_si_003.pdf" class="ext-link">Supporting Information</a>). The binding mode is consistent with type I binding, that is, hinge-region hydrogen bonds and 2,6,9-substituents pointing to their respective pockets (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). In the hinge region, Cys694 backbone forms two classical hydrogen bonds with <b>7d</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) as expected for type I inhibitors. The cyclopentyl ring of <b>7d</b> makes hydrophobic contacts with several hydrophobic residues including the Phe691 gatekeeper. The 1,4-diaminocyclohexyl moiety uses its protonated distal 4-amino group to make a salt bridge with Asp829. Further modeling showed that many of the nonhinge-region interactions would be lost in compounds such as <b>6j</b>, resulting in a loss of activity. The N atom of the <i>N</i>-methyl morpholino group (p<i>K</i><sub>a</sub> of 7.38) loses the proton upon making hydrogen bond with Lys614.</div><figure id="fig1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/medium/jm-2017-015295_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0001.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Docked binding pose of <b>7d</b> (orange sticks) in FLT3. The kinase (cyan cartoon) is modeled in active conformation, and the P-loop (green cartoon), helix-C (magenta), and activation loop (AL; yellow) are highlighted. FLT3 interacting residues are shown as sticks colored gray for carbon, blue for nitrogen, red for oxygen, yellow for sulfur, and white for hydrogen. Figure prepared with Maestro, Schrodinger, LLC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01529&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Protein Kinase Selectivity</h3><div class="NLM_p last">In addition to FLT3-ITD, most of the active compounds were also potent inhibitors of recombinant wild-type FLT3 and, even more importantly, of a recombinant FLT3 variant bearing the D835Y point mutation, which contributes to the development of resistance (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Both FLT3-ITD and FLT3-D835Y display similar sensitivity to majority of our compounds, with GI<sub>50</sub> values in a low nanomolar range. In contrast, quizartinib was at least 10× less potent on D835Y mutant, which is in agreement with published data.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Compound <b>7d</b>, the most active candidate, was then screened for its activity against 309 protein kinases (Carna Biosciences). This screening confirmed <b>7d</b> as a potent inhibitor of FLT3. It also achieved significant inhibition (>90%) against several other kinases at a concentration of 10 nM, notably PDGFRα/β, CLK1, TRK, QIK, CaMK2δ, SIK, YES, FMS, CAMK2γ, KIT (D816V), MNK2, ACK, and SRC (for more details, see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01529/suppl_file/jm7b01529_si_003.pdf" class="ext-link">Table S3</a>).</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Cellular Activity of <b>7d</b> Is Related to FLT3 Inhibition</h3><div class="NLM_p">Because compound <b>7d</b> inhibited the proliferation of FLT3-ITD positive MV4-11 and MOLM-13 cell lines very effectively at low nanomolar concentrations (GI<sub>50</sub> values 2 and 1 nM, respectively), we investigated its molecular mechanism of action in cells. MV4-11 cells were treated for 1 h with increasing concentrations of the compound and analyzed by immunoblotting, revealing that concentrations as low as 1 nM were sufficient to block the autophosphorylation of the FLT3 receptor tyrosine kinase at three different tyrosine residues (589, 591, and 842). Moreover, this inhibition suppressed phosphorylation of several downstream targets of FLT3. Notably, <b>7d</b> abolished phosphorylation of STAT5 at Y694, which is a direct substrate of the oncogenic FLT3-ITD variant. The second pathway affected was the mitogen-activated protein kinase (MAPK) cascade: Two key components of this signaling pathway, ERK1/2 (T202/Y204) and MEK1/2 (S217/221), exhibited reduced phosphorylation upon treatment with our compound. <b>7d</b> also interfered with PI3K/AKT pathway which was confirmed by reduced phosphorylation of AKT at S473 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Similar results were obtained in MV4-11 cells after treatment with clinically tested FLT3 inhibitor quizartinib (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01529/suppl_file/jm7b01529_si_003.pdf" class="ext-link">Figure S3</a>). Because the MAPK and STAT pathways are crucial regulators of cell proliferation, their inhibition induces cell cycle arrest in the G1 phase. To confirm this, MV4-11 cells were treated for 24 h with increasing doses of compound <b>7d</b> and quizartinib, stained with propidium iodide, and analyzed by flow cytometry. Even a 1 nM concentration induced massive G1 arrest. In addition, higher doses increased the number of cells in the sub-G1 phase of the cell cycle, corresponding to an increased number of apoptotic cells (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01529/suppl_file/jm7b01529_si_003.pdf" class="ext-link">Figure S4</a>). This result was verified by immunoblotting, which revealed increased cleavage of the apoptotic marker protein PARP-1 (89 kDa fragment) upon treatment with <b>7d</b> at 10 or 100 nM for 24 h. This cleavage was accompanied by reduced levels of the antiapoptotic protein Mcl-1 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). To confirm that the proapoptotic effect of our compound is closely related to the presence of oncogenic FLT3 variants, we studied the activation of caspases, which play key roles in apoptotic cascades, in MV4-11 (FLT3-ITD) and K562 (no expression of FLT3) cells after treatment with <b>7d</b> for 24 h. Whereas even subnanomolar concentrations of <b>7d</b> induced caspase activation in MV4-11, K562 cells were much less sensitive and required vastly greater concentrations for caspase induction (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C).</div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/medium/jm-2017-015295_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Effect of <b>7d</b> on FLT3 and some of its downstream signaling pathways. PCNA was used as a control for protein loading. Densitometric analysis is available from <a href="/doi/suppl/10.1021/acs.jmedchem.7b01529/suppl_file/jm7b01529_si_003.pdf" class="ext-link">Figure S2</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01529&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/medium/jm-2017-015295_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effect of <b>7d</b> on cell cycle (A) and apoptosis (B, C) in the MV4-11 and K562 cell lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01529&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Activity in MV4-11 Xenograft</h3><div class="NLM_p">To determine the efficacy of compound <b>7d</b> in vivo, we compared its effects to that of quizartinib using human tumor xenografts grown in immunocompromised mice. First, we determined that treatment with <b>7d</b> caused no gross toxicity in rats (at doses up to 100 mg/kg i.v. or p.o.; for more details see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01529/suppl_file/jm7b01529_si_003.pdf" class="ext-link">Supporting Information</a>). Next, a single dose of 10 mg/kg of <b>7d</b> or quizartinib was administered i.p. to mice with subcutaneously implanted MV4-11 xenografts. Control mice were injected with an equal volume of diluent alone. Tumors were harvested at 4 post-treatment time points: 2, 24, 36, and 48 h after <b>7d</b>, quizartinib, or vehicle injection. The protein lysates were analyzed to detect phosphorylation of the target oncogenic tyrosine kinase FLT3-ITD and its downstream signaling molecules (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01529/suppl_file/jm7b01529_si_003.pdf" class="ext-link">Figure S5</a>). Compound <b>7d</b> effectively inhibited FLT3-ITD autophosphorylation in MV4-11 xenografts (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A), and unlike quizartinib (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B),<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22−24)</a> it sustained this inhibition of phosphorylation at all analyzed time points. Next, we investigated the inhibition of the key downstream effectors of FLT3-ITD, namely p-STAT5 and p-ERK1/2 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A, B). Treatment with <b>7d</b> reduced STAT5 phosphorylation by over 95% after 24 h, which was a slightly stronger effect than that of quizartinib (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01529/suppl_file/jm7b01529_si_003.pdf" class="ext-link">Figure S5</a>). Mirroring the results observed for p-FLT3, the suppression of STAT5 phosphorylation induced by <b>7d</b> was sustained over 48 h (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A), whereas a rebound in STAT5 phosphorylation was detected in lysates from quizartinib-treated tumors (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B).</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/medium/jm-2017-015295_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>7d</b> induces sustained suppression of FLT3-ITD signaling in MV4-11 xenograft tumors. Subcutaneous mouse xenografts were treated with 10 mg/kg <b>7d</b> (A) or quizartinib (B), and the phosphorylation status of FLT3 and its downstream signaling molecules was analyzed by immunoblotting at the indicated times. GAPDH was used as a control for protein loading. Each line represents a separate animal.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01529&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In contrast to the results observed for p-STAT5, p-ERK1/2 was only transiently inhibited in the tumor tissue, exhibiting similar rebound kinetics for both tested inhibitors in all animals (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A, B). Two hours after treatment with <b>7d</b> or quizartinib, the suppression of ERK1/2 phosphorylation was reduced by 95% relative to controls (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01529/suppl_file/jm7b01529_si_003.pdf" class="ext-link">Figure S5</a>). However, its phosphorylation was restored within 24 h of treatment with either compound, suggesting that there is an adaptive feedback mechanism capable of ERK1/2 reactivation in response to FLT3-ITD inhibition. Similar behavior was observed in earlier studies using quizartinib<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and sorafenib.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51166" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51166" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have presented the synthesis of a new generation of highly potent FLT3 inhibitors with a 2,6,9-trisubstutituted purine scaffold. A focused library of 49 compounds was prepared, some members of which exhibited selective nanomolar activity against AML cell lines expressing an oncogenic variant of FLT3. The lead compound <b>7d</b> inhibited FLT3 autophosphorylation and deactivated its downstream signaling pathways, leading to cell cycle arrest and apoptosis in MV4-11 cells. Docking of <b>7d</b> to FLT3 suggests a type I binding mode and explains the structural determinants of its potency. Experiments with subcutaneously implanted MV4-11 xenografts confirmed that a single dose of the tested compound induced sustained inhibition of FLT3 in vivo. In conclusion, we suggest this series to be followed for development of potent and specific FLT3 inhibitors for use as drug candidates for treating AML.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20524" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20524" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Reagents and General Methods</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> Chemistry</h4><div class="NLM_p last">Melting points were determined on a Büchi melting point B-540 apparatus and are uncorrected. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Jeol 500 ECA instrument operating at 500 MHz for <sup>1</sup>H and 126 MHz for <sup>13</sup>C or on a Bruker Avance 300 spectrometer (300 MHz) at ambient temperature in DMSO-<i>d</i><sub>6</sub> or CDCl<sub>3</sub>. Chemical shifts are reported in ppm. Coupling constants (<i>J</i>) are reported in hertz (Hz), and the following abbreviations are used: singlet (s), doublet (d), triplet (t), quartet (q), quintet (qui), sextet (sex), septet (sep), multiplet (m). Mass spectra were recorded using an LCQ ion trap mass spectrometer (Finnigan MAT). The chromatographic purity of the compounds was determined using HPLC-DAD-MS. An Alliance 2695 separations module (Waters) linked simultaneously to a PDA 996 (Waters) and a Q-Tof micro (Waters) benchtop quadrupole orthogonal acceleration time-of-flight tandem mass spectrometer were used. Samples were dissolved in methanol and diluted to a concentration of 10 μg·mL<sup>–1</sup> in the mobile phase (initial conditions). Then, 10 μL of the solution was injected on a RP-column (150 mm × 2.1 mm; 3.5 μm; Symmetry C18, Waters). The column was kept in a thermostat at 25 °C. Solvent (A) consisted of 15 mM formic acid adjusted to pH 4.0 with ammonium hydroxide. Methanol was used as the organic modifier (solvent B). At flow rate of 0.2 mL·min<sup>–1</sup>, the following binary gradient was used: 0 min, 10% B; 0–24 min, a linear gradient to 90% B, followed by 10 min isocratic elution of 90% B. At the end of the gradient, the column was re-equilibrated to the initial conditions for 10 min. The effluent was introduced into the DAD (scanning range 210–400 nm, with 1.2 nm resolution), and an electrospray source was applied (source temperature 110 °C, capillary voltage +3.0 kV, cone voltage +20 V, desolvation temperature 250 °C). Nitrogen was used as both the desolvation gas (500 L·h<sup>–1</sup>) and the cone gas (50 L·h<sup>–1</sup>). The mass spectrometer was operated in positive (ESI+) ionization mode, and data were acquired in the 50–1000 <i>m</i>/<i>z</i> range. Elemental analyses were performed using an EA1112 CHN analyzer (Thermo Finnigan); the results obtained for C, H, and N were within acceptable limits of the expected values. Merck silica gel Kieselgel 60 (230–400 mesh) was used for column chromatography. The purity of biologically evaluated compounds was >95% as determined by HPLC-DAD-MS and elemental analysis.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> General Procedure for the Preparation of Derivatives <b>4</b></h4><div class="NLM_p">4-Fluoronitrobenzene (<b>2a</b>) or 5-bromo-2-nitropyridine (<b>2b</b>) (1.00 mmol), the appropriate secondary amine (1.05 mmol), and potassium carbonate (2.00 mmol) in ethanol (10 mL) were heated under an argon atmosphere in a sealed tube at 100 °C for 4 h. The completion of the reaction was checked with TLC on silica (chloroform–methanol, 19:1). After cooling to room temperature, the reaction mixture was evaporated under reduced pressure. The residue was partitioned between dichloromethane (25 mL) and water (25 mL). The water phase was extracted twice with dichloromethane (25 mL). The combined organic phases were washed with water and brine, dried over sodium sulfate, and concentrated under reduced pressure. The crude product (<b>3</b>) was then used directly without further purification.</div><div class="NLM_p last">The crude product (<b>3</b>) from the previous step (0.75 mmol) was hydrogenated under atmospheric pressure in methanol (50 mL) with 5% wt. palladium on a charcoal (50 mg). After consumption of hydrogen, the reaction mixture was filtered through Celite, washed with methanol, and evaporated under reduced pressure. The crude product was dissolved in 2 M hydrochloric acid (50 mL) and extracted with dichloromethane (25 mL). The water phase was neutralized with 5% sodium hydrogen carbonate, then the precipitate was filtered off and washed with water. The crude product was dried in a vacuum desiccator.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> 4-(5-Nitro-pyridin-2-yl)-morpholine (<b>3a</b>)</h4><div class="NLM_p last">Yield: 85%. Elemental analysis: Calcd for C<sub>9</sub>H<sub>11</sub>N<sub>3</sub>O<sub>3</sub> (209.21): C, 51.67; H, 5.30; N, 20.09. Found: C, 51.57; H, 5.48; N, 19.74. HPLC-MS (ESI+): 210.31 (99.8%). GC-MS (EI, M+ (rel. int. <i>m</i>/<i>z</i>)): 209 (18), 124 (100), 87 (28). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 2.92–2.98 (m, 4H), 3.71–3.75 (m, 4H), 6.52 (d, <i>J</i> = 9.5, 1H), 8.15 (s, 1H), 9.02 (d, <i>J</i> = 9.5, 1H).</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 6-(4-Nitro-phenyl)-2-oxa-6-aza-spiro[3.3]heptane (<b>3b</b>)</h4><div class="NLM_p last">Yield: 72%. Elemental analysis: Calcd for C<sub>11</sub>H<sub>12</sub>N<sub>2</sub>O<sub>3</sub> (220.22): C, 59.99; H, 5.49; N, 12.72. Found: C, 59.66; H, 5.12; N, 12.19. HPLC-MS (ESI+): 221.36 (99.7%). GC-MS (EI, M+ (rel. int. <i>m</i>/<i>z</i>)): 220 (21), 150 (100), 120 (57). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 4.19–4.21(m, 4H), 4.70–4.72 (m, 4H), 6.44 (d, <i>J</i> = 9.15, 2H), 8.04 (d, <i>J</i> = 9.15, 2H).</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 6-Morpholin-4-yl-pyridin-3-ylamine (<b>4a</b>)</h4><div class="NLM_p last">Yield: 98%. Elemental analysis: Calcd for C<sub>9</sub>H<sub>13</sub>N<sub>3</sub>O (179.22): C, 60.32; H, 7.31; N, 23.45. Found: C, 59.96; H, 6.83; N, 23.19. HPLC-MS (ESI+): 180.28 (99.8%). GC-MS (EI, M+ (rel. int. <i>m</i>/<i>z</i>)): 179 (22), 124 (100). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 3.05 (s(br, 2H), 3.30–3.34 (m, 4H), 3.79–3.82 (m, 4H), 6.55 (d, <i>J</i> = 8.5, 1H), 6.98 (s, 1H), 7.78 (d, <i>J</i> = 8.5, 1H).</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 4-(2-Oxa-6-aza-spiro[3.3]hept-6-yl)-phenylamine (<b>4b</b>)</h4><div class="NLM_p last">Yield: 58%. Elemental analysis: Calcd for C<sub>11</sub>H<sub>14</sub>N<sub>2</sub>O (190.24): C, 69.45; H, 7.42; N, 14.73. Found: C, 69.13; H, 7.12; N, 14.96. HPLC-MS (ESI+): 191.5 (99.7%). GC-MS (EI, M+ (rel. int. <i>m</i>/<i>z</i>): 190 (11), 132 (100). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 3.72–3.75(m, 4H), 4.40 (s (br), 2H), 4.65–4.68 (m, 4H), 6.21 (d, <i>J</i> = 8.16, 2H), 6.46 (d, <i>J</i> = 8.15, 2H)</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> General Procedure for the Preparation of Compounds <b>5a</b> – <b>5m</b></h4><div class="NLM_p last">To a suspension of 9-cyclopentyl-2,6-dichloro-9<i>H</i>-purine (<b>13</b>) (1.98 mmol) in a mixture of <i>n</i>-propanol (10 mL) and <i>N,N</i>-diisopropyl-<i>N</i>-ethylamine (8.72 mmol), appropriate amine (2.18 mmol) was added. The suspension was heated with stirring in a sealed tube under an argon atmosphere at 100 °C for 2–6 h. The reaction was checked by TLC. After completion of the reaction, the reaction mixture was cooled to room temperature and evaporated under reduced pressure. The residue was partitioned between water (50 mL) and dichloromethane (50 mL), and the water phase was extracted two times more with the same volume of dichloromethane. The combined organic phases were washed with water and brine and evaporated under reduced pressure. The crude product was crystallized from petroleum ether:ethyl acetate 3:1.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 4-(Bromo-phenyl)-(2-chloro-9-isopropyl-<i>9H</i>-purin-6-yl)-amine (<b>5a</b>)</h4><div class="NLM_p last">Yield: 89% m.p.: 154–156 °C. Elemental analysis: Calcd for C<sub>14</sub>H<sub>13</sub>BrClN<sub>5</sub> (366.64): C, 45.86; H, 3.57; N, 19.10. Found: C, 45.94; H, 3.81; N, 18.82. HPLC-MS (ESI+): 367.6 (97.8%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.49 (d, <i>J</i> = 7.0, 6H), 4.70 (sep, <i>J</i> = 7.0, 1H), 7.49 (d, <i>J</i> = 9.00, 2H), 7.80 (d, <i>J</i> = 9.00, 2H), 8.44 (s, 1H), 10.39 (s, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 126 MHz) δ ppm 22.63, 47.49, 115.61, 119.74, 123.45, 131.84, 137.88, 141.17, 150.92, 152.38, 152.69.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 4-(Bromo-phenyl)-(2-chloro-9-cyclopentyl-<i>9H</i>-purin-6-yl)-amine (<b>5b</b>)</h4><div class="NLM_p last">Yield: 85% m.p.: 193–194 °C. Elemental analysis: Calcd for C<sub>16</sub>H<sub>15</sub>BrClN<sub>5</sub> (392.69): C, 48.94; H, 3.85; N, 17.83. Found: C, 49.06; H, 3.94; N, 17.49. HPLC-MS (ESI+): 393.7 (98.4%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.87–1.92 (m, 2H), 1.92–1.99 (m, 4H), 2.01–2.23 (m, 2H), 4.85 (qui, <i>J</i> = 7.17, 1H), 7.54 (d, <i>J</i> = 8.73, 2H), 7.84 (d, <i>J</i> = 8.73, 2H), 8.45 (s, 1H), 10.42 (s, 1H).</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (2-Chloro-9-cyclopentyl-<i>9H</i>-purin-6-yl)-(4-chloro-phenyl)-amine (<b>5c</b>)</h4><div class="NLM_p last">Yield: 78% m.p.: 212–214 °C. Elemental analysis: Calcd for C<sub>16</sub>H<sub>15</sub>Cl<sub>2</sub>N<sub>5</sub> (348.24): C, 55.19; H, 4.34; N, 20.11. Found: C, 55.56; H, 4.05; N, 19.89. HPLC-MS (ESI+): 349.4 (96.4%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.67–1.71(m, 2H), 1.72–1.76(m, 4H), 1.89–2.20 (m, 2H), 4.84 (sep, <i>J</i> =  7.17, 1H), 7.40 (d, <i>J</i> = 8.85, 2H), 7.89(d, <i>J</i> = 8.85, 2H), 8,44 (s, 1H), 10.43 (s, 1H).</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> (9-Benzyl-2-chloro-<i>9H</i>-purin-6-yl)-(4-bromo-phenyl)-amine (<b>5d</b>)</h4><div class="NLM_p last">Yield: 54% m.p.: 231–233 °C. Elemental analysis: Calcd for C<sub>18</sub>H<sub>13</sub>BrClN<sub>5</sub> (414.69): C, 52.13; H, 3.16; N, 16.89. Found: C, 52.02; H, 3.45; N, 16.93. HPLC-MS (ESI+): 415.8 (97.8%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 5.53 (s, 2H), 7.31–7.42 (m, 5H), 7.56 (d, <i>J</i> = 8.43, 2H), 8.03 (d, <i>J</i> = 8.43, 2H), 8.87 (s, 1H), 9.25 (s(br), 1H).</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (9-Benzyl-2-chloro-<i>9H</i>-purin-6-yl)-(4-morpholin-4-ylmethyl-phenyl)-amine (<b>5e</b>)</h4><div class="NLM_p last">Yield: 76%. m.p.: 194–196 °C. Elemental analysis: Calcd for C<sub>23</sub>H<sub>23</sub>ClN<sub>6</sub>O (434.93): C, 63.52; H, 5.33; N, 19.32. Found: C, 63.82; H, 5.12; N, 19.01. HPLC-MS (ESI+): 435.9 (96.2%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.35–2.41 (m, 4H), 3.43 (s, 2H), 3.60 (t, <i>J</i> = 7.85, 4H), 5.41 (s, 2H), 7.26–7.37 (m, 7H), 7.76 (d, <i>J</i> = 8.40, 2H), 8.43 (s, 1H), 10.34 (s, 1H). <sup>13</sup>C NMR (76 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 46.95, 53.64, 62.51, 66.69, 119.26, 121.68, 127.98, 128.43, 129.34, 129.69, 133.32, 137.09, 138.11, 142.85, 151.23, 152.94, 153.08.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (4-Bromo-phenyl)-[2-chloro-9-(tetrahydro-pyran-2-yl)-<i>9H</i>-purin-6-yl]-amine (<b>5f</b>)</h4><div class="NLM_p last">Yield: 76%. m.p.: 143–144 °C. Elemental analysis: Calcd for C<sub>16</sub>H<sub>15</sub>BrClN<sub>5</sub>O (408.69): C, 47.02; H, 3.70; N, 17.14. Found: C, 47.13; H, 3.44; N, 17.11. HPLC-MS ESI+): 410.2 (97.5%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.55–1.58(m, 2H), 1.73–1.76 (m, 1H), 1.95–1.99 (m, 2H), 2.20 (t, <i>J</i> = 5.3, 1H), 3.67–3.75 (m, 1H), 4.00 (d, <i>J</i> = 5.3, 1H), 5.63 (d, <i>J</i> = 10.71, 1H), 7.54 (d, <i>J</i> = 8.79, 2H), 7.82 (d, <i>J</i> = 8.79, 2H), 8.58 (s, 1H), 10.49 (s(br), 1H). <sup>13</sup>C NMR (76 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 22.19, 24.39, 29.81, 67.61, 80.90, 115.19, 118.78, 122.95, 131.25, 138.09, 140.53, 150.22, 152.09, 152.34.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (2-Chloro-9-cyclopentyl-<i>9H</i>-purin-6-yl)-(4-pyrrolidin-1-yl-phenyl)-amine (<b>5g</b>)</h4><div class="NLM_p last">Yield: 92%. m.p.: 168–169 °C. Elemental analysis: Calcd for C<sub>20</sub>H<sub>23</sub>ClN<sub>6</sub> (382.89): C, 62.74; H, 6.05; N, 21.95. Found: C, 62.54; H, 5.82; N, 21.83. HPLC-MS (ESI+): 384 (99.9%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.63–1.81(m, 2H), 1.86–1.99 (m, 8H), 2.14–2.21 (m, 2H), 3.19–3.23 (m, 4H), 4.81 (qui, <i>J</i> = 7.17, 1H), 6.49 (d, <i>J</i> = 8.73, 2H), 7.49 (d, <i>J</i> = 8.73, 2H), 8.28 (s, 1H), 9.89(s, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 24.03, 25.47, 32.57, 48.02, 55.97, 111.85, 119.27, 123.95, 127.55, 140.56, 145.38, 150.70, 152.90, 153.19.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (2-Chloro-9-cyclopentyl-<i>9H</i>-purin-6-yl)-(4-morpholin-4-yl-phenyl)-amine (<b>5h</b>)</h4><div class="NLM_p last">Yield: 72%. m.p.: 145–148 °C. Elemental analysis: Calcd for C<sub>20</sub>H<sub>23</sub>ClN<sub>6</sub>O (398.89): C, 60.22; H, 5.81; N, 21.07. Found: C, 60.25; H, 5.88; N, 21.19. HPLC-MS (ESI+): 400.7 (98.5%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.79–1.83 (m, 2H), 1.85–1.96 (m, 4H), 2.27–2.36 (m, 2H), 3.14–3.18 (m, 4H), 3.88–3.90 (m, 4H), 4.94 (qui, <i>J</i> = 7.32, 1H), 6.97 (d, <i>J</i> = 8.94, 2H), 7.65 (d, <i>J</i> = 8.94, 2H), 7.80 (s (br), 1H), 7.83 (s, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 23.91, 33.04, 49.89, 55.97, 66.96, 116.54, 119.28, 121.89, 130.84, 138.78, 148.11, 150.70, 152.48, 154.03.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 2-Chloro-9-cyclopentyl-<i>9H</i>-purin-6-yl)-[4-(4-ethyl-piperazin-1-yl)-phenyl]-amine (<b>5i</b>)</h4><div class="NLM_p last">Yield: 82%. m.p.: 128–131 °C. Elemental analysis: Calcd for C<sub>22</sub>H<sub>28</sub>ClN<sub>7</sub> (425.96): C, 62.03; H, 6.63; N, 23.02. Found: C, 61.93; H, 6.79; N, 23.22. HPLC-MS (ESI+): 427.3 (99.5%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.16 (t, <i>J</i> = 7.2, 3H), 1.65–1.68 (m, 2H), 1.83–1.95 (m, 4H), 2.26–2.32 (m, 2H), 3.05–3.11 (m, 4H), 3.27–3.35 (m, 4H), 4.78 (qui, <i>J</i> = 6.9, 1H), 6.89 (d, <i>J</i> = 9.00, 2H), 7.57 (d, <i>J</i> = 9.00, 2H), 8.32 (s, 1H), 10.02 (s, 1H). <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 11.27, 24.24, 24.45, 32.19, 32.32, 54.84, 55.48, 63.33, 113.59, 114.68, 122.36, 131.50, 137.37, 140.41, 152.24, 159.16.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (2-Chloro-9-cyclopentyl-<i>9H</i>-purin-6-yl)-(4-morpholin-4-ylmethyl-phenyl)-amine (<b>5j</b>)</h4><div class="NLM_p last">Yield: 69%. m.p.: 123–124 °C. Elemental analysis: Calcd for C<sub>21</sub>H<sub>25</sub>ClN<sub>6</sub>O (412.92): C, 61.08; H, 6.10; N, 20.35. Found: C, 61.33; H, 5.99; N, 20.02. HPLC-MS (ESI+): 414.2 (99.5%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 1.78–1.82 (m, 2H), 1.84–1.99 (m, 4H), 2.28–2.36 (m, 2H), 2.47–2.52 (m, 4H), 3.53 (s, 2H), 3.70–3.74 (m, 4H), 4.95 (qui, <i>J</i> = 5.4, 1H), 7.37(d, <i>J</i> = 8.22, 2H), 7.74 (d, <i>J</i> = 8.22, 2H), 7.86 (s, 1H). <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 23.93, 33.04, 53.51, 56.04, 62.92, 67.06, 119.52, 120.01, 129.42, 132.12, 137.29, 139.07, 150.87, 152.30, 153.87.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 2-Chloro-9-cyclopentyl-<i>9H</i>-purin-6-yl)-[4-(2-oxa-6-aza-spiro[3.3]hept-6-yl)-phenyl]-amine (<b>5k</b>)</h4><div class="NLM_p last">Yield: 74%. m.p.: 119–120 °C. Elemental analysis: Calcd for C<sub>21</sub>H<sub>23</sub>ClN<sub>6</sub>O (410.90): C, 61.38; H, 5.64; N, 20.45. Found: C, 61.14; H, 5.39; N, 20.19. HPLC-MS (ESI+): 411.9 (97.7%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.67–1.72 (m, 2H), 1.84–1.99 (m, 4H), 2.11–2.18 (m, 2H), 3.92–3.94 (m, 4H), 4.70–4.72(m, 4H), 4.81 (qui, <i>J</i> =  5.4, 1H), 6.43 (d, <i>J</i> = 8.70, 2H), 7.53 (d, <i>J</i> = 8.70, 2H), 8.33 (s, 1H), 9.99 (s, 1H).</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> [4-(4-Benzyl-piperazin-1-yl)-phenyl]-(2-chloro-9-cyclopentyl-9<i>H</i>-purin-6-yl)-amine (<b>5l</b>)</h4><div class="NLM_p last">Yield: 79%. mp 181–182 °C. Elemental analysis: Calcd for C<sub>27</sub>H<sub>30</sub>ClN<sub>7</sub> (488.03): C, 66.45; H, 6.20; N, 20.09. Found: C, 66.71; H, 6.41; N, 19.84. HPLC-MS (ESI+): 490.6 (99.9%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 500 MHz) δ ppm 1.62–1.70 (m, 2H), 1.79–1.86 (m, 2H), 1.89–1.97 (m, 2H), 2.10–2.16 (m, 2H), 3.06–3.09 (m, 4H), 3.29–3.31 (m, 4H), 3.49 (s, 2H), 4.78 (qui, <i>J</i> = 7.5, 1H), 6.88 (d, <i>J</i> = 9.0, 2H), 7.21–7.25 (m, 1H), 7.27–7.31 (m, 4H), 7.57 (d, <i>J</i> = 9.0, 2H), 8.32 (s, 1H), 10.03 (s, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 24.03, 32.56, 49.14, 53.09, 56.01, 62.60, 115.99, 119.38, 123.13, 127.51, 128.74, 129.46, 130.91, 138.61, 140.84, 148.10, 150.85, 152.76, 152.99.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 2-Chloro-9-cyclopentyl-<i>9H</i>-purin-6-yl)-(6-morpholin-4-yl-pyridin-3-yl)-amine (<b>5m</b>)</h4><div class="NLM_p last">Yield: 88%. mp 113–115 °C. Elemental analysis: Calcd for C<sub>19</sub>H<sub>22</sub>ClN<sub>7</sub>O (399.88): C, 57.07; H, 5.55; N, 24.52. Found: C, 57.23; H, 5.21; N, 24.14. HPLC-MS (ESI+): 400.9 (99.5%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.79–1.83 (m, 2H), 1.85–1.96 (m, 4H), 2.27–2.36 (m, 2H), 3.14–3.18 (m, 2H), 3.88–3.90 (m, 2H), 4.91 (qui, <i>J</i> = 6.55, 1H), 6.93 (s, 1H), 7.41–7.47 (m, 2H), 7.98 (s, 1H), 8.25 (s(br), 1H).</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> General Procedure for the Preparation of Compounds <b>6a</b>–<b>6o</b>, <b>7a</b>–<b>7f</b>, and <b>8a</b>–<b>8o</b></h4><div class="NLM_p last">The mixture of 2-chloro-9-cyclopentyl-9<i>H</i>-purin-6-subst. amino derivative <b>15</b> (1.00 mmol) and <i>trans</i>-1,4-diaminocyclohexane (10.0 mmol) in 1,2-ethandiole (5 mL) was heated with stirring at 160 °C for 4 h in an argon atmosphere. After cooling to room temperature, the mixture was diluted with ethyl acetate (40 mL) and washed with water (40 mL). The organic phase was washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The crude product was purified by column chromatography on silica using mobile phase chloroform–methanol (4:1, v/v).</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>N</i><sup>2</sup>-(4-Amino-cyclohexyl)-<i>N</i><sup>6</sup>-(4-bromo-phenyl)-9-isopropyl-9H-purine-2,6-diamine (<b>6a</b>)</h4><div class="NLM_p last">Yield: 85%. m.p.: 224–226 °C. Elemental analysis: Calcd for C<sub>20</sub>H<sub>26</sub>BrN<sub>7</sub> (444.37): C, 54.06; H, 5.90; N, 22.06. Found: C, 53.99; H, 5.73; N, 22.23. HPLC-MS (ESI+): 446.0 (97.9%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.07–1.29 (m, 4H), 1.45 (d, <i>J</i> = 6.4, 6H), 1.77 (d, <i>J</i> = 11.8, 2H), 1.93 (d, <i>J</i> = 11.5, 2H), 3.64–3.52 (m, 2H), 4.59–4.49 (sep, <i>J</i> = 6.50, 1H), 6.47 (s(br), 1H), 7.39 (d, <i>J</i> = 8.7, 2H), 7.91 (s, 1H), 7.99(d, <i>J</i> = 8.7, 2H), 9.55 (s(br), 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 22.57, 31.84, 35.76, 46.29, 50.56, 113.53, 114.40, 122.17, 131.42, 136.69, 140.54, 152.20, 158.59.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 1-[6-(4-Bromo-phenylamino)-9-isopropyl-9H-purin-2-ylamino]-propan-2-ol (<b>6b</b>)</h4><div class="NLM_p last">Yield: 79%. m.p.: 178–180 °C. Elemental analysis: Calcd For C<sub>17</sub>H<sub>21</sub>BrN<sub>6</sub>O (405.30): C, 50.38; H, 5.22; N, 20.74. Found: C, 50.59; H, 5.49; N, 20.58. HPLC-MS (ESI+): 407.0 (98.1%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.06 (d, <i>J</i> = 6.2, 3H), 1.46 (d, <i>J</i> = 6.8, 6H), 3.20–3.12 (m, 1H), 3.30–3.23 (m, 2H), 3.81(sep, <i>J</i> = 5.5, 1H), 4.55 (sep, <i>J</i> = 7.0, 1H), 4.70 (s, 1H), 6.50 (t, <i>J</i> = 5.8, 1H), 7.39 (d, <i>J</i> = 8.9, 2H), 7.93 (s, 1H), 7.97 (d, <i>J</i> = 8.7, 2H), 9.55 (s(br), 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 21.93, 22.56, 46.40, 49.82, 65.92, 113.66, 114.68, 122.40, 131.49, 136.78, 140.38, 151.87, 152.24, 159.30.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> <i>N</i><sup>2</sup>-(4-Amino-cyclohexyl)-<i>N</i><sup>6</sup>-(4-bromo-phenyl)-9-cyclopentyl-9<i>H</i>-purine-2,6-diamine (<b>6c</b>)</h4><div class="NLM_p last">Yield: 79%. m.p.: 162–164 °C. Elemental analysis: Calcd For C<sub>22</sub>H<sub>28</sub>BrN<sub>7</sub> (470.42): C, 56.17; H, 6.00; N, 20.84. Found: C, 56.39; H, 5.63; N, 20.51. HPLC-MS (ESI+): 473.0 (99.8%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.09–1.32 (m, 4H), 1.64–1.68 (m, 2H), 1.78–2.08 (m, 12H), 2.57 (m, 1H), 3.58–3.61 (m, 1H), 4.69 (qui, <i>J</i> = 7.11, 1H), 6.50 (d, <i>J</i> = 7.41, 1H), 7.42 (d, <i>J</i> = 8.85, 2H), 7.90 (s, 1H), 8.04 (d, <i>J</i> = 8.85, 2H), 9.58 (s (br), 1H). <sup>13</sup>C NMR (76 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 24.18, 24.48, 31.77, 32.28, 35.67, 49.12, 50.63, 133.53, 122.22, 123.80, 131.42, 137.46, 140.55, 150.85, 152.26, 158.52.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>N</i><sup>2</sup>-(4-Amino-cyclohexyl)-<i>N</i><sup>6</sup>-(4-chloro-phenyl)-9-cyclopentyl-<i>9H</i>-purine-2,6-diamine (<b>6d</b>)</h4><div class="NLM_p last">Yield: 84% m.p.: 113–115 °C. Elemental analysis: Calcd for C<sub>22</sub>H<sub>28</sub>ClN<sub>7</sub> (425.96): C, 62.03; H, 6.63; N, 23.02. Found: C, 61.87; H, 6.89 N, 21.31. HPLC-MS (ESI+): 426.2 (98.7%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.29–1.04 (m, 4H), 1.68–1.56 (m, 2H), 2.11–1.72(m, 10H), 2.56–2.48 (m, 1H), 3.62–3.52 (m, 1H), 4.65 (qui, <i>J</i> = 6.3, 1H), 6.48 (d, <i>J</i> = 4.9, 1H), 7.26 (d, <i>J</i> = 8.5, 2H), 7.87 (s, 1H), 8.06 (d, <i>J</i> = 8.8, 2H), 9.54 (s(br), 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 24.29, 31.77, 32.28, 35.67, 50.56, 50.78, 55.50, 114.48, 121.80, 125.55, 128.51, 137.40, 140.13, 152.27, 158.52.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 1-[6-(4-Chloro-phenylamino)-9-cyclopentyl-<i>9H</i>-purin-2-ylamino]-propan-2-ol (<b>6e</b>)</h4><div class="NLM_p last">Yield: 79% m.p.: 128–129 °C. Elemental analysis: Calcd for C<sub>1<i>9H</i>23</sub>ClN<sub>6</sub>O (386.88): C, 58.99; H, 5.99; N, 21.72. Found: C, 58.63; H, 6.22 N, 21.94. HPLC-MS (ESI+): 387.3 (98.7%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.09 (d, <i>J</i> =  6.18, 3H), 1.63–1.67 (m, 2H), 1.87–2.00 (m, 4H), 2.09–2.21 (m, 2H), 3.14–3.22 (m, 2H), 3.75–3.89 (m, 1H), 4.67 (sep, <i>J</i> =  7.41, 1H), 4.72 (s(br), 1H), 6.54 (t, <i>J</i> =  5.19, 1H), 7.30 (d, <i>J</i> =  8.67, 2H), 7.89 (s, 1H), 8.06 (d, <i>J</i> = 8.67, 2H), 9.58 (s, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 76 MHz) δ ppm 21.29, 23.63, 31.66, 49.20, 54.81, 65.28, 114.12, 121.36, 125.07, 127.96, 136.74, 139.33, 151.67, 158.67.</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 1-[6-(4-Bromo-phenylamino)-9-cyclopentyl-<i>9H</i>-purin-2-ylamino]-propan-2-ol (<b>6f</b>)</h4><div class="NLM_p last">Yield: 94%. m.p.: 133–134 °C. Elemental analysis: Calcd for C<sub>19</sub>H<sub>23</sub>BrN<sub>6</sub>O (431.33): C, 52.91; H, 5.37; N, 19.48. Found: C, 52.84; H, 5.19 N, 19.56. HPLC-MS (ESI+): 433.0 (98.0%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.05 (d, <i>J</i> =  6.23, 3H), 1.62–1.67 (m, 2H), 1.80–1.86 (m, 2H), 1.92–1.97 (m, 2H), 2.04–2.09 (m, 2H), 3.11–3.17 (m, 1H), 3.25–3.29 (m, 1H), 3.81 (sep, <i>J</i> = 5.8, 1H), 4.63–4.68 (m, 2H), 6.51 (t, <i>J</i> =  5.28, 1H), 7.39 (d, <i>J</i> =  8.85, 2H), 7.89 (s, 1H), 7.99 (d, <i>J</i> = 8.85, 2H), 9.56 (s, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 126 MHz) δ ppm 21.95, 24.27, 32.31, 49.83, 55.42, 60.25, 65.88, 113.64, 114.78, 122.43, 131.48, 137.40, 140.41, 152.28, 159.27.</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (<i>R</i>)-3-[6-(4-Bromo-phenylamino)-9-cyclopentyl-<i>9H</i>-purin-2-ylamino]-2-methyl-propan-1-ol (<b>6g</b>)</h4><div class="NLM_p last">Yield: 85%. m.p.: 156–158 °C. Elemental analysis: Calcd for C<sub>20</sub>H<sub>25</sub>BrN<sub>6</sub>O (445.36): C, 53.94; H, 5.66; N, 18.87. Found: C, 53.67; H, 5.49 N, 18.41. HPLC-MS (ESI+): 447.07 (97.2%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.86 (t, <i>J</i> = 7.4, 3H), 1.46 (qui, <i>J</i> = 7.0, 1H), 1.68–1.57 (m, 3H), 1.88–1.79 (m, 2H), 2.00–1.90 (m, 2H), 2.11–2.02 (m, 2H), 3.52–3.45 (m, 1H), 3.83–3.74 (m, 1H), 4.60 (t, <i>J</i> = 5.2, 1H), 4.66 (qui, <i>J</i> = 7.7, 1H), 6.23 (d, <i>J</i> = 8.1, 1H), 7.39 (d, <i>J</i> = 8.9, 2H), 7.88 (s,1H), 7.98 (d, <i>J</i> = 7.7, 2H), 9.52 (s, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.26, 24.24, 24.44, 32.19, 32.31, 54.84, 55.47, 63.32, 113.59, 114.67, 122.35, 131.49, 137.37, 140.41, 152.24, 159.15.</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>N</i><sup>2</sup>-(4-Amino-cyclohexyl)-9-benzyl-<i>N</i><sup>6</sup>-(4-bromo-phenyl)-<i>9H</i>-purine-2,6-diamine (<b>6h</b>)</h4><div class="NLM_p last">Yield: 82%. m.p.: 129–131 °C. Elemental analysis: Calcd for C<sub>24</sub>H<sub>26</sub>BrN<sub>7</sub> (492.41): C, 58.54; H, 5.32; N, 19.91. Found: C, 58.66; H, 5.39 N, 19.82. HPLC-MS (ESI+): 493.5 (98.1%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.15–1.26 (m, 4H), 1.80 (d, <i>J</i> = 9.0, 2H), 1.92 (d, <i>J</i> = 9.0, 2H), 2.57–2.63 (m, 1H), 3.55–3.62 (m, 1H), 5.19 (s, 2H), 6.60 (s(br), 1H), 7.23–7.32 (m, 5H), 7.39 (d, <i>J</i> = 8.0, 2H), 7.94 (s, 1H), 8.00 (d, <i>J</i> = 8.0, 2H), 9.67 (s(br), 1H).</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 1-[9-Benzyl-6-(4-bromo-phenylamino)-<i>9H</i>-purin-2-ylamino]-propan-2-ol (<b>6i</b>)</h4><div class="NLM_p last">Yield: 96% m.p.: 148–149 °C. Elemental analysis: Calcd for C<sub>21</sub>H<sub>21</sub>BrN<sub>6</sub>O (453.34): C, 55.64; H, 4.67; N, 18.54. Found: C, 55.41; H, 5.02 N, 18.20. HPLC-MS (ESI+): 454.5 (97.8%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.08 (d, <i>J</i> = 6.21, 3H), 3.13–3.22 (m, 2H), 3.81 (sep, <i>J</i> = 5.37, 1H), 4.67 (d, <i>J</i> = 5.26, 1H), 5.24 (s, 2H), 6.61 (t, <i>J</i> = 5.46, 1H), 7.24–7.44 (m, 5H), 7.42 (d, <i>J</i> = 8.91, 2H), 7.98 (s, 1H), 8.01 (d, <i>J</i> = 8.91, 2H), 9.64 (s(br), 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 21.92, 46.27, 49.84, 65.80, 113.74, 114.21, 122.48, 128.16, 129.15, 131.49, 137.89, 138.74, 140.33, 152.30, 159.69.</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (9-Benzyl-2-morpholin-4-yl-<i>9H</i>-purin-6-yl)-(4-bromo-phenyl)-amine (<b>6j</b>)</h4><div class="NLM_p last">Yield: 87% m.p.: 171–172 °C. Elemental analysis: Calcd for C<sub>22</sub>H<sub>21</sub>BrN<sub>6</sub>O (465.36): C, 56.78; H, 4.55; N, 18.06. Found: C, 56.53; H, 4.71 N, 17.83. HPLC-MS (ESI+): 466.5 (97.6%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 3.63–3.68 (m, 8H), 5.28 (s, 2H), 7.28–7.36 (m, 5H), 7.47 (d, <i>J</i> = 8.82, 2H), 7.84 (d, <i>J</i> = 8.82, 2H), 8.07 (s, 1H), 9.79 (s, 1H). <sup>13</sup>C NMR (76 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 44.77, 45.77, 65.94, 113.52, 113.76, 122.22, 127.61, 127.71, 128.56, 131.01, 137.16, 139.02, 139.22, 151.33, 158.44.</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> [9-Benzyl-2-(4-methyl-piperazin-1-yl)-<i>9H</i>-purin-6-yl]-(4-bromo-phenyl)-amine (<b>6k</b>)</h4><div class="NLM_p last">Yield: 88% m.p.: 162–164 °C. Elemental analysis: Calcd for C<sub>23</sub>H<sub>26</sub>BrN<sub>7</sub> (480.40): C, 57.50; H, 5.46; N, 20.41. Found: C, 57.38; H, 5.14 N, 20.11. HPLC-MS (ESI+): 481.8 (96.2%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.17 (s, 3H), 2.32–2.36 (m, 4H), 3.69–3.72 (m, 4H), 5.26 (s, 2H), 7.26–7.34 (m, 5H), 7.47 (d, <i>J</i> = 8.79, 2H), 7.85 (d, <i>J</i> = 8.79, 2H), 8.03 (s, 1H), 9.76 (s (br), 1H). <sup>13</sup>C NMR (76 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 44.16, 45.78, 54.37, 113.45, 113.54, 122.11, 127.57, 127.69, 128.52, 130.98, 137.16, 138.80, 139.30, 151.31, 151.74, 158.35.</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> <i>N</i><sup>2</sup>-(4-Amino-cyclohexyl)-<i>N</i><sup>6</sup>-(4-bromo-phenyl)-9-(tetrahydro-pyran-2-yl)-<i>9H</i>-purine-2,6-diamine (<b>6l</b>)</h4><div class="NLM_p last">Yield: 94% m.p.: 114-115 °C. Elemental analysis: Calcd for C<sub>22</sub>H<sub>28</sub>BrN<sub>7</sub>O (486.41): C, 54.32; H, 5.80; N, 20.16. Found: C, 54.38; H, 5.91 N, 19.84. HPLC-MS (ESI+): 488.3 (98.1%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.30–1.13 (m, 4H), 1.56–1.48 (m, 2H), 1.68–1.59 (m, 1H), 1.78 (d, <i>J</i> = 11.3, 2H), 1.97–1.82 (m, 3H), 2.58–2.49 (m, 1H), 3.63–3.52 (m, 1H), 3.96 (d, <i>J</i> = 12.4, 1H), 5.40 (d, <i>J</i> = 10.7, 1H), 6.60 (s, 1H), 7.40 (d, <i>J</i> = 8.6, 2H), 8.05–7.94 (m, 3H), 9.64 (s (br), 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 23.21, 25.10, 30.46, 31.75, 35.33, 50.46, 50.97, 68.18, 80.97, 80.97, 113.70, 113.82, 122.22, 131.44, 136.67, 140.40, 152.21, 158.91.</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 1-[6-(4-Bromo-phenylamino)-9-(tetrahydro-pyran-2-yl)-<i>9H</i>-purin-2-ylamino]-propan-2-ol (<b>6m</b>)</h4><div class="NLM_p last">Yield: 79%. m.p.: 127–128 °C. Elemental analysis: Calcd for C<sub>19</sub>H<sub>23</sub>BrN<sub>6</sub>O<sub>2</sub> (447.33): C, 51.01; H, 5.18; N, 18.79. Found: C, 51.12; H, 5.26 N, 18.57. HPLC-MS (ESI+): 449.2 (98.7%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.09 (d, <i>J</i> = 6.15, 3H), 1.54–1.58 (m, 2H), 1.63–1.70 (m, 1H), 1.88–1.95 (m, 2H), 2.21–2.28 (m, 1H), 3.15–3.26 (m, 2H), 3.62–3.66 (m, 1H), 3.84 (sep, <i>J</i> = 5.7, 1H), 3.98–4.02 (m, 1H), 4.71 (t, <i>J</i> = 10.26, 1H), 5.47 (d, <i>J</i> = 10.02, 1H), 6.62 (t, <i>J</i> = 5.34, 1H), 7.43 (d, <i>J</i> = 8.79, 2H), 8.01 (d, <i>J</i> = 8.79, 2H), 8.06 (s, 1H), 9.64 (s(br), 1H). <sup>13</sup>C NMR (76 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 21.30, 22.53, 24.48, 29.91, 49.24, 54.82, 65.27, 67.53, 80.33, 113.18, 113.50, 121.87, 130.87, 136.10, 139.64, 151.65, 159.02.</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (4-Bromo-phenyl)-[2-morpholin-4-yl-9-(tetrahydro-pyran-2-yl)-<i>9H</i>-purin-6-yl]-amine (<b>6n</b>)</h4><div class="NLM_p last">Yield: 72%. m.p.: 133–134 °C. Elemental analysis: Calcd for C<sub>20</sub>H<sub>23</sub>BrN<sub>6</sub>O<sub>2</sub> (459.34): C, 52.30; H, 5.05; N, 18.30. Found: C, 51.87; H, 4.91 N, 17.94. HPLC-MS (ESI+): 461.0 (97.2%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.52–1.56 (m, 2H), 1.67–1.71 (m, 1H), 1.89–1.97 (m, 2H), 2.18–2.29 (m, 1H), 3.64–3.69 (m, 9H), 3.99 (d, <i>J</i> = 11.43, 1H), 5.53 (d, <i>J</i> = 10.05, 1H), 7.48 (d, <i>J</i> = 8.76, 2H), 7.85 (d, <i>J</i> = 8.76, 2H), 8,15 (s, 1H), 9.80 (s (br), 1H). <sup>13</sup>C NMR (76 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 22.47, 24.51, 30.00, 44.73, 66.00, 67.53, 80.33, 113.56, 122.22, 131.01, 137.09, 139.17, 151.14, 151.32, 158.32.</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> (4-Bromo-phenyl)-[2-(4-methyl-piperazin-1-yl)-9-(tetrahydro-pyran-2-yl)-<i>9H</i>-purin-6-yl]-amine (<b>6o</b>)</h4><div class="NLM_p last">Yield: 95%. m.p.: 169–171 °C. Elemental analysis: Calcd for C<sub>21</sub>H<sub>26</sub>BrN<sub>7</sub>O (472.38): C, 53.39; H, 5.55; N, 20.76. Found: C, 53.61; H, 5.28 N, 20.49. HPLC-MS (ESI+): 473.5 (99.1%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ ppm 1.53–1.56 (m, 2H), 1.63–1.72 (m, 1H), 1.88–1.92 (m, 2H), 2.18–2.22 (m, 4H), 2.33–2.38 (m, 4H), 3.65–3.72 (m, 5H), 3.98 (d, <i>J</i> = 11.22, 1H), 5.56 (d, <i>J</i> = 6.54, 1H), 7.48 (d, <i>J</i> = 8.58, 2H), 7.84 (d, <i>J</i> = 8.58, 2H), 8.13 (s, 1H), 9.76 (s(br), 1H). <sup>13</sup>C NMR (76 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 22.46, 24.51, 30.06, 44.10, 45.79, 54.46, 67.51, 80.23, 113.44, 122.12, 131.00, 136.90, 139.24, 151.22, 158.26.</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> <i>N</i><sup>2</sup>-(4-Amino-cyclohexyl)-9-cyclopentyl-<i>N</i><sup>6</sup>-(4-pyrrolidin-1-yl-phenyl)-<i>9H</i>-purine-2,6-diamine (<b>7a</b>)</h4><div class="NLM_p last">Yield: 92%. m.p.: 216–217 °C. Elemental analysis: Calcd for C<sub>26</sub>H<sub>36</sub>N<sub>8</sub> (460.62): C, 67.80; H, 7.88; N, 24.33. Found: C, 67.71; H, 7.49; N, 24.01. HPLC-MS (ESI+): 461.7 (99.6%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.17–1.38 (m, 2H), 1.74–2.06 (m, 14H), 2.20–2.24 (m, 4H), 2.75 (sep, <i>J</i> = 4.26, 1H), 3.27–3.31 (m, 4H), 3.81 (sex, <i>J</i> = 5.97, 1H), 4.69–4.79 (m, 2H), 6.56 (d, <i>J</i> = 8.73, 2H), 7.36 (s(br), 1H), 7.52 (s, 1H), 7.58 (d, <i>J</i> = 8.73, 2H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 24.38, 24.51, 25.42, 31.84, 32.31, 35.78, 48.12, 50.57, 53.14, 55.10, 111.81, 121.34, 122.41, 123.09, 129.84, 136.51, 144.22, 152.67, 158.74.</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> <i>N</i><sup>2</sup>-(4-Amino-cyclohexyl)-9-cyclopentyl-<i>N</i><sup>6</sup>-(4-morpholin-4-yl-phenyl)-<i>9H</i>-purine-2,6-diamine (<b>7b</b>)</h4><div class="NLM_p last">Yield: 88%. m.p.: 189–191 °C. Elemental analysis: Calcd for C<sub>26</sub>H<sub>36</sub>N<sub>8</sub>O (476.62): C, 65.52; H, 7.61; N, 23.51. Found: C, 65.23; H, 7.58; N, 23.11. HPLC-MS (ESI+): 476.9 (99.0%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.05–0.97 (m, 4H), 1.73–1.60 (m, 2H), 1.88–1.78 (m, 2H), 1.99–1.89 (m, 2H), 2.19–2.08 (m, 2H), 2.33 (dd, <i>J</i> = 13.8, <i>J</i> = 6.8, 2H), 3.07 (d, <i>J</i> = 3.2, 4H), 3.31 (s, 3H), 3.45–3.36 (m, 1H), 4.37–4.30 (m, 1H), 4.78 (p, <i>J</i> = 7.4, 1H), 6.89 (d, <i>J</i> = 8.4, 2H), 7.57 (d, <i>J</i> = 8.1, 2H), 8.32 (s, 1H), 10.02 (s, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 12.52, 19.10, 24.03, 32.56, 49.08, 52.17, 52.88, 56.02, 56.55, 115.90, 119.39, 123.15, 130.87, 140.83, 148.13, 150.86, 152.78, 153.01.</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>N</i><sup>2</sup>-(4-Amino-cyclohexyl)-9-cyclopentyl-<i>N</i><sup>6</sup>-[4-(4-ethyl-piperazin-1-yl)-phenyl]-<i>9H</i>-purine-2,6-diamine (<b>7c</b>)</h4><div class="NLM_p last">Yield: 76%. m.p.: 105–108 °C. Elemental analysis: Calcd for C<sub>28</sub>H<sub>41</sub>N<sub>9</sub> (503.70): C, 66.77; H, 8.20; N, 25.03. Found: C, 66.84; H, 8.02; N, 25.32. HPLC-MS (ESI+): 504.8 (98.4%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.16 (t, <i>J</i> = 7.20, 3H,), 1.23–1.44 (m, 4H), 1.76–2.32 (m, 14H), 2.48 (q, <i>J</i> = 7.20, 2H), 2.60–2.66 (m, 4H), 2.85 (m, 1H), 3.20–3.22 (m, 4H), 3.80 (m, 1H), 4.70 (d, <i>J</i> = 5.25, 1H), 4.76 (qui, <i>J</i> = 6.83, 1H), 6.95 (d, <i>J</i> = 8.76, 1H), 7.40 (s (br), 1H), 7.45 (s, 1H), 7.66 (d, <i>J</i> = 8.76, 1H).</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> <i>N</i><sup>2</sup>-(4-Amino-cyclohexyl)-9-cyclopentyl-<i>N</i><sup>6</sup>-(4-morpholin-4-ylmethyl-phenyl)-<i>9H</i>-purine-2,6-diamine (<b>7d</b>)</h4><div class="NLM_p last">Yield: 94%. m.p.: 133–135 °C. Elemental analysis: Calcd for C<sub>27</sub>H<sub>38</sub>N<sub>8</sub>O (490.64): C, 66.09; H, 7.81; N, 22.84. Found: C, 66.04; H, 7.59; N, 22.61. HPLC-MS (ESI+): 491.65 (98.2%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.30–1.05 (m, 4H), 1.69–1.56 (m, 2H), 2.12–1.72 (m, 10H), 2.27–2.32 (m, 4H), 2.53 (t, <i>J</i> = 10.4, 1H), 3.36 (s, 2H), 3.50–3.56 (m, 4H), 3.68–3.56 (m, 1H), 4.72–4.59 (sep, <i>J</i> = 7.5, 1H), 6.39 (s(br), 1H), 7.15 (d, <i>J</i> = 8.0, 2H), 7.84 (s, 1H), 7.92 (d, <i>J</i> = 8.0, 2H), 9.32 (s(br), 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 24.31, 31.76, 32.29, 35.57, 50.53, 53.65, 55.34, 62.67, 66.74, 114.51, 120.25, 129.42, 131.24, 137.12, 139.90, 152.50, 158.63.</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> <i>N</i><sup>2</sup>-(4-Amino-cyclohexyl)-9-cyclopentyl-<i>N</i><sup>6</sup>-[4-(2-oxa-6-aza-spiro[3.3]hept-6-yl)-phenyl]-<i>9H</i>-purine-2,6-diamine (<b>7e</b>)</h4><div class="NLM_p last">Yield: 82%. m.p.: 146–147 °C. Elemental analysis: Calcd for C<sub>27</sub>H<sub>36</sub>N<sub>8</sub>O (488.63): C, 66.37; H, 7.43; N, 22.93. Found: C, 66.11; H, 7.08; N, 22.69. HPLC-MS (ESI+): 489.7 (98.3%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.67–2.07 (m, 14H), 2.11–2.18 (m, 2H), 2.45–2.50 (m, 4H), 4.71–4.74 (m, 4H), 3.92–3.94 (m, 4H), 4.83 (qui, <i>J</i> =  5.4, 1H), 5.48 (d, <i>J</i> = 5.44, 1H), 6.48 (d, <i>J</i> = 8.50, 2H), 7.55 (d, <i>J</i> = 8.50, 2H), 8.32 (s, 1H), 9.95 (s, 1H).</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> <i>N</i><sup>2</sup>-(4-Amino-cyclohexyl)-<i>N</i><sup>6</sup>-[4-(4-benzyl-piperazin-1-yl)-phenyl]-9-cyclopentyl-<i>9H</i>-purine-2,6-diamine (<b>7f</b>)</h4><div class="NLM_p last">Yield: 92%. m.p.: 149–150 °C. Elemental analysis: Calcd for C<sub>33</sub>H<sub>43</sub>N<sub>9</sub> (565.77): C, 70.06; H, 7.66; N, 22.28. Found: C, 69.82; H, 7.48; N, 22.01. HPLC-MS (ESI+): 568.8 (99.9%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.28–1.12 (m, 8H), 1.70–1.58 (m, 4H), 2.11–1.74 (m, 19H), 2.65–2.57 (m, 2H), 3.02 (t, <i>J</i> = 9.8, 7H), 3.49 (d, <i>J</i> = 3.3, 9H), 3.62–3.54 (m, 4H), 4.69–4.59 (m, 2H), 6.29 (s(br), 1H), 6.82 (d, <i>J</i> = 8.8, 4H), 7.26–7.19 (m, 2H), 7.32–7.28 (m, 8H), 7.84–7.74 (m, 6H), 9.10 (s(br), 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 31.49, 32.29, 34.18, 49.62, 50.29, 53.16, 62.61, 116.25, 121.62, 127.51, 128.73, 128.73, 129.47, 133.19, 138.60, 146.85, 158.66.</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> <i>N</i><sup>2</sup>-(4-Amino-butyl)-9-cyclopentyl-<i>N</i><sup>6</sup>-(4-morpholin-4-ylmethyl-phenyl)-<i>9H</i>-purine-2,6-diamine (<b>8a</b>)</h4><div class="NLM_p last">Yield: 85%. m.p.: 140–141 °C. Elemental analysis: Calcd for C<sub>25</sub>H<sub>36</sub>N<sub>8</sub>O (464.61): C, 64.63; H, 7.81; N, 24.12. Found: C, 64.47; H, 7.43; N, 23.88. HPLC-MS (ESI+): 465.8 (96.7%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.38–1.66 (m, 6H), 1.87–1.92 (m, 6H), 2.07–2.09 (m, 4H), 2.53 (t, <i>J</i> = 6.78,2H), 3.17 (q, <i>J</i> = 6.39, 2H), 3.30 (s, 2H), 3.39–3.55 (m, 4H), 4.69 (qui, <i>J</i> = 7.11, 1H), 6.64 (t, <i>J</i> = 5.34, 1H), 7.18 (d, <i>J</i> = 8.28, 2H), 7.88 (s, 1H), 7.95 (d, <i>J</i> = 8.28, 2H), 9.34 (s (br), 1H).</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> <i>N</i><sup>2</sup>-(5-Amino-pentyl)-9-cyclopentyl-<i>N</i><sup>6</sup>-(4-morpholin-4-ylmethyl-phenyl)-<i>9H</i>-purine-2,6-diamine (<b>8b</b>)</h4><div class="NLM_p last">Yield: 74%. m.p.: 118–120 °C. Elemental analysis: Calcd for C<sub>26</sub>H<sub>38</sub>N<sub>8</sub>O (478.63): C, 65.24; H, 8.00; N, 23.14. Found: C, 65.56; H, 8.05; N, 22.92. HPLC-MS (ESI+): 479.90 (99.7%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.33–1.44 (m, 4H), 1.52–1.56 (m, 2H), 1.63–1.70 (m, 2H), 1.87–2.35 (m, 8H), 2.31–2.34 (m, 4H), 2.53 (t, <i>J</i> = 6.42, 2H), 3.26 (q, <i>J</i> =  6.42, 2H), 3.40(s, 2H), 3.55–3.58 (m, 4H), 4.69 (qui, <i>J</i> = 7.80, 1H), 6.60 (t, <i>J</i> = 4.89, 1H), 7.18 (d, <i>J</i> = 8.40, 2H), 7.88 (s, 1H), 7.95 (d, <i>J</i> = 8.40, 2H), 9.33 (s (br), 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 24.25, 24.62, 29.79, 32.30, 33.36, 42.04, 53.64, 55.37, 62.66, 66.75, 114.56, 120.27, 129.43, 131.26, 136.98, 139.88, 152.22, 152.52, 158.20, 159.35.</div></div><div id="sec4_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> <i>N</i><sup>2</sup>-(6-Amino-hexyl)-9-cyclopentyl-<i>N</i><sup>6</sup>-(4-morpholin-4-ylmethyl-phenyl)-<i>9H</i>-purine-2,6-diamine (<b>8c</b>)</h4><div class="NLM_p last">Yield: 74%. m.p.: 135–136 °C. Elemental analysis: Calcd for C<sub>27</sub>H<sub>40</sub>N<sub>8</sub>O (492.66): C, 65.82; H, 8.18; N, 22.74. Found: C, 65.96; H, 8.02; N, 22.64. HPLC-MS (ESI+): 493.93 (99.4%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.25–1.34 (m, 6H), 1.51–1.57 (m, 2H), 1.63–1.70 (m, 2H), 1.87–2.09 (m, 6H), 2.31–2.35 (m, 4H), 3.00 (s(br), 2H), 3.26 (q, <i>J</i> =  6.75, 2H), 3.39 (s, 2H), 3.53–3.59 (m, 4H), 4.69 (qui, <i>J</i> = 6.96, 1H), 6.62 (t, <i>J</i> = 6.18, 1H), 7.17 (d, <i>J</i> = 8.25, 2H), 7.88 (s, 1H), 7.95 (d, <i>J</i> = 8.25, 2H), 9.32 (s(br), 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 24.26, 26.87, 27.18, 29.94, 32.29, 33.48, 41.97, 53.64, 55.40, 62.67, 66.76, 114.57, 120.26, 129.41, 131.25, 136.98, 139.89, 152.22, 152.52, 159.36.</div></div><div id="sec4_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> <i>N</i><sup>2</sup>-Benzyl-9-cyclopentyl-<i>N</i><sup>6</sup>-(4-morpholin-4-ylmethyl-phenyl)-<i>9H</i>-purine-2,6-diamine (<b>8d</b>)</h4><div class="NLM_p last">Yield: 48%. m.p.: 173–175 °C. Elemental analysis: Calcd for C<sub>28</sub>H<sub>33</sub>N<sub>7</sub>O (483.61): C, 69.54; H, 6.88; N, 20.27. Found: C, 69.28; H, 7.07; N, 20.02. HPLC-MS (ESI+): 484.7 (96.5%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.71–1.58 (m, 2H), 1.87–1.77 (m, 4H), 2.02–1.91 (m, 2H), 2.19–2.06 (m, 2H), 3.09–2.96 (m, 2H), 3.14–3.18 (m, 2H), 3.81–3.71 (m, 2H), 3.90 (d, <i>J</i> = 12.1, 2H), 4.10 (t, <i>J</i> = 5.6, 2H), 4.20 (s, 2H), 4.50 (s, 2H), 4.80(qui, <i>J</i> = 7.0, 1H), 7.18–7.21 (m, 2H), 7.27–7.38 (m, 7H), 7.59–7.47 (m, 2H), 8.34 (s, 1H), 9.03 (s, 1H), 9.62 (s, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 24.00, 31.82, 45.20, 50.31, 50.95, 59.06, 63.56120.14, 127.17, 127.24, 127.78, 128.75, 128.79, 129.14, 129.45, 130.67, 132.39, 132.61, 140.14, 140.60.</div></div><div id="sec4_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 9-Cyclopentyl-<i>N</i><sup>2</sup>-(4-methoxy-benzyl)-<i>N</i><sup>6</sup>-(4-morpholin-4-ylmethyl-phenyl)-<i>9H</i>-purine-2,6-diamine (<b>8e</b>)</h4><div class="NLM_p last">Yield: 64%. m.p.: 228–230 °C. Elemental analysis: Calcd for C<sub>29</sub>H<sub>34</sub>N<sub>6</sub>O<sub>2</sub> (513.63): C, 69.85; H, 6.87; N, 16.85. Found: C, 69.54; H, 6.59; N, 16.91. HPLC-MS (ESI+): 514.61 (95.5%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.68–1.58 (m, 2H), 1.86–1.78 (m, 2H), 1.99–1.89 (m, 2H), 2.10–2.01 (m, 2H), 2.28–2.32 (s, 4H), 3.51–3.56 (m, 4H), 3.65 (s, 3H), 3.71–3.68 (m, 2H), 4.38 (d, <i>J</i> = 6.0 2H), 4.66 (qui, <i>J</i> = 7.5, 1H), 6.80 (d, <i>J</i> = 8.5, 2H), 6.85–7.12 (m, 4H), 7.24 (d, <i>J</i> = 6.5, 3H), 7.82 (s, 2H), 7.86 (s, 1H), 9.30 (s, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 24.19, 32.23, 44.64, 53.61, 55.51, 62.62, 66.74, 113.91, 114.09, 120.37, 128.91, 129.14, 129.45, 129.91, 131.31, 133.65, 137.18, 139.67, 152.50, 158.39, 159.11.</div></div><div id="sec4_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> (9-Cyclopentyl-2-morpholin-4-yl-<i>9H</i>-purin-6-yl)-(4-morpholin-4-ylmethyl-phenyl)-amine (<b>8f</b>)</h4><div class="NLM_p last">Yield: 96%. m.p.: 274–276 °C. Elemental analysis: Calcd for C<sub>25</sub>H<sub>33</sub>N<sub>7</sub>O<sub>2</sub> (463.58): C, 64.77; H, 7.18; N, 21.15. Found: C, 64.69; H, 7.01; N, 21.42. HPLC-MS (ESI+): 465.69 (99.8%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.62–1.66 (m, 2H), 1.80–1.87 (m, 2H), 1.90–1.98 (m, 2H), 2.08–2.12 (m, 2H), 2.29–2.33 (m, 4H), 3.36 (s, 2H), 3.52–3.55 (m, 4H), 3.62–3.65 (m, 1H), 4.71 (qui, <i>J</i> = 7.5, 1H), 7.18 (d, <i>J</i> = 8.00, 2H), 7.80 (d, <i>J</i> = 8.00, 2H), 7.96 (s, 1H), 9.50 (s, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 24.31, 32.36, 45.44, 53.69, 55.45, 62.66, 66.60, 66.74, 114.90, 120.42, 129.54, 131.72, 138.11, 139.41, 151.92, 152.16, 158.77</div></div><div id="sec4_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> [9-Cyclopentyl-2-(4-methyl-piperazin-1-yl)-<i>9H</i>-purin-6-yl]-(4-morpholin-4-ylmethyl-phenyl)-amine (<b>8g</b>)</h4><div class="NLM_p last">Yield: 96%. m.p.: 248–250 °C. Elemental analysis: Calcd for C<sub>25</sub>H<sub>33</sub>N<sub>7</sub>O<sub>2</sub> (476.62): C, 65.52; H, 7.61; N, 23.51. Found: C, 65.74; H, 7.92; N, 23.37. HPLC-MS (ESI+): 478.83 (99.7%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.10 (s, 3H), 1.62–1.69 (m, 2H), 1.83–1.90 (m, 2H), 1.90–1.96 (m, 2H), 2.08–2.114 (m, 2H), 2.19 (s, 3H), 2.28–2.32 (m, 4H), 2.34–2.38 (m, 4H), 3.36 (s, 2H), 3.50–3.55 (m, 4H), 3.65–3.69 (m, 4H), 4.70 (qui, <i>J</i> = 7.50, 1H), 7.18 (d, <i>J</i> = 8.50, 2H), 7.79 (d, <i>J</i> = 8.50 2H), 7.95 (s, 1H), 9.47 (s, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 24.29, 32.39, 44.73, 46.34, 53.68, 54.97, 55.35, 62.65, 66.73, 114.66, 120.44, 129.54, 131.64, 137.92, 139.47, 152.01, 152.13, 158.67.</div></div><div id="sec4_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> (9-Cyclopentyl-2-piperidin-1-yl-<i>9H</i>-purin-6-yl)-(4-morpholin-4-ylmethyl-phenyl)-amine (<b>8h</b>)</h4><div class="NLM_p last">Yield: 96%. m.p.: 163–164 °C. Elemental analysis: Calcd for C<sub>26</sub>H<sub>35</sub>N<sub>7</sub>O (461.60): C, 67.65; H, 7.64; N, 21.24. Found: C, 67.29; H, 7.38; N, 21.03. HPLC-MS (ESI+): 463.78 (99.7%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.20 (s, 1H), 1.71–1.59 (m, 2H), 1.89–1.79 (m, 2H), 1.95 (td, <i>J</i> = 14.4, 7.0, 2H), 2.10 (td, <i>J</i> = 11.7, 6.7, 2H), 2.31 (s, 4H), 3.28 (s, 1H), 3.36 (s, 2H), 3.53 (t, <i>J</i> = 4.4, 4H), 3.68–3.61 (m, 9H), 4.71 (p, <i>J</i> = 7.7, 1H), 7.18 (d, <i>J</i> = 8.5, 2H), 7.80 (d, <i>J</i> = 8.5, 2H), 7.96 (s, 1H), 9.50 (s, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 24.31, 32.36, 45.43, 53.69, 55.44, 62.65, 66.59, 66.73, 114.89, 120.49, 129.54, 131.72, 138.10, 139.40, 151.91, 152.15, 158.76.</div></div><div id="sec4_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 2-[9-Cyclopentyl-6-(4-morpholin-4-ylmethyl-phenylamino)-<i>9H</i>-purin-2-ylamino]-ethanol (<b>8i</b>)</h4><div class="NLM_p last">Yield: 94%. m.p.: 127–128 °C. Elemental analysis: Calcd for C<sub>23</sub>H<sub>31</sub>N<sub>7</sub>O<sub>2</sub> (437.54): C, 63.14; H, 7.14; N, 22.41. Found: C, 63.28; H, 7.01; N, 22.30. HPLC-MS (ESI+): 439.60 (98.6%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.74–1.57 (m, 4H), 1.89–1.76 (m, 2H), 1.99–1.89 (m, 2H), 2.14–2.01 (m, 2H), 2.30 (s, 4H), 3.32–3.25 (s, 2H), 3.49–3.43 (m, 2H), 3.53 (s, 4H), 4.47 (t, <i>J</i> = 4.4, 1H), 4.66 (qui, <i>J</i> = 7.5, 1H), 6.54 (t, <i>J</i> = 5.1, 1H), 7.15 (d, <i>J</i> = 8.2, 2H), 7.86 (s, 1H), 7.91 (d, <i>J</i> = 8.2, 2H), 9.30 (s, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 24.21, 32.34, 33.07, 39.14, 53.64, 55.34, 59.43, 62.65, 66.73, 114.52, 120.26, 129.51, 131.27, 136.96, 139.83, 152.13, 152.50, 159.40.</div></div><div id="sec4_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 3-[9-Cyclopentyl-6-(4-morpholin-4-ylmethyl-phenylamino)-<i>9H</i>-purin-2-ylamino]-propan-1-ol (<b>8j</b>)</h4><div class="NLM_p last">Yield: 96%. m.p.: 136–139 °C. Elemental analysis: Calcd for C<sub>24</sub>H<sub>33</sub>N<sub>7</sub>O<sub>2</sub> (451.56): C, 63.84; H, 7.37; N, 21.71. Found: C, 63.49; H, 7.54; N, 21.42. HPLC-MS (ESI+): 452.63 (97.8%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.70–1.59 (m, 3H), 1.88–1.80 (m, 3H), 1.99–1.89 (m, 3H), 2.14–2.03 (m, 3H), 2.30 (s, 6H), 4.70–4.61 (m, 3H), 6.42 (t, <i>J</i> = 5.2, 1H), 7.15 (d, <i>J</i> = 8.1, 3H), 7.87 (s, 1H), 7.89 (d, <i>J</i> = 8.5, 3H), 9.31 (s, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 24.22, 32.33, 44.63, 53.65, 55.36, 60.63, 62.66, 66.73, 120.29, 129.52, 131.29, 137.07, 139.78, 152.52, 159.33.</div></div><div id="sec4_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 4-[9-Cyclopentyl-6-(4-morpholin-4-ylmethyl-phenylamino)-<i>9H</i>-purin-2-ylamino]-butan-1-ol (<b>8k</b>)</h4><div class="NLM_p last">Yield: 88%. m.p.: 119–121 °C. Elemental analysis: Calcd for C<sub>25</sub>H<sub>35</sub>N<sub>7</sub>O<sub>2</sub> (451.56): C, 64.49; H, 7.58; N, 21.06. Found: C, 64.49; H, 7.62; N, 20.85. HPLC-MS (ESI+): 466.49 (98.4%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.45 (qui, <i>J</i> = 6.5, 2H), 1.53 (qui, <i>J</i> = 6.5, 2H), 1.69–1.60 (m, 2H), 1.89–1.77 (m, 2H), 2.00–1.89 (m, 2H), 2.12–2.02 (m, 2H), 2.28–2.32 (m, 4H), 3.24 (q, <i>J</i> = 6.5, 2H), 3.48 (s, 2H), 3.51–3.57(m, 4H), 4.38 (t, <i>J</i> = 5.0, 1H), 4.66 (qui, <i>J</i> = 7.0, 1H), 6.58 (t, <i>J</i> = 5.4, 1H), 7.15 (d, <i>J</i> = 8.3, 2H), 7.85 (s, 1H), 7.91 (d, <i>J</i> = 8.3, 2H), 9.29 (s, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 24.25, 26.52, 30.76, 32.30, 41.77, 53.63, 55.36, 61.25, 62.72, 66.73, 112.78, 114.55, 120.24, 129.49, 131.26, 137.00, 139.92, 152.48, 159.37.</div></div><div id="sec4_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> <i>N</i><sup>2</sup>-(4-Amino-cyclohexyl)-9-cyclopentyl-<i>N</i><sup>6</sup>-(6-morpholin-4-yl-pyridin-3-yl)-<i>9H</i>-purine-2,6-diamine (<b>8l</b>)</h4><div class="NLM_p last">Yield: 94%. m.p.: 283–284 °C. Elemental analysis: Calcd for C<sub>25</sub>H<sub>35</sub>N<sub>9</sub>O (477.61): C, 62.87; H, 7.39; N, 26.39. Found: C, 62.61; H, 7.11; N, 26.02. HPLC-MS (ESI+): 478.57 (98.2%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.29–1.49 (m, 4H), 1.77–1.79 (m, 2H), 1.97–2.04 (m, 4H), 2.21–2.26 (m, 6H), 2.86 (sep, <i>J</i> =  5.26, 1H), 3.14–3.18 (m, 4H), 3.83 (sex, <i>J</i> = 4.02, 1H), 3.88–3.91 (m, 4H), 4.73 (qui, <i>J</i> =  5.74, 1H), 4.86 (d, <i>J</i> =  4.02, 1H), 6.91 (s, 1h), 7.46–7.49 (m, 2H), 8.02 (s, 1H), 8.26 (s(br), 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 30.98, 31.92, 32.27, 46.39, 49.84, 66.53, 107.07, 129.22, 131.27, 137.14, 140.49, 152.67, 155.60, 158.56.</div></div><div id="sec4_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 9-Cyclopentyl-2-morpholin-4-yl-<i>9H</i>-purin-6-yl)-(6-morpholin-4-yl-pyridin-3-yl)-amine (<b>8m</b>)</h4><div class="NLM_p last">Yield: 87%. m.p.: 220–222 °C. Elemental analysis: Calcd for C<sub>23</sub>H<sub>30</sub>N<sub>8</sub>O (450.54): C, 61.31; H, 6.71; N, 24.87. Found: C, 61.54; H, 6.48; N, 24.26. HPLC-MS (ESI+): 451.57 (97.6%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.61–1.67 (m, 2H), 1.83–1.83 (m, 2H), 1.91–1.96 (m, 2H), 2.07–2.09 (m, 2H), 3.38–3.40 (m, 4H), 3.61–3.68 (m, 12H), 4.70 (qui, <i>J</i> =  5.26, 1H), 6.80 (d, <i>J</i> = 9.0, 1H), 7.91–7.97 (m, 2H), 8.52 (s, 1H), 9.41 (s, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 24.23, 32.35, 45.34, 46.28, 55.56, 66.52, 107.19, 114.70, 128.54, 130.08, 131.77, 138.03, 140.68, 151.74, 152.29, 155.81, 158.84.</div></div><div id="sec4_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> <i>N</i><sup>2</sup>-(4-Amino-butyl)-9-cyclopentyl-<i>N</i><sup>6</sup>-(4-morpholin-4-yl-phenyl)-9<i>H</i>-purine-2,6-diamine (<b>8n</b>)</h4><div class="NLM_p last">Yield: 88%. m.p.: 237–239 °C. Elemental analysis: Calcd for C<sub>24</sub>H<sub>34</sub>N<sub>8</sub>O (450.58): C, 63.97; H, 7.61; N, 24.87. Found: C, 64.11; H, 7.38; N, 24.59. HPLC-MS (ESI+): 451.8 (100.0%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.39–1.45 (m, 2H), 1.54–1.59 (m, 2H), 1.65–1.69 (m, 2H), 1.87–2.10 (m, 6H), 2.58 (t, <i>J</i> = 6.60, 2H), 2.97 (s(br), 2H), 3.02–3.05 (m, 4H), 3.27 (q, <i>J</i> = 6.36, 2H), 3.72–3.75 (m, 4H), 4.68 (qui, <i>J</i> = 7.26, 1H), 6.86 (d, <i>J</i> = 8.94, 2H), 7.81 (d, <i>J</i> =  8.94, 2H), 7.85 (s, 1H), 9.14 (s(br), 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 24.24, 27.35, 30.89, 32.32, 41.86, 49.77, 55.34, 66.71, 114.40, 115.87, 121.70, 133.41, 136.65, 146.80, 151.99, 152.59, 157.99, 159.40.</div></div><div id="sec4_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> <i>N</i><sup>2</sup>-(4-amino-butyl)-9-cyclopentyl-<i>N</i><sup>6</sup>-[4-(4-ethyl-piperazin-1-yl)-phenyl]-9<i>H</i>-purine-2,6-diamine (<b>8o</b>)</h4><div class="NLM_p last">Yield: 92%. m.p.: 163–165 °C. Elemental analysis: Calcd for C<sub>26</sub>H<sub>39</sub>N<sub>9</sub> (477.65): C, 65.38; H, 8.23; N, 26.39. Found: C, 65.29; H, 7.89; N, 26.39. HPLC-MS (ESI+): 478.91 (96.7%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.02 (t, <i>J</i> = 7.11, 3H), 1.38–1.42 (m, 2H), 1.51–1.57 (m, 2H), 1.63–1.68 (m, 2H), 1.85–2.09 (m, 6H), 2.35 (q, <i>J</i> = 7.11, 2H), 2.55 (t, <i>J</i> = 7.26, 2H), 2.98 (s(br), 2H), 3.03–3.06 (m, 4H), 3.22–3.29 (m, 6H), 4.67 (qui, <i>J</i> = 7.62, 1H), 6.52 (t, <i>J</i> = 5.94, 1H), 6.85 (d, <i>J</i> = 8.70, 2H), 7.80 (d, <i>J</i> = 8.70, 2H), 7.85 (s, 1H), 9.11 (s(br), 1H). <sup>13</sup>C NMR (76 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.94, 23.62, 26.74, 31.69, 40.05, 46.28, 48.88, 51.56, 52.36, 54.28, 112.18, 115.43, 121.10, 132.43, 136.20, 146.23, 151.97, 158.81.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Kinase Assays</h3><div class="NLM_p last">FLT3 WT, FLT3 ITD, and FLT3 D835Y were purchased from ProQinase. The kinase reactions were assayed with peptide substrate (1 mg/mL AGLT (poly(Ala,Glu,Lys,Tyr) 6:2:5:1 hydrobromide) in the presence of 1 μM ATP, 0.05 μCi [γ-<sup>33</sup>P]ATP, and the test compound in a final volume of 10 μL, all in a reaction buffer (60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl<sub>2</sub>, 3 mM MnCl<sub>2</sub>, 3 μM Na-orthovanadate, 1.2 mM DTT, 2.5 μg/50 μL PEG<sub>20.000</sub>). The reactions were stopped by adding 5 μL of 3% aq. H<sub>3</sub>PO<sub>4</sub>. Aliquots were spotted onto P-81 phosphocellulose (Whatman), washed 3× with 0.5% aq. H<sub>3</sub>PO<sub>4</sub>, and finally air-dried. Kinase inhibition was quantified using a FLA-7000 digital image analyzer. The concentration of the test compounds required to reduce the kinase’s activity by 50% was determined from dose–response curves and reported as the IC<sub>50</sub> value.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Kinase Selectivity Profiling</h3><div class="NLM_p last">Preliminary protein kinase selectivity of compound <b>7d</b> was evaluated at a single concentration (10 nM) by screening against 309 enzymes at Carna Biosciences.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Cell Culture</h3><div class="NLM_p last">Human cell lines were obtained from the American Type Culture Collection or the German Collection of Microorganisms and Cell Cultures and were cultivated according to the provider’s instructions. Briefly, MV4-11, MOLM-13, and THP-1, U937 were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum, penicillin (100 U/mL), and streptomycin (100 μg/mL). Kasumi-1 and HCC-827 were maintained in RPMI-1640 medium supplemented with 20% fetal bovine serum, penicillin (100 U/mL), and streptomycin (100 μg/mL). K562, MCF-7, and BJ cell lines were cultivated in DMEM medium supplemented with 10% fetal bovine serum, penicillin (100 U/mL), and streptomycin (100 μg/mL). MRC-5 cells were cultivated in EMEM medium supplemented with 10% fetal bovine serum, 1% NEAA, penicillin (100 U/mL), and streptomycin (100 μg/mL). Human umbilical vein endothelial cells (HUVEC) were isolated and cultivated as described previously.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Murine parental Ba/F3 cell line was maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum, penicillin (100 U/mL), streptomycin (100 μg/mL), and murine IL-3 (2 ng/mL). Ba/F3 FLT3-ITD cells were cultivated in RPMI-1640 medium supplemented with 10% fetal bovine serum, penicillin (100 U/mL), and streptomycin (100 μg/mL).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> All cell lines were cultivated at 37 °C in 5% CO<sub>2</sub>.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Cell Viability Assays</h3><div class="NLM_p last">For the cytotoxicity assays, cells were treated in triplicate with six different doses of each compound for 72 h. After treatments, Calcein AM solution was added for 1 h, and fluorescence from live cells was measured at 485 nm/538 nm (excitation/emission) using a Fluoroskan Ascent microplate reader (Labsystems). The GI<sub>50</sub> value, the drug concentration lethal to 50% of the cells, was calculated from the dose response curves that resulted from the assays.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Flow Cytometry</h3><div class="NLM_p last">Asynchronous cells were seeded and, after a pre-incubation period, treated with tested compounds for 24 h. After the staining with propidium iodide, DNA content was analyzed by flow cytometry using a 488 nm laser (BD FACS Verse with software BD FACSuiteTM, version 1.0.6.). Cell cycle distribution was analyzed using ModFit LT (Verity Software House).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Immunoblotting</h3><div class="NLM_p last">Cell lysates were prepared, and then proteins were separated on SDS-polyacrylamide gels and electroblotted onto nitrocellulose membranes. After blocking, overnight incubation with specific primary antibodies, and incubation with peroxidase-conjugated secondary antibodies, peroxidase activity was detected with SuperSignal West Pico reagents (Thermo Scientific) using a CCD camera LAS-4000 (Fujifilm). The following specific antibodies were purchased from Cell signaling: anti-FLT3 (8F2) and anti-phospho-FLT3 Y589/591 (30D4), anti-phospho-FLT3 Y591 (33G6), anti-phospho-FLT3 Y842 (10A8), anti-STAT5, anti-phospho-STAT5 Y694, anti-ERK1/2, anti-phospho-ERK1/2 T202/Y204, anti-MEK1/2 (D1A5), anti-phospho-MEK1/2 S217/221 (41G9), anti-AKT (C67E7), and anti-phospho-AKT S473 (D9E). Anti-GAPDH was purchased from Sigma-Aldrich, and anti-PCNA (clone PC-10) was generously gifted by Dr. B. Vojtěšek.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Caspase-3/7 Assay</h3><div class="NLM_p last">Cellular caspase-3/7 activity was measured according to a previously published procedure.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> MV4-11 and K562 cells were cultivated in a 96-well plate overnight. On the next day, the cells were treated with increasing concentrations of compound <b>7d</b> for 24 h. After incubation, 3× caspase-3/7 assay buffer (150 mM HEPES pH 7.4, 450 mM NaCl, 150 mM KCl, 30 mM MgCl<sub>2</sub>, 1.2 mM EGTA, 1.5% Nonidet P40, 0.3% CHAPS, 30% sucrose, 30 mM DTT, 3 mM PMSF) containing 150 μM peptide substrate Ac-DEVD-AMC (Enzo Life Sciences) was added, and after 2 h incubation, the caspase-3/7 activity was measured using a Fluoroskan Ascent microplate reader (Labsystems) at 346 nm/442 nm (excitation/emission).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> In Vivo Efficacy</h3><div class="NLM_p">Female athymic nu/nu mice (ENVIGO) were subcutaneously implanted with MV4-11 (5 × 10<sup>6</sup> cells in log-phase) in a mixture with Matrigel (Corning) on day 0. Body weights and tumor growth were assessed 3 times per week. The latter was measured by caliperation (using vernier caliper), and tumor volumes were calculated using the formula: tumor volume [mm<sup>3</sup>] = width<sup>2</sup> × (length/2) [mm; mm]. The treatment began when the tumors reached a mean volume of about 640 mm<sup>3</sup> (approximately 14 days after inoculation). Quizartinib and <b>7d</b> were formulated in saline or acidified saline (pH 6.8 for application) and were administered as single doses of 10 mg/kg by intraperitoneal (i.p.) injection. Control animals received saline only. The tumors were harvested at various post-treatment intervals, and after harvesting, they were mechanically disintegrated and lysed in ice cold lysis buffer. Proteins from the lysates (50 μg of total protein) were separated by SDS/PAGE, transferred to a nitrocellulose membrane, and immunoblotted with specific primary antibodies at 4 °C overnight. The HRP-conjugated secondary antibodies used for detection were incubated with membrane for 1 h at RT, and immunoblots were scanned using a Li-COR system (Li-COR Biosciences).</div><div class="NLM_p last">All aspects of the animal study met the accepted criteria for the care and experimental use of laboratory animals, and protocols were reviewed by the Ethical Committee of Faculty of Medicine and Dentistry, Palacky University in Olomouc and approved by the Ministry of Education, Youth and Sports of the Czech Republic.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Homology Modeling and Molecular Docking</h3><div class="NLM_p last">The X-ray crystal structure of FLT3 available from PDB (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB">1RJB</a>) is in an inactive conformation. We have therefore built the active DFG-in conformation of FLT3 by homology modeling based on the c-KIT kinase template (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG">1PKG</a>). The dimer of active c-KIT contains two identical chains, chain A was selected. With default setting of Prime in Schrodinger 2017 we built the homology model and subjected it to energy minimization using the OPLS3 all-atom force field.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The docking was carried out with Glide using the homology model structure (Schrodinger Suite; Small-Molecule Drug Discovery Suite 2016–1, Schrödinger, LLC, New York, NY, 2016). FLT3 model was checked for steric clashes as well as for correct protonation states and hydrogen bonding patterns.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> No explicit water molecules were present. The protein grid was created using default settings. All ligands were converted from 2D to 3D using Ligprep module (Schrodinger Suite). Docking was performed with Glide (version 75103) in standard precision (SP) mode with flexible ligand docking and verified by induced fit docking (IFD) (Schrodinger Suite 2017; Schrodinger LLC, New York, NY). The first stage of IFD protocol performed an initial softened-potential docking of the ligand to rigid receptor, with van der Waals radii scaling of 0.50 for both FLT3 kinase homology model and ligands. Sampling of the protein for each of top 20 ligand poses was performed using Prime. Residues within 5 Å of any ligand were refined, and this consisted of the side chain conformational search and optimization, followed by full minimization of the residues and ligand. Complexes within 30.0 kcal/mol of minimum energy structure were taken forward for redocking. The related ligand was redocked into each low energy, induced-fit structure with default Glide settings.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i83"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01529" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64252" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64252" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b01529" class="ext-link">10.1021/acs.jmedchem.7b01529</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">FLT3 model with docked lead compound <b>7d</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01529/suppl_file/jm7b01529_si_001.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01529/suppl_file/jm7b01529_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Mean and SD values of enzyme–inhibitory and antiproliferative activities of novel compounds, preliminary kinase selectivity profile of <b>7d</b>, control experiments with quizartinib (FLT3 and its downstream signaling pathway inhibition, cell cycle in the MV4-11 cell line), quantification of phosphorylation levels in cell lysates and tumor tissue harvested from xenografts, NMR spectra of prepared compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01529/suppl_file/jm7b01529_si_003.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01529/suppl_file/jm7b01529_si_001.pdb">jm7b01529_si_001.pdb (201.02 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01529/suppl_file/jm7b01529_si_002.csv">jm7b01529_si_002.csv (2.7 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01529/suppl_file/jm7b01529_si_003.pdf">jm7b01529_si_003.pdf (13.61 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b01529" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18263" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18263" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vladimír Kryštof</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Growth Regulators, Centre of the Region Haná for Biotechnological
and Agricultural Research, Palacký
University and Institute of Experimental Botany AS CR, Šlechtitelů 27, 783 71 Olomouc, Czech Republic</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5838-2118" title="Orcid link">http://orcid.org/0000-0001-5838-2118</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a8dec4c9ccc1c5c1da86c3dad1dbdcc7cee8ddd8c7c486cbd2"><span class="__cf_email__" data-cfemail="aed8c2cfcac7c3c7dc80c5dcd7dddac1c8eedbdec1c280cdd4">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tomáš Gucký</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical Biology and Genetics, Centre of the Region Haná
for Biotechnological and Agricultural Research, Faculty of Science, Palacký University, Šlechtitelů 27, 783 71 Olomouc, Czech Republic</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eva Řezníčková</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Growth Regulators, Centre of the Region Haná for Biotechnological
and Agricultural Research, Palacký
University and Institute of Experimental Botany AS CR, Šlechtitelů 27, 783 71 Olomouc, Czech Republic</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tereza Radošová Muchová</span> - <span class="hlFld-Affiliation affiliation">Department
of Biology, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 3, 775 15 Olomouc, Czech Republic</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Radek Jorda</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Growth Regulators, Centre of the Region Haná for Biotechnological
and Agricultural Research, Palacký
University and Institute of Experimental Botany AS CR, Šlechtitelů 27, 783 71 Olomouc, Czech Republic</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zuzana Klejová</span> - <span class="hlFld-Affiliation affiliation">Department
of Biology, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 3, 775 15 Olomouc, Czech Republic</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Veronika Malínková</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical Biology and Genetics, Centre of the Region Haná
for Biotechnological and Agricultural Research, Faculty of Science, Palacký University, Šlechtitelů 27, 783 71 Olomouc, Czech Republic</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karel Berka</span> - <span class="hlFld-Affiliation affiliation">Department
of Physical Chemistry, Regional Centre of Advanced Technologies and
Materials, Faculty of Science, Palacky University, 17. listopadu 12, 771 46 Olomouc, Czech Republic</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9472-2589" title="Orcid link">http://orcid.org/0000-0001-9472-2589</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Václav Bazgier</span> - <span class="hlFld-Affiliation affiliation">Department
of Physical Chemistry, Regional Centre of Advanced Technologies and
Materials, Faculty of Science, Palacky University, 17. listopadu 12, 771 46 Olomouc, Czech Republic</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haresh Ajani</span> - <span class="hlFld-Affiliation affiliation">Department
of Physical Chemistry, Regional Centre of Advanced Technologies and
Materials, Faculty of Science, Palacky University, 17. listopadu 12, 771 46 Olomouc, Czech Republic</span>; 
    <span class="hlFld-Affiliation affiliation">Institute
of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 166 10 Prague 6, Czech Republic</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1223-3819" title="Orcid link">http://orcid.org/0000-0002-1223-3819</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin Lepšík</span> - <span class="hlFld-Affiliation affiliation">Institute
of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 166 10 Prague 6, Czech Republic</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vladimír Divoký</span> - <span class="hlFld-Affiliation affiliation">Department
of Biology, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 3, 775 15 Olomouc, Czech Republic</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>T.G. and E.Ř. contributed equally. T.G. and V.M. prepared compounds, E.Ř. and R.J. performed biochemical and cellular experiments, T.R.M. and Z.K. performed animal experiments, V.B., K.B., H.A., and M.L. performed computational experiments, and V.D. and V.K. designed the study and drafted the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ACK-d248e4903-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i85">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67333" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67333" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors wish to acknowledge the support of the Ministry of Education, Youth and Sports of the Czech Republic (National Program of Sustainability I, LO1204), from the Large Infrastructures for Research, Experimental Development and Innovations (IT4Innovations National Supercomputing Center, LM2015070), ELIXIR CZ research infrastructure project (MEYS Grant No: LM2015047) including access to computing and storage facilities, the Ministry of Health of the Czech Republic (15-28951A), and Palacký University in Olomouc (IGA_PrF_2018_032, IGA_PrF_2018_006). HUVECs were kindly provided by Prof. J. Ulrichová (Palacký University, Olomouc, Czech Republic). Murine parental Ba/F3 cells and Ba/F3 cells stably transfected with FLT3-ITD were kindly provided by Prof. J. Duyster and Prof. R. Zeiser, respectively (University of Freiburg, Germany). H.A. and M.L. thank the Czech Academy of Sciences (RVO 61388963) and the European Regional Development Fund (OP RDE CZ.02.1.01/0.0/0.0/16_019/0000729).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">CDK</td><td class="NLM_def"><p class="first last">cyclin-dependent kinase</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase</p></td></tr><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">FMS-like tyrosine kinase 3</p></td></tr><tr><td class="NLM_term">GAPDH</td><td class="NLM_def"><p class="first last">glyceraldehyde-3-phosphate dehydrogenase</p></td></tr><tr><td class="NLM_term">HUVEC</td><td class="NLM_def"><p class="first last">human umbilical vein endothelial cells</p></td></tr><tr><td class="NLM_term">ITD</td><td class="NLM_def"><p class="first last">internal tandem duplication</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">PARP-1</td><td class="NLM_def"><p class="first last">poly(ADP-ribose) polymerase 1</p></td></tr><tr><td class="NLM_term">PCNA</td><td class="NLM_def"><p class="first last">proliferating cell nuclear antigen</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">TRK</td><td class="NLM_def"><p class="first last">tropomyosin receptor kinase</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i87">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72262" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72262" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 30 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, N.</span></span> <span> </span><span class="NLM_article-title">Realizing the promise of cancer predisposition genes</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>505</i></span>,  <span class="NLM_fpage">302</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1038/nature12981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1038%2Fnature12981" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=505&publication_year=2014&pages=302-308&author=N.+Rahman&title=Realizing+the+promise+of+cancer+predisposition+genes&doi=10.1038%2Fnature12981"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnature12981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12981%26sid%3Dliteratum%253Aachs%26aulast%3DRahman%26aufirst%3DN.%26atitle%3DRealizing%2520the%2520promise%2520of%2520cancer%2520predisposition%2520genes%26jtitle%3DNature%26date%3D2014%26volume%3D505%26spage%3D302%26epage%3D308%26doi%3D10.1038%2Fnature12981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J.</span></span> <span> </span><span class="NLM_article-title">The roles of FLT3 in hematopoiesis and leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">1532</span>– <span class="NLM_lpage">1542</span>, <span class="refDoi"> DOI: 10.1182/blood-2002-02-0492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1182%2Fblood-2002-02-0492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=12176867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslyhsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2002&pages=1532-1542&author=D.+Gillilandauthor=J.+Griffin&title=The+roles+of+FLT3+in+hematopoiesis+and+leukemia&doi=10.1182%2Fblood-2002-02-0492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The roles of FLT3 in hematopoiesis and leukemia</span></div><div class="casAuthors">Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1532-1542</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">FLT3 is a receptor tyrosine kinase expressed by immature hematopoietic cells and is important for the normal development of stem cells and the immune system.  The ligand for FLT3 is expressed by marrow stromal cells and other cells and synergized with other growth factors to stimulate proliferation of stem cells, progenitor cells, dendritic cells, and natural killer cells.  Mutations of FLT3 have been detected in about 30% of patients with acute myelogenous leukemia and a small no. of patients with acute lymphocytic leukemia or myelodysplastic syndrome.  Patients with FLT3 mutations tend to have a poor prognosis.  The mutations most often involve small tandem duplications of amino acids within the juxtamembrane domain of the receptor and result in constitutive tyrosine kinase activity.  Expression of a mutant FLT3 receptor in murine marrow cells results in a lethal myeloproliferative syndrome and preliminary studies suggest that mutant FLT3 cooperates with other leukemia oncogenes to confer a more aggressive phenotype.  Taken together, these results suggest that FLT3 is an attractive therapeutic target for kinase inhibitors or other approaches for patients with mutations of this gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYQc2WkC8EQbVg90H21EOLACvtfcHk0ljbGS2UekP8Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslyhsLc%253D&md5=f6d04b227f5c5baf5c22cfba6e693ff1</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1182%2Fblood-2002-02-0492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2002-02-0492%26sid%3Dliteratum%253Aachs%26aulast%3DGilliland%26aufirst%3DD.%26aulast%3DGriffin%26aufirst%3DJ.%26atitle%3DThe%2520roles%2520of%2520FLT3%2520in%2520hematopoiesis%2520and%2520leukemia%26jtitle%3DBlood%26date%3D2002%26volume%3D100%26spage%3D1532%26epage%3D1542%26doi%3D10.1182%2Fblood-2002-02-0492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabs, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civin, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span> <span> </span><span class="NLM_article-title">Localization of the human stem cell tyrosine kinase-1 gene (FLT3) to 13Q12-->Q13</span>. <i>Cytogenet. Cell Genet.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1159/000134046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1159%2F000134046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=7789184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADyaK2MXnsF2quro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1995&pages=255-257&author=C.+Carowauthor=E.+Kimauthor=A.+Hawkinsauthor=H.+Webbauthor=C.+Griffinauthor=E.+Jabsauthor=C.+I.+Civinauthor=D.+Small&title=Localization+of+the+human+stem+cell+tyrosine+kinase-1+gene+%28FLT3%29+to+13Q12%2D%2D%3EQ13&doi=10.1159%2F000134046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Localization of the human stem cell tyrosine kinase-1 gene (FLT3) to 13q12→q13</span></div><div class="casAuthors">Carow, C. E.; Kim, E.; Hawkins, A. L.; Webb, H. D.; Griffin, C. A.; Jabs, E. W.; Civin, C. I.; Small, D.</div><div class="citationInfo"><span class="NLM_cas:title">Cytogenetics and Cell Genetics</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">255-7</span>CODEN:
                <span class="NLM_cas:coden">CGCGBR</span>;
        ISSN:<span class="NLM_cas:issn">0301-0171</span>.
    
            (<span class="NLM_cas:orgname">Karger</span>)
        </div><div class="casAbstract">The authors have previously reported the cloning of stem cell tyrosine kinase-1 (STK-1, gene symbol FLT3), the human homolog of the mouse Flk2/Flt3 gene (Small et al., 1994).  This growth factor receptor is expressed in CD34+ human bone marrow (stem/progenitor) cells.  The authors have mapped the gene for STK-1 using PCR screening of a human-rodent somatic cell hybrid panel, and fluorescence in situ mol. hybridization (FISH) of STK-1 genomic probes to mitotic chromosomes of normal human lymphocytes.  The results of both analyses show that the gene for STK-1 (FLT3) localizes to chromosome 13q12→q13.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRJa_lpqYqSbVg90H21EOLACvtfcHk0ljbGS2UekP8Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnsF2quro%253D&md5=200dafceeae2d055045e814f93f3106c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1159%2F000134046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000134046%26sid%3Dliteratum%253Aachs%26aulast%3DCarow%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DE.%26aulast%3DHawkins%26aufirst%3DA.%26aulast%3DWebb%26aufirst%3DH.%26aulast%3DGriffin%26aufirst%3DC.%26aulast%3DJabs%26aufirst%3DE.%26aulast%3DCivin%26aufirst%3DC.%2BI.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DLocalization%2520of%2520the%2520human%2520stem%2520cell%2520tyrosine%2520kinase-1%2520gene%2520%2528FLT3%2529%2520to%252013Q12--%253EQ13%26jtitle%3DCytogenet.%2520Cell%2520Genet.%26date%3D1995%26volume%3D70%26spage%3D255%26epage%3D257%26doi%3D10.1159%2F000134046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiike, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonoda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misawa, S.</span></span> <span> </span><span class="NLM_article-title">Internal tandem duplication of the flt3 gene found in acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1911</span>– <span class="NLM_lpage">1918</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=8946930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A280%3ADyaK2s7gt1Kqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1996&pages=1911-1918&author=M.+Nakaoauthor=S.+Yokotaauthor=T.+Iwaiauthor=H.+Kanekoauthor=S.+Horiikeauthor=K.+Kashimaauthor=Y.+Sonodaauthor=T.+Fujimotoauthor=S.+Misawa&title=Internal+tandem+duplication+of+the+flt3+gene+found+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Internal tandem duplication of the flt3 gene found in acute myeloid leukemia</span></div><div class="casAuthors">Nakao M; Yokota S; Iwai T; Kaneko H; Horiike S; Kashima K; Sonoda Y; Fujimoto T; Misawa S</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1911-8</span>
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    </div><div class="casAbstract">We analyzed mRNA expression of the flt3 gene in 30 patients with acute myeloid leukemia (AML) and 50 with acute lymphoblastic leukemia (ALL).  Using reverse transcriptase-polymerase chain reaction (RT-PCR), expression of flt3 was observed in 61 patients; 22 (73%) with AML and 39 (78%) with ALL.  Among these, five patients with AML (one M2, two M4, and two M5) showed unexpected longer transcripts with a primer combination which could amplify the transmembrane (TM) domain through the juxtamembrane (JM) domain.  For those patients who expressed flt3 mRNA, the extracellular domain of the flt3 gene was also examined by RT-PCR, but no length abnormality was seen in this region.  We further analyzed the TM domain through the second tyrosine kinase domain by genomic amplifications.  The five patients who showed aberrant flt3 transcripts exhibited abnormal longer PCR products in addition to the germline products at a region corresponding to the JM through the first TK (TK1) domains.  Sequence analyses of the abnormal RT-PCR products demonstrated that partial sequences were tandemly duplicated.  Because all these altered transcripts were in-frame, deduced protein products could be expected.  Sequence analyses of the genomic DNA revealed that three of the five patients showed a simple internal duplication within exon 11; one had an internal duplication (26 bp) with a 4-bp insertion; and in the fifth patient, a 136-bp sequence from the 3' part of exon 11 to intron 11 and the first 16-bp sequence of exon 12 were each duplicated with 1-bp insertion.  In order to confirm the tumor specificity of these alterations, DNA samples obtained at complete remission were also analyzed in the three patients harboring an flt3 duplication, but no abnormal PCR product other than germline was detected in any of the samples.  Our results suggest that an internal tandem duplication at the JM/TK1 domains of the flt3 gene is a somatic change detected preferentially in AML, possibly containing a monocytic component.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQL5G2hUkeODSA3UY9EwTNrfW6udTcc2ebGsgKSzhT84bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s7gt1Kqsg%253D%253D&md5=da0c7f21e6c4daf68bd4b1ae38a92891</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNakao%26aufirst%3DM.%26aulast%3DYokota%26aufirst%3DS.%26aulast%3DIwai%26aufirst%3DT.%26aulast%3DKaneko%26aufirst%3DH.%26aulast%3DHoriike%26aufirst%3DS.%26aulast%3DKashima%26aufirst%3DK.%26aulast%3DSonoda%26aufirst%3DY.%26aulast%3DFujimoto%26aufirst%3DT.%26aulast%3DMisawa%26aufirst%3DS.%26atitle%3DInternal%2520tandem%2520duplication%2520of%2520the%2520flt3%2520gene%2520found%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D1996%26volume%3D10%26spage%3D1911%26epage%3D1918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stirewalt, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopecky, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meshinchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogosova-Agadjanyan, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linsley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slovak, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willman, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radich, J. P.</span></span> <span> </span><span class="NLM_article-title">Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">3724</span>– <span class="NLM_lpage">3726</span>, <span class="refDoi"> DOI: 10.1182/blood-2005-08-3453</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1182%2Fblood-2005-08-3453" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2006&pages=3724-3726&author=D.+L.+Stirewaltauthor=K.+J.+Kopeckyauthor=S.+Meshinchiauthor=J.+H.+Engelauthor=E.+L.+Pogosova-Agadjanyanauthor=J.+Linsleyauthor=M.+L.+Slovakauthor=C.+L.+Willmanauthor=J.+P.+Radich&title=Size+of+FLT3+internal+tandem+duplication+has+prognostic+significance+in+patients+with+acute+myeloid+leukemia&doi=10.1182%2Fblood-2005-08-3453"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-08-3453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-08-3453%26sid%3Dliteratum%253Aachs%26aulast%3DStirewalt%26aufirst%3DD.%2BL.%26aulast%3DKopecky%26aufirst%3DK.%2BJ.%26aulast%3DMeshinchi%26aufirst%3DS.%26aulast%3DEngel%26aufirst%3DJ.%2BH.%26aulast%3DPogosova-Agadjanyan%26aufirst%3DE.%2BL.%26aulast%3DLinsley%26aufirst%3DJ.%26aulast%3DSlovak%26aufirst%3DM.%2BL.%26aulast%3DWillman%26aufirst%3DC.%2BL.%26aulast%3DRadich%26aufirst%3DJ.%2BP.%26atitle%3DSize%2520of%2520FLT3%2520internal%2520tandem%2520duplication%2520has%2520prognostic%2520significance%2520in%2520patients%2520with%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2006%26volume%3D107%26spage%3D3724%26epage%3D3726%26doi%3D10.1182%2Fblood-2005-08-3453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pemmaraju, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span> <span> </span><span class="NLM_article-title">FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">3293</span>– <span class="NLM_lpage">3304</span>, <span class="refDoi"> DOI: 10.1002/cncr.25908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1002%2Fcncr.25908" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=3293-3304&author=N.+Pemmarajuauthor=H.+Kantarjianauthor=F.+Ravandiauthor=J.+Cortes&title=FLT3+inhibitors+in+the+treatment+of+acute+myeloid+leukemia%3A+the+start+of+an+era%3F&doi=10.1002%2Fcncr.25908"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fcncr.25908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.25908%26sid%3Dliteratum%253Aachs%26aulast%3DPemmaraju%26aufirst%3DN.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DFLT3%2520inhibitors%2520in%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%253A%2520the%2520start%2520of%2520an%2520era%253F%26jtitle%3DCancer%26date%3D2011%26volume%3D117%26spage%3D3293%26epage%3D3304%26doi%3D10.1002%2Fcncr.25908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wander, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fathi, A. T.</span></span> <span> </span><span class="NLM_article-title">The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond</span>. <i>Ther. Adv. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1177/2040620714532123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1177%2F2040620714532123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=24883179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1SlsrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=65-77&author=S.+A.+Wanderauthor=M.+J.+Levisauthor=A.+T.+Fathi&title=The+evolving+role+of+FLT3+inhibitors+in+acute+myeloid+leukemia%3A+quizartinib+and+beyond&doi=10.1177%2F2040620714532123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond</span></div><div class="casAuthors">Wander, Seth A.; Levis, Mark J.; Fathi, Amir T.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Hematology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">65-77</span>CODEN:
                <span class="NLM_cas:coden">TAHHAT</span>;
        ISSN:<span class="NLM_cas:issn">2040-6207</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Acute myeloid leukemia remains assocd. with poor outcomes despite advances in our understanding of the complicated mol. events driving leukemogenesis and malignant progression.  Those patients harboring mutations in the FLT3 receptor tyrosine kinase have a particularly poor prognosis; however, significant excitement has been generated by the emergence of a variety of targeted inhibitors capable of suppressing FLT3 signaling in vivo.  Here we will review results from preclin. studies and early clin. trials evaluating both first- and second-generation FLT3 inhibitors.  Early FLT3 inhibitors (including sunitinib, midostaurin, and lestaurtinib) demonstrated significant promise in preclin. models of FLT3 mutant AML.  Unfortunately, many of these compds. failed to achieve robust and sustained FLT3 inhibition in early clin. trials, at best resulting in only transient decreases in peripheral blast counts.  These results have prompted the development of second-generation FLT3 inhibitors, epitomized by the novel agent quizartinib.  These second-generation inhibitors have demonstrated enhanced FLT3 specificity and have been generally well tolerated in early clin. trials.  Several FLT3 inhibitors have reached phase III clin. trials, and a variety of phase I/II trials exploring a role for these novel compds. in conjunction with conventional chemotherapy or hematopoietic stem cell transplantation are ongoing.  Finally, mol. insights provided by FLT3 inhibitors have shed light upon the variety of mechanisms underlying the acquisition of resistance and have provided a rationale supporting the use of combinatorial regimens with other emerging targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdBjhHfJvx77Vg90H21EOLACvtfcHk0lj0HIeND1qI5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1SlsrjN&md5=8cd3430a461df381c6480d42d4d75c0e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1177%2F2040620714532123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2040620714532123%26sid%3Dliteratum%253Aachs%26aulast%3DWander%26aufirst%3DS.%2BA.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DFathi%26aufirst%3DA.%2BT.%26atitle%3DThe%2520evolving%2520role%2520of%2520FLT3%2520inhibitors%2520in%2520acute%2520myeloid%2520leukemia%253A%2520quizartinib%2520and%2520beyond%26jtitle%3DTher.%2520Adv.%2520Hematol.%26date%3D2014%26volume%3D5%26spage%3D65%26epage%3D77%26doi%3D10.1177%2F2040620714532123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pemmaraju, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreeff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span> <span> </span><span class="NLM_article-title">Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">943</span>– <span class="NLM_lpage">954</span>, <span class="refDoi"> DOI: 10.1517/13543784.2014.911839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1517%2F13543784.2014.911839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=24749672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1WitL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=943-954&author=N.+Pemmarajuauthor=H.+Kantarjianauthor=M.+Andreeffauthor=J.+Cortesauthor=F.+Ravandi&title=Investigational+FMS-like+tyrosine+kinase+3+inhibitors+in+treatment+of+acute+myeloid+leukemia&doi=10.1517%2F13543784.2014.911839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia</span></div><div class="casAuthors">Pemmaraju, Naveen; Kantarjian, Hagop; Andreeff, Michael; Cortes, Jorge; Ravandi, Farhad</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">943-954</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Outcomes for the majority of patients with acute myeloid leukemia (AML) remain poor.  Over the past decade, significant progress has been made in the understanding of the cytogenetic and mol. determinants of AML pathogenesis.  One such advance is the identification of recurring mutations in the FMS-like tyrosine kinase 3 gene (FLT3).  Currently, this marker, which appears in approx. one-third of all AML patients, not only signifies a poorer prognosis but also identifies an important target for therapy.  FLT3 inhibitors have now undergone clin. evaluation in Phase I, II and III clin. trials, as both single agents and in combination with chemotherapeutics.  Unfortunately, to date, none of the FLT3 inhibitors have gained FDA approval for the treatment of patients with AML.  Yet, several promising FLT3 inhibitors are being evaluated in all phases of drug development.  Areas covered: This review aims to highlight the agents furthest along in their development.  It also focuses on those FLT3 inhibitors that are being evaluated in combination with other anti-leukemia agents.  Expert opinion: The authors believe that the field of research for FLT3 inhibitors remains promising, despite the historically poor prognosis of this subgroup of patients with AML.  The most promising areas of research will likely be the elucidation of the mechanisms of resistance to FLT3 inhibitors, and development of potent FLT3 inhibitors alone or in combination with hypomethylating agents, cytotoxic chemotherapy or with other targeted agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzTT7YoH9KV7Vg90H21EOLACvtfcHk0lj0HIeND1qI5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1WitL8%253D&md5=b624124fc07e406fe1c802b2e6f6a94c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1517%2F13543784.2014.911839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2014.911839%26sid%3Dliteratum%253Aachs%26aulast%3DPemmaraju%26aufirst%3DN.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DAndreeff%26aufirst%3DM.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DRavandi%26aufirst%3DF.%26atitle%3DInvestigational%2520FMS-like%2520tyrosine%2520kinase%25203%2520inhibitors%2520in%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2014%26volume%3D23%26spage%3D943%26epage%3D954%26doi%3D10.1517%2F13543784.2014.911839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buaboonnam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orwick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janke, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inaba, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. D.</span></span> <span> </span><span class="NLM_article-title">Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">3607</span>– <span class="NLM_lpage">3615</span>, <span class="refDoi"> DOI: 10.1182/blood-2013-07-513044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1182%2Fblood-2013-07-513044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=24046014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVKjsL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=3607-3615&author=E.+I.+Zimmermanauthor=D.+C.+Turnerauthor=J.+Buaboonnamauthor=S.+Huauthor=S.+Orwickauthor=M.+S.+Robertsauthor=L.+J.+Jankeauthor=A.+Ramachandranauthor=C.+F.+Stewartauthor=H.+Inabaauthor=S.+D.+Baker&title=Crenolanib+is+active+against+models+of+drug-resistant+FLT3-ITD-positive+acute+myeloid+leukemia&doi=10.1182%2Fblood-2013-07-513044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia</span></div><div class="casAuthors">Zimmerman, Eric I.; Turner, David C.; Buaboonnam, Jassada; Hu, Shuiying; Orwick, Shelley; Roberts, Michael S.; Janke, Laura J.; Ramachandran, Abhijit; Stewart, Clinton F.; Inaba, Hiroto; Baker, Sharyn D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3607-3615</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">FLT3 kinase internal tandem duplication (ITD) mutations are common in acute myeloid leukemia (AML) and are assocd. with poor clin. outcomes.  Although initial responses to FLT3 tyrosine kinase inhibitors (TKIs) are obsd. in FLT3-ITD-pos. patients, subsequent relapse often occurs upon acquisition of secondary FLT3 kinase domain (KD) mutations, primarily at residues D835 and F691.  Using biochem. assays, we detd. that crenolanib, a novel TKI, demonstrates type I properties and is active against FLT3 contg. ITD and/or D835- or F691-activating mutations.  Potent activity was obsd. in FLT3-ITD-pos. AML cell lines.  Crenolanib delayed the outgrowth of MV4-11 cells in a xenograft mouse model, whereas in combination with the type II TKI sorafenib, a significant decrease in leukemic burden (P < .001) and prolonged survival (P < .01) was obsd. compared with either type I or II TKI alone.  Crenolanib was active against Ba/F3 cells harboring FLT3-ITD and secondary KD mutations and sorafenib-resistant MOLM-13 cells contg. FLT3-ITD/D835Y both in vitro and in vivo.  In addn., crenolanib inhibited drug-resistant AML primary blasts with FLT3-ITD and D835H/Y mutations.  These preclin. data demonstrate that crenolanib is effective against FLT3-ITD contg. secondary KD mutations, suggesting that crenolanib may be a useful therapeutic agent for TKI-naive and drug-resistant FLT3-ITD-pos. AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBQ8ZNZvhAw7Vg90H21EOLACvtfcHk0lgbH8EJHk8nCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVKjsL%252FE&md5=5d4052c5b3d470a2a9d14104286271ce</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-07-513044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-07-513044%26sid%3Dliteratum%253Aachs%26aulast%3DZimmerman%26aufirst%3DE.%2BI.%26aulast%3DTurner%26aufirst%3DD.%2BC.%26aulast%3DBuaboonnam%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DS.%26aulast%3DOrwick%26aufirst%3DS.%26aulast%3DRoberts%26aufirst%3DM.%2BS.%26aulast%3DJanke%26aufirst%3DL.%2BJ.%26aulast%3DRamachandran%26aufirst%3DA.%26aulast%3DStewart%26aufirst%3DC.%2BF.%26aulast%3DInaba%26aufirst%3DH.%26aulast%3DBaker%26aufirst%3DS.%2BD.%26atitle%3DCrenolanib%2520is%2520active%2520against%2520models%2520of%2520drug-resistant%2520FLT3-ITD-positive%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26spage%3D3607%26epage%3D3615%26doi%3D10.1182%2Fblood-2013-07-513044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajkhowa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span> <span> </span><span class="NLM_article-title">Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">260</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-10-745133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1182%2Fblood-2016-10-745133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=27908881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosVKitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=257-260&author=L.+Y.+Leeauthor=D.+Hernandezauthor=T.+Rajkhowaauthor=S.+C.+Smithauthor=J.+R.+Ramanauthor=B.+Nguyenauthor=D.+Smallauthor=M.+Levis&title=Preclinical+studies+of+gilteritinib%2C+a+next-generation+FLT3+inhibitor&doi=10.1182%2Fblood-2016-10-745133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor</span></div><div class="casAuthors">Lee, Lauren Y.; Hernandez, Daniela; Rajkhowa, Trivikram; Smith, Samuel C.; Raman, Jayant Ranganathan; Nguyen, Bao; Small, Donald; Levis, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-260</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">This article describes about the activity of gilteritinib and compared it with 4 other FLT3 TKIs in clin. development: midostaurin, sorafenib, quizartinib, and crenolanib.  In this article, inhibitory activity of gilteritinib against different forms of FLT3 in leukemia cells are studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKpTUQzYy5lrVg90H21EOLACvtfcHk0lgbH8EJHk8nCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosVKitL0%253D&md5=75429ea03b906ea92d24033613f0315b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-10-745133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-10-745133%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DL.%2BY.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DRajkhowa%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DS.%2BC.%26aulast%3DRaman%26aufirst%3DJ.%2BR.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DLevis%26aufirst%3DM.%26atitle%3DPreclinical%2520studies%2520of%2520gilteritinib%252C%2520a%2520next-generation%2520FLT3%2520inhibitor%26jtitle%3DBlood%26date%3D2017%26volume%3D129%26spage%3D257%26epage%3D260%26doi%3D10.1182%2Fblood-2016-10-745133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3)</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1007/s10822-012-9572-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1007%2Fs10822-012-9572-z" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=437-450&author=A.+Poulsenauthor=A.+Williamauthor=S.+Blanchardauthor=A.+Leeauthor=H.+Nagarajauthor=H.+Wangauthor=E.+Teoauthor=E.+Tanauthor=K.+C.+Gohauthor=B.+Dymock&title=Structure-based+design+of+oxygen-linked+macrocyclic+kinase+inhibitors%3A+discovery+of+SB1518+and+SB1578%2C+potent+inhibitors+of+Janus+kinase+2+%28JAK2%29+and+Fms-like+tyrosine+kinase-3+%28FLT3%29&doi=10.1007%2Fs10822-012-9572-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs10822-012-9572-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-012-9572-z%26sid%3Dliteratum%253Aachs%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DWilliam%26aufirst%3DA.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DTeo%26aufirst%3DE.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DDymock%26aufirst%3DB.%26atitle%3DStructure-based%2520design%2520of%2520oxygen-linked%2520macrocyclic%2520kinase%2520inhibitors%253A%2520discovery%2520of%2520SB1518%2520and%2520SB1578%252C%2520potent%2520inhibitors%2520of%2520Janus%2520kinase%25202%2520%2528JAK2%2529%2520and%2520Fms-like%2520tyrosine%2520kinase-3%2520%2528FLT3%2529%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2012%26volume%3D26%26spage%3D437%26epage%3D450%26doi%3D10.1007%2Fs10822-012-9572-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1038/leu.2011.218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1038%2Fleu.2011.218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=21860433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFGgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=236-243&author=K.+C.+Gohauthor=V.+Novotny-Diermayrauthor=S.+Hartauthor=L.+C.+Ongauthor=Y.+K.+Lohauthor=A.+Cheongauthor=Y.+C.+Tanauthor=C.+Huauthor=R.+Jayaramanauthor=A.+D.+Williamauthor=E.+T.+Sunauthor=B.+W.+Dymockauthor=K.+H.+Ongauthor=K.+Ethirajuluauthor=F.+Burrowsauthor=J.+M.+Wood&title=TG02%2C+a+novel+oral+multi-kinase+inhibitor+of+CDKs%2C+JAK2+and+FLT3+with+potent+anti-leukemic+properties&doi=10.1038%2Fleu.2011.218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties</span></div><div class="casAuthors">Goh, K. C.; Novotny-Diermayr, V.; Hart, S.; Ong, L. C.; Loh, Y. K.; Cheong, A.; Tan, Y. C.; Hu, C.; Jayaraman, R.; William, A. D.; Sun, E. T.; Dymock, B. W.; Ong, K. H.; Ethirajulu, K.; Burrows, F.; Wood, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-243</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3.  It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs.  TG02 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis.  Primary cultures of progenitor cells derived from acute myeloid leukemia (AML) and polycythemia vera patients are very sensitive to TG02.  Comparison with ref. inhibitors that block only one of the main targets of TG02 demonstrate the benefit of combined CDK and JAK2/FLT3 inhibition in cell lines as well as primary cells.  In vivo, TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling.  TG02 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60).  These data demonstrate that TG02 is active in various models of leukemia and provide a rationale for the ongoing clin. evaluation of TG02 in patients with advanced leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMelEE91r_BrVg90H21EOLACvtfcHk0ljqtYJA7qL7hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFGgtLc%253D&md5=30af7dc302f9c421924b5b0062e82655</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fleu.2011.218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2011.218%26sid%3Dliteratum%253Aachs%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DLoh%26aufirst%3DY.%2BK.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DOng%26aufirst%3DK.%2BH.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DBurrows%26aufirst%3DF.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DTG02%252C%2520a%2520novel%2520oral%2520multi-kinase%2520inhibitor%2520of%2520CDKs%252C%2520JAK2%2520and%2520FLT3%2520with%2520potent%2520anti-leukemic%2520properties%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26spage%3D236%26epage%3D243%26doi%3D10.1038%2Fleu.2011.218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragains, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coberly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenback, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksterowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alba, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quéva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickramasinghe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, K.</span></span> <span> </span><span class="NLM_article-title">Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">880</span>– <span class="NLM_lpage">889</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0858</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1158%2F1535-7163.MCT-13-0858" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=24526162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=880-889&author=K.+Keeganauthor=C.+Liauthor=Z.+Liauthor=J.+Maauthor=M.+Ragainsauthor=S.+Coberlyauthor=D.+Hollenbackauthor=J.+Eksterowiczauthor=L.+Liangauthor=M.+Weidnerauthor=J.+Huardauthor=X.+Wangauthor=G.+Albaauthor=J.+Orfauthor=M.+C.+Loauthor=S.+Zhaoauthor=R.+Ngoauthor=A.+Chenauthor=L.+Liuauthor=T.+Carlsonauthor=C.+Qu%C3%A9vaauthor=L.+R.+McGeeauthor=J.+Medinaauthor=A.+Kambauthor=D.+Wickramasingheauthor=K.+Dai&title=Preclinical+evaluation+of+AMG+925%2C+a+FLT3%2FCDK4+dual+kinase+inhibitor+for+treating+acute+myeloid+leukemia&doi=10.1158%2F1535-7163.MCT-13-0858"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia</span></div><div class="casAuthors">Keegan, Kathleen; Li, Cong; Li, Zhihong; Ma, Ji; Ragains, Mark; Coberly, Suzanne; Hollenback, David; Eksterowicz, John; Liang, Lingming; Weidner, Margaret; Huard, Justin; Wang, Xianghong; Alba, Grace; Orf, Jessica; Lo, Mei-Chu; Zhao, Sharon; Ngo, Rachel; Chen, Ada; Liu, Lily; Carlson, Timothy; Queva, Christophe; McGee, Lawrence R.; Medina, Julio; Kamb, Alexander; Wickramasinghe, Dineli; Dai, Kang</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">880-889</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) remains a serious unmet medical need.  Despite high remission rates with chemotherapy std.-of-care treatment, the disease eventually relapses in a major proportion of patients.  Activating Fms-like tyrosine kinase 3 (FLT3) mutations are found in approx. 30% of patients with AML.  Targeting FLT3 receptor tyrosine kinase has shown encouraging results in treating FLT3-mutated AML.  Responses, however, are not sustained and acquired resistance has been a clin. challenge.  Treatment options to overcome resistance are currently the focus of research.  We report here the preclin. evaluation of AMG 925, a potent, selective, and bioavailable FLT3/cyclin-dependent kinase 4 (CDK4) dual kinase inhibitor.  AMG 925 inhibited AML xenograft tumor growth by 96% to 99% without significant body wt. loss.  The antitumor activity of AMG 925 correlated with the inhibition of STAT5 and RB phosphorylation, the pharmacodynamic markers for inhibition of FLT3 and CDK4, resp.  In addn., AMG 925 was also found to inhibit FLT3 mutants (e.g., D835Y) that are resistant to the current FLT3 inhibitors (e.g., AC220 and sorafenib).  CDK4 is a cyclin D-dependent kinase that plays an essential central role in regulating cell proliferation in response to external growth signals.  A crit. role of the CDK4-RB pathway in cancer development has been well established.  CDK4-specific inhibitors are being developed for treating RB-pos. cancer.  AMG 925, which combines inhibition of two kinases essential for proliferation and survival of FLT3-mutated AML cells, may improve and prolong clin. responses.  Mol Cancer Ther; 13(4); 880-9. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI4p2uOyF0ObVg90H21EOLACvtfcHk0ljERYvA58Lh6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurs%253D&md5=7343fdb82e66c9115c8b018a260aadde</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0858%26sid%3Dliteratum%253Aachs%26aulast%3DKeegan%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DRagains%26aufirst%3DM.%26aulast%3DCoberly%26aufirst%3DS.%26aulast%3DHollenback%26aufirst%3DD.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DWeidner%26aufirst%3DM.%26aulast%3DHuard%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DAlba%26aufirst%3DG.%26aulast%3DOrf%26aufirst%3DJ.%26aulast%3DLo%26aufirst%3DM.%2BC.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DNgo%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DCarlson%26aufirst%3DT.%26aulast%3DQu%25C3%25A9va%26aufirst%3DC.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%26aulast%3DKamb%26aufirst%3DA.%26aulast%3DWickramasinghe%26aufirst%3DD.%26aulast%3DDai%26aufirst%3DK.%26atitle%3DPreclinical%2520evaluation%2520of%2520AMG%2520925%252C%2520a%2520FLT3%252FCDK4%2520dual%2520kinase%2520inhibitor%2520for%2520treating%2520acute%2520myeloid%2520leukemia%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D880%26epage%3D889%26doi%3D10.1158%2F1535-7163.MCT-13-0858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksterowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribble, M. W.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alba, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connors, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeGraffenreid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deignan, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquette, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huard, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaizerman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lively, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMinn, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihalic, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattabiraman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piper, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Queva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragains, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suchomel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wanska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehn, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickramasinghe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3430</span>– <span class="NLM_lpage">3449</span>, <span class="refDoi"> DOI: 10.1021/jm500118j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500118j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3430-3449&author=Z.+Liauthor=X.+Wangauthor=J.+Eksterowiczauthor=M.+W.+Gribbleauthor=G.+Q.+Albaauthor=M.+Ayresauthor=T.+J.+Carlsonauthor=A.+Chenauthor=X.+Chenauthor=R.+Choauthor=R.+V.+Connorsauthor=M.+DeGraffenreidauthor=J.+T.+Deignanauthor=J.+Duquetteauthor=P.+Fanauthor=B.+Fisherauthor=J.+Fuauthor=J.+N.+Huardauthor=J.+Kaizermanauthor=K.+S.+Keeganauthor=C.+Liauthor=K.+Liauthor=Y.+Liauthor=L.+Liangauthor=W.+Liuauthor=S.+E.+Livelyauthor=M.+C.+Loauthor=J.+Maauthor=D.+L.+McMinnauthor=J.+T.+Mihalicauthor=K.+Modiauthor=R.+Ngoauthor=K.+Pattabiramanauthor=D.+E.+Piperauthor=C.+Quevaauthor=M.+L.+Ragainsauthor=J.+Suchomelauthor=S.+Thibaultauthor=N.+Walkerauthor=X.+Wangauthor=Z.+Wangauthor=M.+Wanskaauthor=P.+M.+Wehnauthor=M.+F.+Weidnerauthor=A.+J.+Zhangauthor=X.+Zhaoauthor=A.+Kambauthor=D.+Wickramasingheauthor=K.+Daiauthor=L.+R.+McGeeauthor=J.+C.+Medina&title=Discovery+of+AMG+925%2C+a+FLT3+and+CDK4+dual+kinase+inhibitor+with+preferential+affinity+for+the+activated+state+of+FLT3&doi=10.1021%2Fjm500118j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3</span></div><div class="casAuthors">Li, Zhihong; Wang, Xianghong; Eksterowicz, John; Gribble, Michael W.; Alba, Grace Q.; Ayres, Merrill; Carlson, Timothy J.; Chen, Ada; Chen, Xiaoqi; Cho, Robert; Connors, Richard V.; DeGraffenreid, Michael; Deignan, Jeffrey T.; Duquette, Jason; Fan, Pingchen; Fisher, Benjamin; Fu, Jiasheng; Huard, Justin N.; Kaizerman, Jacob; Keegan, Kathleen S.; Li, Cong; Li, Kexue; Li, Yunxiao; Liang, Lingming; Liu, Wen; Lively, Sarah E.; Lo, Mei-Chu; Ma, Ji; McMinn, Dustin L.; Mihalic, Jeffrey T.; Modi, Kriti; Ngo, Rachel; Pattabiraman, Kanaka; Piper, Derek E.; Queva, Christophe; Ragains, Mark L.; Suchomel, Julia; Thibault, Steve; Walker, Nigel; Wang, Xiaodong; Wang, Zhulun; Wanska, Malgorzata; Wehn, Paul M.; Weidner, Margaret F.; Zhang, Alex J.; Zhao, Xiaoning; Kamb, Alexander; Wickramasinghe, Dineli; Dai, Kang; McGee, Lawrence R.; Medina, Julio C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3430-3449</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors describe the structural optimization of a lead compd. that exhibits dual inhibitory activities against FLT3 and CDK4.  A series of pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidine derivs. was synthesized, and SAR anal., using cell-based assays, led to the discovery of AMG 925 (I), a potent and orally bioavailable dual inhibitor of CDK4 and FLT3, including many FLT3 mutants reported to date.  Compd. I inhibits the proliferation of a panel of human tumor cell lines including Colo205 (Rb+) and U937 (FLT3WT) and induced cell death in MOLM13 (FLT3ITD) and even in MOLM13 (FLT3ITD, D835Y), which exhibits resistance to a no. of FLT3 inhibitors currently under clin. development.  At well-tolerated doses, compd. I leads to significant growth inhibition of MOLM13 xenografts in nude mice, and the activity correlates with inhibition of STAT5 and Rb phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcJdjH0aU8KrVg90H21EOLACvtfcHk0lhJHrEHYY72XQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D&md5=4047a6ea068dbde57896da520fbdf0d3</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm500118j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500118j%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DGribble%26aufirst%3DM.%2BW.%26aulast%3DAlba%26aufirst%3DG.%2BQ.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DCarlson%26aufirst%3DT.%2BJ.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCho%26aufirst%3DR.%26aulast%3DConnors%26aufirst%3DR.%2BV.%26aulast%3DDeGraffenreid%26aufirst%3DM.%26aulast%3DDeignan%26aufirst%3DJ.%2BT.%26aulast%3DDuquette%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DHuard%26aufirst%3DJ.%2BN.%26aulast%3DKaizerman%26aufirst%3DJ.%26aulast%3DKeegan%26aufirst%3DK.%2BS.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLively%26aufirst%3DS.%2BE.%26aulast%3DLo%26aufirst%3DM.%2BC.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DMcMinn%26aufirst%3DD.%2BL.%26aulast%3DMihalic%26aufirst%3DJ.%2BT.%26aulast%3DModi%26aufirst%3DK.%26aulast%3DNgo%26aufirst%3DR.%26aulast%3DPattabiraman%26aufirst%3DK.%26aulast%3DPiper%26aufirst%3DD.%2BE.%26aulast%3DQueva%26aufirst%3DC.%26aulast%3DRagains%26aufirst%3DM.%2BL.%26aulast%3DSuchomel%26aufirst%3DJ.%26aulast%3DThibault%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWanska%26aufirst%3DM.%26aulast%3DWehn%26aufirst%3DP.%2BM.%26aulast%3DWeidner%26aufirst%3DM.%2BF.%26aulast%3DZhang%26aufirst%3DA.%2BJ.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DKamb%26aufirst%3DA.%26aulast%3DWickramasinghe%26aufirst%3DD.%26aulast%3DDai%26aufirst%3DK.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520of%2520AMG%2520925%252C%2520a%2520FLT3%2520and%2520CDK4%2520dual%2520kinase%2520inhibitor%2520with%2520preferential%2520affinity%2520for%2520the%2520activated%2520state%2520of%2520FLT3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3430%26epage%3D3449%26doi%3D10.1021%2Fjm500118j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gucký, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zatloukal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazgier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Řezníčková, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Béres, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryštof, V.</span></span> <span> </span><span class="NLM_article-title">A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">6234</span>– <span class="NLM_lpage">6247</span>, <span class="refDoi"> DOI: 10.1021/jm4006884</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4006884" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6234-6247&author=T.+Guck%C3%BDauthor=R.+Jordaauthor=M.+Zatloukalauthor=V.+Bazgierauthor=K.+Berkaauthor=E.+%C5%98ezn%C3%AD%C4%8Dkov%C3%A1author=T.+B%C3%A9resauthor=M.+Strnadauthor=V.+Kry%C5%A1tof&title=A+novel+series+of+highly+potent+2%2C6%2C9-trisubstituted+purine+cyclin-dependent+kinase+inhibitors&doi=10.1021%2Fjm4006884"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm4006884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4006884%26sid%3Dliteratum%253Aachs%26aulast%3DGuck%25C3%25BD%26aufirst%3DT.%26aulast%3DJorda%26aufirst%3DR.%26aulast%3DZatloukal%26aufirst%3DM.%26aulast%3DBazgier%26aufirst%3DV.%26aulast%3DBerka%26aufirst%3DK.%26aulast%3D%25C5%2598ezn%25C3%25AD%25C4%258Dkov%25C3%25A1%26aufirst%3DE.%26aulast%3DB%25C3%25A9res%26aufirst%3DT.%26aulast%3DStrnad%26aufirst%3DM.%26aulast%3DKry%25C5%25A1tof%26aufirst%3DV.%26atitle%3DA%2520novel%2520series%2520of%2520highly%2520potent%25202%252C6%252C9-trisubstituted%2520purine%2520cyclin-dependent%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6234%26epage%3D6247%26doi%3D10.1021%2Fjm4006884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zatloukal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gucky, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reznickova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pospisil, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malinkova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamcova, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystof, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.06.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1016%2Fj.ejmech.2012.06.036" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2013&pages=61-72&author=M.+Zatloukalauthor=R.+Jordaauthor=T.+Guckyauthor=E.+Reznickovaauthor=J.+Vollerauthor=T.+Pospisilauthor=V.+Malinkovaauthor=H.+Adamcovaauthor=V.+Krystofauthor=M.+Strnad&title=Synthesis+and+in+vitro+biological+evaluation+of+2%2C6%2C9-trisubstituted+purines+targeting+multiple+cyclin-dependent+kinases&doi=10.1016%2Fj.ejmech.2012.06.036"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.06.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.06.036%26sid%3Dliteratum%253Aachs%26aulast%3DZatloukal%26aufirst%3DM.%26aulast%3DJorda%26aufirst%3DR.%26aulast%3DGucky%26aufirst%3DT.%26aulast%3DReznickova%26aufirst%3DE.%26aulast%3DVoller%26aufirst%3DJ.%26aulast%3DPospisil%26aufirst%3DT.%26aulast%3DMalinkova%26aufirst%3DV.%26aulast%3DAdamcova%26aufirst%3DH.%26aulast%3DKrystof%26aufirst%3DV.%26aulast%3DStrnad%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520in%2520vitro%2520biological%2520evaluation%2520of%25202%252C6%252C9-trisubstituted%2520purines%2520targeting%2520multiple%2520cyclin-dependent%2520kinases%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D61%26spage%3D61%26epage%3D72%26doi%3D10.1016%2Fj.ejmech.2012.06.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sengupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhmedov, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span> <span> </span><span class="NLM_article-title">Mitsunobu coupling of nucleobases and alcohols: an efficient, practical synthesis for novel nonsugar carbon nucleosides</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">5012</span>– <span class="NLM_lpage">5015</span>, <span class="refDoi"> DOI: 10.1021/jo070515+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo070515%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=5012-5015&author=W.+Luauthor=S.+Senguptaauthor=J.+L.+Petersenauthor=N.+G.+Akhmedovauthor=X.+Shi&title=Mitsunobu+coupling+of+nucleobases+and+alcohols%3A+an+efficient%2C+practical+synthesis+for+novel+nonsugar+carbon+nucleosides&doi=10.1021%2Fjo070515%2B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjo070515%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo070515%252B%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DW.%26aulast%3DSengupta%26aufirst%3DS.%26aulast%3DPetersen%26aufirst%3DJ.%2BL.%26aulast%3DAkhmedov%26aufirst%3DN.%2BG.%26aulast%3DShi%26aufirst%3DX.%26atitle%3DMitsunobu%2520coupling%2520of%2520nucleobases%2520and%2520alcohols%253A%2520an%2520efficient%252C%2520practical%2520synthesis%2520for%2520novel%2520nonsugar%2520carbon%2520nucleosides%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2007%26volume%3D72%26spage%3D5012%26epage%3D5015%26doi%3D10.1021%2Fjo070515%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, N.
G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Browne, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drysdale, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foloppe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geoffrey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matassova, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roughley, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoepfer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scriven, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmonite, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surgenor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brough, P.</span></span> <span> </span><span class="NLM_article-title">Targeting conserved water molecules: design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">6770</span>– <span class="NLM_lpage">6789</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2012.08.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1016%2Fj.bmc.2012.08.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=23018093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVSltrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=6770-6789&author=N.%0AG.+Daviesauthor=H.+Browneauthor=B.+Davisauthor=M.+J.+Drysdaleauthor=N.+Foloppeauthor=S.+Geoffreyauthor=B.+Gibbonsauthor=T.+Hartauthor=R.+Hubbardauthor=M.+R.+Jensenauthor=H.+Mansellauthor=A.+Masseyauthor=N.+Matassovaauthor=J.+D.+Mooreauthor=J.+Murrayauthor=R.+Prattauthor=S.+Rayauthor=A.+Robertsonauthor=S.+D.+Roughleyauthor=J.+Schoepferauthor=K.+Scrivenauthor=H.+Simmoniteauthor=S.+Stokesauthor=A.+Surgenorauthor=P.+Webbauthor=M.+Woodauthor=L.+Wrightauthor=P.+Brough&title=Targeting+conserved+water+molecules%3A+design+of+4-aryl-5-cyanopyrrolo%5B2%2C3-d%5Dpyrimidine+Hsp90+inhibitors+using+fragment-based+screening+and+structure-based+optimization&doi=10.1016%2Fj.bmc.2012.08.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting conserved water molecules: Design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization</span></div><div class="casAuthors">Davies, Nicholas G. M.; Browne, Helen; Davis, Ben; Drysdale, Martin J.; Foloppe, Nicolas; Geoffrey, Stephanie; Gibbons, Ben; Hart, Terance; Hubbard, Roderick; Jensen, Michael Rugaard; Mansell, Howard; Massey, Andrew; Matassova, Natalia; Moore, Jonathan D.; Murray, James; Pratt, Robert; Ray, Stuart; Robertson, Alan; Roughley, Stephen D.; Schoepfer, Joseph; Scriven, Kirsten; Simmonite, Heather; Stokes, Stephen; Surgenor, Allan; Webb, Paul; Wood, Mike; Wright, Lisa; Brough, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6770-6789</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Inhibitors of the Hsp90 mol. chaperone are showing promise as anti-cancer agents.  Here the authors describe a series of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine ATP competitive Hsp90 inhibitors that were identified following structure-driven optimization of purine hits revealed by NMR based screening of a proprietary fragment library.  Ligand-Hsp90 x-ray structures combined with mol. modeling led to the rational displacement of a conserved water mol. leading to enhanced affinity for Hsp90 as measured by fluorescence polarization, isothermal titrn. calorimetry and surface plasmon resonance assays.  This displacement was achieved with a nitrile group, presenting an example of efficient gain in binding affinity with minimal increase in mol. wt.  Some compds. in this chem. series inhibit the proliferation of human cancer cell lines in vitro and cause depletion of oncogenic Hsp90 client proteins and concomitant elevation of the co-chaperone Hsp70.  In addn., one compd. was demonstrated to be orally bioavailable in the mouse.  This work demonstrates the power of structure-based design for the rapid evolution of potent Hsp90 inhibitors and the importance of considering conserved water mols. in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMAwVhZUzKD7Vg90H21EOLACvtfcHk0ljZVCHqwMdmew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVSltrvN&md5=69c85da95d07bd488f07eaf503c978f4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.08.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.08.050%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DN.%2BG.%26aulast%3DBrowne%26aufirst%3DH.%26aulast%3DDavis%26aufirst%3DB.%26aulast%3DDrysdale%26aufirst%3DM.%2BJ.%26aulast%3DFoloppe%26aufirst%3DN.%26aulast%3DGeoffrey%26aufirst%3DS.%26aulast%3DGibbons%26aufirst%3DB.%26aulast%3DHart%26aufirst%3DT.%26aulast%3DHubbard%26aufirst%3DR.%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DMansell%26aufirst%3DH.%26aulast%3DMassey%26aufirst%3DA.%26aulast%3DMatassova%26aufirst%3DN.%26aulast%3DMoore%26aufirst%3DJ.%2BD.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DPratt%26aufirst%3DR.%26aulast%3DRay%26aufirst%3DS.%26aulast%3DRobertson%26aufirst%3DA.%26aulast%3DRoughley%26aufirst%3DS.%2BD.%26aulast%3DSchoepfer%26aufirst%3DJ.%26aulast%3DScriven%26aufirst%3DK.%26aulast%3DSimmonite%26aufirst%3DH.%26aulast%3DStokes%26aufirst%3DS.%26aulast%3DSurgenor%26aufirst%3DA.%26aulast%3DWebb%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DWright%26aufirst%3DL.%26aulast%3DBrough%26aufirst%3DP.%26atitle%3DTargeting%2520conserved%2520water%2520molecules%253A%2520design%2520of%25204-aryl-5-cyanopyrrolo%255B2%252C3-d%255Dpyrimidine%2520Hsp90%2520inhibitors%2520using%2520fragment-based%2520screening%2520and%2520structure-based%2520optimization%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D6770%26epage%3D6789%26doi%3D10.1016%2Fj.bmc.2012.08.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zorn, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimura, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barros, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220)</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e0121177</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0121177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1371%2Fjournal.pone.0121177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=25837374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Gmsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0121177&author=J.+A.+Zornauthor=Q.+Wangauthor=E.+Fujimuraauthor=T.+Barrosauthor=J.+Kuriyan&title=Crystal+structure+of+the+FLT3+kinase+domain+bound+to+the+inhibitor+Quizartinib+%28AC220%29&doi=10.1371%2Fjournal.pone.0121177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the FLT3 kinase domain bound to the inhibitor quizartinib (AC220)</span></div><div class="casAuthors">Zorn, Julie A.; Wang, Qi; Fujimura, Eric; Barros, Tiago; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e0121177/1-e0121177/15</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">More than 30% of acute myeloid leukemia (AML) patients possess activating mutations in the receptor tyrosine kinase FMS-like tyrosine kinase 3 or FLT3.  A small-mol. inhibitor of FLT3 (known as quizartinib or AC220) that is currently in clin. trials appears promising for the treatment of AML.  Here, we report the co-crystal structure of the kinase domain of FLT3 in complex with quizartinib.  FLT3 with quizartinib bound adopts an "Abl-like"inactive conformation with the activation loop stabilized in the "DFG-out"orientation and folded back onto the kinase domain.  This conformation is similar to that obsd. for the uncomplexed intracellular domain of FLT3 as well as for related receptor tyrosine kinases, except for a localized induced fit in the activation loop.  The co-crystal structure reveals the interactions between quizartinib and the active site of FLT3 that are key for achieving its high potency against both wild-type FLT3 as well as a FLT3 variant obsd. in many AML patients.  This co-complex further provides a structural rationale for quizartinib-resistance mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOXAklBbZKP7Vg90H21EOLACvtfcHk0ljZVCHqwMdmew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Gmsr%252FM&md5=d3c23bf8a8e242dd35e20e6e9b2de924</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0121177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0121177%26sid%3Dliteratum%253Aachs%26aulast%3DZorn%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DFujimura%26aufirst%3DE.%26aulast%3DBarros%26aufirst%3DT.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520FLT3%2520kinase%2520domain%2520bound%2520to%2520the%2520inhibitor%2520Quizartinib%2520%2528AC220%2529%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0121177%26doi%3D10.1371%2Fjournal.pone.0121177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasater, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCreery, M. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damon, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perl, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeschke, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogan, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. P.</span></span> <span> </span><span class="NLM_article-title">Crenolanib is a selective type I pan-FLT3 inhibitor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">5319</span>– <span class="NLM_lpage">5324</span>, <span class="refDoi"> DOI: 10.1073/pnas.1320661111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1073%2Fpnas.1320661111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=24623852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1Snsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=5319-5324&author=C.+C.+Smithauthor=E.+A.+Lasaterauthor=K.+C.+Linauthor=Q.+Wangauthor=M.+Q.+McCreeryauthor=W.+K.+Stewartauthor=L.+E.+Damonauthor=A.+E.+Perlauthor=G.+R.+Jeschkeauthor=M.+Sugitaauthor=M.+Carrollauthor=S.+C.+Koganauthor=J.+Kuriyanauthor=N.+P.+Shah&title=Crenolanib+is+a+selective+type+I+pan-FLT3+inhibitor&doi=10.1073%2Fpnas.1320661111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Crenolanib is a selective type I pan-FLT3 inhibitor</span></div><div class="casAuthors">Smith, Catherine Choy; Lasater, Elisabeth A.; Lin, Kimberly C.; Wang, Qi; McCreery, Melissa Quino; Stewart, Whitney K.; Damon, Lauren E.; Perl, Alexander E.; Jeschke, Grace R.; Sugita, Mayumi; Carroll, Martin; Kogan, Scott C.; Kuriyan, John; Shah, Neil P.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5319-5324</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Tyrosine kinase inhibitors (TKIs) represent transformative therapies for several malignancies.  Two crit. features necessary for maximizing TKI tolerability and response duration are kinase selectivity and invulnerability to resistance-conferring kinase domain (KD) mutations in the intended target.  No prior TKI has demonstrated both of these properties.  Aiming to maximize selectivity, medicinal chemists have largely sought to create TKIs that bind to an inactive (type II) kinase conformation.  The investigational type I TKI crenolanib is a potent inhibitor of Fms tyrosine kinase-3 (FLT3) internal tandem duplication, a validated therapeutic target in human acute myeloid leukemia (AML), as well as all secondary KD mutants previously shown to confer resistance to the first highly active FLT3 TKI quizartinib.  Moreover, crenolanib is highly selective for FLT3 relative to the closely related protein tyrosine kinase KIT, demonstrating that simultaneous FLT3/KIT inhibition, a prominent feature of other clin. active FLT3 TKIs, is not required for AML cell cytotoxicity in vitro and may contribute to undesirable toxicity in patients.  A satn. mutagenesis screen of FLT3-internal tandem duplication failed to recover any resistant colonies in the presence of a crenolanib concn. well below what has been safely achieved in humans, suggesting that crenolanib has the potential to suppress KD mutation-mediated clin. resistance.  Crenolanib represents the first TKI to exhibit both kinase selectivity and invulnerability to resistance-conferring KD mutations, which is unexpected of a type I inhibitor.  Crenolanib has significant promise for achieving deep and durable responses in FLT3-mutant AML, and may have a profound impact upon future medicinal chem. efforts in oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwxReAanOwB7Vg90H21EOLACvtfcHk0ljoBz7bhiKFMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1Snsbw%253D&md5=955f1f242a1690247ae239050e2a8a8f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1320661111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1320661111%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DLasater%26aufirst%3DE.%2BA.%26aulast%3DLin%26aufirst%3DK.%2BC.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DMcCreery%26aufirst%3DM.%2BQ.%26aulast%3DStewart%26aufirst%3DW.%2BK.%26aulast%3DDamon%26aufirst%3DL.%2BE.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26aulast%3DJeschke%26aufirst%3DG.%2BR.%26aulast%3DSugita%26aufirst%3DM.%26aulast%3DCarroll%26aufirst%3DM.%26aulast%3DKogan%26aufirst%3DS.%2BC.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DN.%2BP.%26atitle%3DCrenolanib%2520is%2520a%2520selective%2520type%2520I%2520pan-FLT3%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D5319%26epage%3D5324%26doi%3D10.1073%2Fpnas.1320661111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stecula, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. P.</span></span> <span> </span><span class="NLM_article-title">FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2390</span>– <span class="NLM_lpage">2392</span>, <span class="refDoi"> DOI: 10.1038/leu.2015.165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1038%2Fleu.2015.165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=26108694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Wrtb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=2390-2392&author=C.+C.+Smithauthor=K.+Linauthor=A.+Steculaauthor=A.+Saliauthor=N.+P.+Shah&title=FLT3+D835+mutations+confer+differential+resistance+to+type+II+FLT3+inhibitors&doi=10.1038%2Fleu.2015.165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors</span></div><div class="casAuthors">Smith, C. C.; Lin, K.; Stecula, A.; Sali, A.; Shah, N. P.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2390-2392</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activating mutations in FLT3 occur in ∼30% of adult acute myeloid leukemia, primarily consisting of internal tandem duplication (ITD) mutations (∼25%) and point mutations in the tyrosine kinase domain (∼5%), commonly at the activation loop residue D835.  Secondary kinase domain mutations in FLT3-ITD, particularly at the D835 residue are frequently assocd. with acquired clin. resistance to effective FLT3 tyrosine kinase inhibitors (TKIs).  Mol. docking studies have suggested that D835 mutations primarily confer resistance by stabilizing an active Asp-Phe-Gly in ('DFG-in') kinase conformation unfavorable to the binding of type II FLT3 TKIs, which target a 'DFG-out' inactive conformation.  We profiled the activity of active type II FLT3 TKIs against D835 kinase domain mutants that have been clin. detected to date.  We found that type II inhibitors (quizartinib, sorafenib, ponatinib and PLX3397) retain activity against specific D835 substitutions.  Modeling studies suggest that bulky hydrophobic substitutions (D835Y/V/I/F) at this residue are particularly resistant, whereas mutations that preserve interactions between D835 and S838 are relatively sensitive (D835E/N).  All mutants retain sensitivity to the type I inhibitor crenolanib.  These results suggest that patients with relatively sensitive D835 mutations should be included in clin. trials of type II FLT3 TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQhZ7jQYhBcbVg90H21EOLACvtfcHk0ligM7kGLkElgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Wrtb%252FJ&md5=f6de44ca15604b8429a5dab811fe8eeb</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.165%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DStecula%26aufirst%3DA.%26aulast%3DSali%26aufirst%3DA.%26aulast%3DShah%26aufirst%3DN.%2BP.%26atitle%3DFLT3%2520D835%2520mutations%2520confer%2520differential%2520resistance%2520to%2520type%2520II%2520FLT3%2520inhibitors%26jtitle%3DLeukemia%26date%3D2015%26volume%3D29%26spage%3D2390%26epage%3D2392%26doi%3D10.1038%2Fleu.2015.165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawardane, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belli, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratz, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprankle, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, S. S.</span></span> <span> </span><span class="NLM_article-title">AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">2984</span>– <span class="NLM_lpage">2992</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-05-222034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1182%2Fblood-2009-05-222034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=19654408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht12qurzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=2984-2992&author=P.+P.+Zarrinkarauthor=R.+N.+Gunawardaneauthor=M.+D.+Cramerauthor=M.+F.+Gardnerauthor=D.+Brighamauthor=B.+Belliauthor=M.+W.+Karamanauthor=K.+W.+Pratzauthor=G.+Pallaresauthor=Q.+Chaoauthor=K.+G.+Sprankleauthor=H.+K.+Patelauthor=M.+Levisauthor=R.+C.+Armstrongauthor=J.+Jamesauthor=S.+S.+Bhagwat&title=AC220+is+a+uniquely+potent+and+selective+inhibitor+of+FLT3+for+the+treatment+of+acute+myeloid+leukemia+%28AML%29&doi=10.1182%2Fblood-2009-05-222034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)</span></div><div class="casAuthors">Zarrinkar, Patrick P.; Gunawardane, Ruwanthi N.; Cramer, Merryl D.; Gardner, Michael F.; Brigham, Daniel; Belli, Barbara; Karaman, Mazen W.; Pratz, Keith W.; Pallares, Gabriel; Chao, Qi; Sprankle, Kelly G.; Patel, Hitesh K.; Levis, Mark; Armstrong, Robert C.; James, Joyce; Bhagwat, Shripad S.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2984-2992</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Activating mutations in the receptor tyrosine kinase FLT3 are present in up to approx. 30% of acute myeloid leukemia (AML) patients, implicating FLT3 as a driver of the disease and therefore as a target for therapy.  We report the characterization of AC220, a second-generation FLT3 inhibitor, and a comparison of AC220 with the first-generation FLT3 inhibitors CEP-701, MLN-518, PKC-412, sorafenib, and sunitinib.  AC220 exhibits low nanomolar potency in biochem. and cellular assays and exceptional kinase selectivity, and in animal models is efficacious at doses as low as 1 mg/kg given orally once daily.  The data reveal that the combination of excellent potency, selectivity, and pharmacokinetic properties is unique to AC220, which therefore is the first drug candidate with a profile that matches the characteristics desirable for a clin. FLT3 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_RzDr7kzxsLVg90H21EOLACvtfcHk0ligM7kGLkElgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht12qurzN&md5=4f8368a7b2eab9d1234ef36e01f5f260</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-05-222034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-05-222034%26sid%3Dliteratum%253Aachs%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DBelli%26aufirst%3DB.%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DPratz%26aufirst%3DK.%2BW.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DBhagwat%26aufirst%3DS.%2BS.%26atitle%3DAC220%2520is%2520a%2520uniquely%2520potent%2520and%2520selective%2520inhibitor%2520of%2520FLT3%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D2984%26epage%3D2992%26doi%3D10.1182%2Fblood-2009-05-222034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gunawardane, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepomuceno, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooks, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricono, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belli, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, R. C.</span></span> <span> </span><span class="NLM_article-title">Transient exposure to quizartinib mediates sustained inhibition of FLT3 signaling while specifically inducing apoptosis in FLT3-activated leukemia cells</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">447</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1158%2F1535-7163.MCT-12-0305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=23412931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC3sXls12qsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=438-447&author=R.+N.+Gunawardaneauthor=R.+R.+Nepomucenoauthor=A.+M.+Rooksauthor=J.+P.+Huntauthor=J.+M.+Riconoauthor=B.+Belliauthor=R.+C.+Armstrong&title=Transient+exposure+to+quizartinib+mediates+sustained+inhibition+of+FLT3+signaling+while+specifically+inducing+apoptosis+in+FLT3-activated+leukemia+cells&doi=10.1158%2F1535-7163.MCT-12-0305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Transient Exposure to Quizartinib Mediates Sustained Inhibition of FLT3 Signaling while Specifically Inducing Apoptosis in FLT3-Activated Leukemia Cells</span></div><div class="casAuthors">Gunawardane, Ruwanthi N.; Nepomuceno, Ronald R.; Rooks, Allison M.; Hunt, Jeremy P.; Ricono, Jill M.; Belli, Barbara; Armstrong, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">438-447</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Fms-like tyrosine kinase 3 (FLT3) is implicated in the pathogenesis of acute myeloid leukemia (AML).  FLT3-activating internal tandem duplication (ITD) mutations are found in approx. 30% of patients with AML and are assocd. with poor outcome in this patient population.  Quizartinib (AC220) has previously been shown to be a potent and selective FLT3 inhibitor.  In the current study, we expand on previous observations by showing that quizartinib potently inhibits the phosphorylation of FLT3 and downstream signaling mols. independent of FLT3 genotype, yet induces loss of viability only in cells expressing constitutively activated FLT3.  We further show that transient exposure to quizartinib, whether in vitro or in vivo, leads to prolonged inhibition of FLT3 signaling, induction of apoptosis, and drastic redns. in tumor vol. and pharmacodynamic endpoints.  In vitro expts. suggest that these prolonged effects are mediated by slow binding kinetics that provide for durable inhibition of the kinase following drug removal/clearance.  Together these data suggest quizartinib, with its unique combination of selectivity and potent/sustained inhibition of FLT3, may provide a safe and effective treatment against FLT3-driven leukemia.  Mol Cancer Ther; 12(4); 438-47. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS9XnwyldyrrVg90H21EOLACvtfcHk0lit9PRtJ7MCkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXls12qsrc%253D&md5=7943cbb662d1e010628ffac4437da6c1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0305%26sid%3Dliteratum%253Aachs%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DNepomuceno%26aufirst%3DR.%2BR.%26aulast%3DRooks%26aufirst%3DA.%2BM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DRicono%26aufirst%3DJ.%2BM.%26aulast%3DBelli%26aufirst%3DB.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26atitle%3DTransient%2520exposure%2520to%2520quizartinib%2520mediates%2520sustained%2520inhibition%2520of%2520FLT3%2520signaling%2520while%2520specifically%2520inducing%2520apoptosis%2520in%2520FLT3-activated%2520leukemia%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D438%26epage%3D447%26doi%3D10.1158%2F1535-7163.MCT-12-0305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kampa-Schittenhelm, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akmut, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schittenhelm, M. M.</span></span> <span> </span><span class="NLM_article-title">Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">19</span>, <span class="refDoi"> DOI: 10.1186/1476-4598-12-19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1186%2F1476-4598-12-19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=23497317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotFCms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=19&author=K.+M.+Kampa-Schittenhelmauthor=M.+C.+Heinrichauthor=F.+Akmutauthor=H.+D%C3%B6hnerauthor=K.+D%C3%B6hnerauthor=M.+M.+Schittenhelm&title=Quizartinib+%28AC220%29+is+a+potent+second+generation+class+III+tyrosine+kinase+inhibitor+that+displays+a+distinct+inhibition+profile+against+mutant-FLT3%2C+-PDGFRA+and+-KIT+isoforms&doi=10.1186%2F1476-4598-12-19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms</span></div><div class="casAuthors">Kampa-Schittenhelm, Kerstin Maria; Heinrich, Michael Charles; Akmut, Figen; Doehner, Hartmut; Doehner, Konstanze; Schittenhelm, Marcus Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">19</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Activating mutations of class III receptor tyrosine kinases (RTK) FLT3, PDGFR and KIT are assocd. with multiple human neoplasms including hematol. malignancies, for example: systemic mast cell disorders (KIT), non-CML myeloproliferative neoplasms (PDGFR) and subsets of acute leukemias (FLT3 and KIT).  First generation tyrosine kinase inhibitors (TKI) are rapidly being integrated into routine cancer care.  However, the expanding spectrum of TK-mutations, bioavailability issues and the emerging problem of primary or secondary TKI-therapy resistance have lead to the search for novel second generation TKIs to improve target potency and to overcome resistant clones.  Quizartinib was recently demonstrated to be a selective FLT3 inhibitor with excellent pharmacokinetics and promising in vivo activity in a phase II study for FLT3 ITD + AML patients.  In vitro kinase assays have suggested that in addn. to FLT3, quizartinib also targets related class III RTK isoforms.  Methods: Various FLT3 or KIT leukemia cell lines and native blasts were used to det. the antiproliferative and proapoptotic efficacy of quizartinib.  To better compare differences between the mutant kinase isoforms, we generated an isogenic BaF3 cell line expressing different FLT3, KIT or BCR/ABL isoforms.  Using immunoblotting, we examd. the effects of quizartinib on activation of mutant KIT or FLT3 isoforms.  Results: Kinase inhibition of (mutant) KIT , PDGFR and FLT3 isoforms by quizartinib leads to potent inhibition of cellular proliferation and induction of apoptosis in in vitro leukemia models as well as in native leukemia blasts treated ex vivo.  However, the sensitivity patterns vary widely depending on the underlying (mutant)-kinase isoform, with some isoforms being relatively insensitive to this agent (e.g. FLT3 D835V and KIT codon D816 mutations).  Evaluation of sensitivities in an isogenic cellular background confirms a direct assocn. with the underlying mutant-TK isoform - which is further validated by immunoblotting expts. demonstrating kinase inhibition consistent with the cellular sensitivity/resistance to quizartinib.  Conclusion: Quizartinib is a potent second-generation class III receptor TK-inhibitor - but specific, mutation restricted spectrum of activity may require mutation screening prior to therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzNdFVikwovbVg90H21EOLACvtfcHk0lit9PRtJ7MCkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotFCms78%253D&md5=592fee7ae105d731fdf0390745932ada</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-12-19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-12-19%26sid%3Dliteratum%253Aachs%26aulast%3DKampa-Schittenhelm%26aufirst%3DK.%2BM.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DAkmut%26aufirst%3DF.%26aulast%3DD%25C3%25B6hner%26aufirst%3DH.%26aulast%3DD%25C3%25B6hner%26aufirst%3DK.%26aulast%3DSchittenhelm%26aufirst%3DM.%2BM.%26atitle%3DQuizartinib%2520%2528AC220%2529%2520is%2520a%2520potent%2520second%2520generation%2520class%2520III%2520tyrosine%2520kinase%2520inhibitor%2520that%2520displays%2520a%2520distinct%2520inhibition%2520profile%2520against%2520mutant-FLT3%252C%2520-PDGFRA%2520and%2520-KIT%2520isoforms%26jtitle%3DMol.%2520Cancer%26date%3D2013%26volume%3D12%26spage%3D19%26doi%3D10.1186%2F1476-4598-12-19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruner, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, A. C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratz, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratilas, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span> <span> </span><span class="NLM_article-title">Signaling adaptation to TKI treatment reactivates ERK signaling in FLT3/ITD leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">33</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=33&author=J.+K.+Brunerauthor=L.+Liauthor=H.+S.+Maauthor=A.+C.+R.+Qinauthor=M.+J.+Levisauthor=K.+W.+Pratzauthor=C.+A.+Pratilasauthor=D.+Small&title=Signaling+adaptation+to+TKI+treatment+reactivates+ERK+signaling+in+FLT3%2FITD+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBruner%26aufirst%3DJ.%2BK.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DH.%2BS.%26aulast%3DQin%26aufirst%3DA.%2BC.%2BR.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DPratz%26aufirst%3DK.%2BW.%26aulast%3DPratilas%26aufirst%3DC.%2BA.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DSignaling%2520adaptation%2520to%2520TKI%2520treatment%2520reactivates%2520ERK%2520signaling%2520in%2520FLT3%252FITD%2520leukemia%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26spage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. D.</span></span> <span> </span><span class="NLM_article-title">Technique for assessment of leukocyte adherence to human umbilical vein endothelial cell monolayers</span>. <i>J. Pharmacol. Toxicol. Methods</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/1056-8719(94)90056-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1016%2F1056-8719%2894%2990056-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=7532469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADyaK2MXitFensro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1994&pages=73-77&author=P.+E.+McGregorauthor=D.+K.+Agrawalauthor=J.+D.+Edwards&title=Technique+for+assessment+of+leukocyte+adherence+to+human+umbilical+vein+endothelial+cell+monolayers&doi=10.1016%2F1056-8719%2894%2990056-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Technique for assessment of leukocyte adherence to human umbilical vein endothelial cell monolayers</span></div><div class="casAuthors">McGregor, Patrick E.; Agrawal, Devendra K.; Edwards, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">73-7</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The interaction between endothelial cells and immune/inflammatory cells plays an important role in the pathogenesis of vascular diseases.  Inflammatory cells also activate endothelial cells and release both proliferative and cytotoxic mediators.  In order to exam. the interaction between leukocytes and endothelial cells and the effect of various drugs, we established the methodol. for isolating and culturing the endothelial cells from human umbilical vein.  Endothelial cells were harvested by using 0.1% collagenase within 48 h of collecting the cord.  Cells were grown to confluency in 96-well plates in Medium 199 contg. 20% fetal calf serum, endothelial cell growth supplement, heparin, and antibiotics.  Using this method, we obtained a confluent layer of the cells in all the 96 wells within 48 h.  We then examd. the effect of peptides, endothelin-1, substance P, and neurokinin-A on the adherence of human blood neutrophils (purity and viability > 98%) to endothelial monolayers.  All the peptides enhanced (p < 0.05) the adherence of neutrophils to endothelial cells in a time-dependent manner.  This method of endothelial cell culturing is reliable, reproducible, and effective in evaluating the role of various mediators and drugs on the adherence of various white blood cells to endothelium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFJIlJ5a1oLbVg90H21EOLACvtfcHk0li5hDorVbSiLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXitFensro%253D&md5=6e65f5298d5d3d65c8e2209b51a8fb82</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2F1056-8719%2894%2990056-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F1056-8719%252894%252990056-6%26sid%3Dliteratum%253Aachs%26aulast%3DMcGregor%26aufirst%3DP.%2BE.%26aulast%3DAgrawal%26aufirst%3DD.%2BK.%26aulast%3DEdwards%26aufirst%3DJ.%2BD.%26atitle%3DTechnique%2520for%2520assessment%2520of%2520leukocyte%2520adherence%2520to%2520human%2520umbilical%2520vein%2520endothelial%2520cell%2520monolayers%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D1994%26volume%3D32%26spage%3D73%26epage%3D77%26doi%3D10.1016%2F1056-8719%2894%2990056-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgartner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Sullivan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterhouse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taromi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apostolova, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illert, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchinger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquesne, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt-Graeff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osswald, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tugues, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeifer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Follo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lübbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rummelt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wäsch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haag, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidts, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultheiss, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettinger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thimme, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanriver, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuong, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmati, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ditschkowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jilg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leiber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerull, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengerke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pabst, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobbe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rösler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doostkam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meckel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stabla, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzelder, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halbach, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dengjel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackanson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtick, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheid, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spyridonidis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stölzel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ordemann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicre-de-Fontbrune, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihorst, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuball, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehlert, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cahn, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuchenbauer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunjes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraverty, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kröger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayuk, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vago, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaeger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuster, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisdorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Velden, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dörfel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethge, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilgendorf, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochhaus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrieux, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Börries, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magenau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labopin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henden, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLornan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mufti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezvani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negrin, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burchert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beelen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackensen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Bubnoff, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herr, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Socié, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligiuri, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggiero, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Häcker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duyster, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blazar, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeiser, R.</span></span> <span> </span><span class="NLM_article-title">Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">282</span>– <span class="NLM_lpage">291</span>, <span class="refDoi"> DOI: 10.1038/nm.4484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1038%2Fnm.4484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=29431743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFCiu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=282-291&author=N.+R.+Mathewauthor=F.+Baumgartnerauthor=L.+Braunauthor=D.+O%E2%80%99Sullivanauthor=S.+Thomasauthor=M.+Waterhouseauthor=T.+A.+M%C3%BCllerauthor=K.+Hankeauthor=S.+Taromiauthor=P.+Apostolovaauthor=A.+L.+Illertauthor=W.+Melchingerauthor=S.+Duquesneauthor=A.+Schmitt-Graeffauthor=L.+Osswaldauthor=K.+L.+Yanauthor=A.+Weberauthor=S.+Tuguesauthor=S.+Spathauthor=D.+Pfeiferauthor=M.+Folloauthor=R.+Clausauthor=M.+L%C3%BCbbertauthor=C.+Rummeltauthor=H.+Bertzauthor=R.+W%C3%A4schauthor=J.+Haagauthor=A.+Schmidtsauthor=M.+Schultheissauthor=D.+Bettingerauthor=R.+Thimmeauthor=E.+Ullrichauthor=Y.+Tanriverauthor=G.+L.+Vuongauthor=R.+Arnoldauthor=P.+Hemmatiauthor=D.+Wolfauthor=M.+Ditschkowskiauthor=C.+Jilgauthor=K.+Wilhelmauthor=C.+Leiberauthor=S.+Gerullauthor=J.+Halterauthor=C.+Lengerkeauthor=T.+Pabstauthor=T.+Schroederauthor=G.+Kobbeauthor=W.+R%C3%B6slerauthor=S.+Doostkamauthor=S.+Meckelauthor=K.+Stablaauthor=S.+K.+Metzelderauthor=S.+Halbachauthor=T.+Brummerauthor=Z.+Huauthor=J.+Dengjelauthor=B.+Hackansonauthor=C.+Schmidauthor=U.+Holtickauthor=C.+Scheidauthor=A.+Spyridonidisauthor=F.+St%C3%B6lzelauthor=R.+Ordemannauthor=L.+P.+M%C3%BCllerauthor=F.+Sicre-de-Fontbruneauthor=G.+Ihorstauthor=J.+Kuballauthor=J.+E.+Ehlertauthor=D.+Fegerauthor=E.+M.+Wagnerauthor=J.+Y.+Cahnauthor=J.+Schnellauthor=F.+Kuchenbauerauthor=D.+Bunjesauthor=R.+Chakravertyauthor=S.+Richardsonauthor=S.+Gillauthor=N.+Kr%C3%B6gerauthor=F.+Ayukauthor=L.+Vagoauthor=F.+Ciceriauthor=A.+M.+M%C3%BCllerauthor=T.+Kondoauthor=T.+Teshimaauthor=S.+Klaegerauthor=B.+Kusterauthor=D.+D.+H.+Kimauthor=D.+Weisdorfauthor=W.+van+der+Veldenauthor=D.+D%C3%B6rfelauthor=W.+Bethgeauthor=I.+Hilgendorfauthor=A.+Hochhausauthor=G.+Andrieuxauthor=M.+B%C3%B6rriesauthor=H.+Buschauthor=J.+Magenauauthor=P.+Reddyauthor=M.+Labopinauthor=J.+H.+Antinauthor=A.+S.+Hendenauthor=G.+R.+Hillauthor=G.+A.+Kennedyauthor=M.+Barauthor=A.+Sarmaauthor=D.+McLornanauthor=G.+Muftiauthor=B.+Oranauthor=K.+Rezvaniauthor=O.+Shahauthor=R.+S.+Negrinauthor=A.+Naglerauthor=M.+Prinzauthor=A.+Burchertauthor=A.+Neubauerauthor=D.+Beelenauthor=A.+Mackensenauthor=N.+von+Bubnoffauthor=W.+Herrauthor=B.+Becherauthor=G.+Soci%C3%A9author=M.+A.+Caligiuriauthor=E.+Ruggieroauthor=C.+Boniniauthor=G.+H%C3%A4ckerauthor=J.+Duysterauthor=J.+Finkeauthor=E.+Pearceauthor=B.+R.+Blazarauthor=R.+Zeiser&title=Sorafenib+promotes+graft-versus-leukemia+activity+in+mice+and+humans+through+IL-15+production+in+FLT3-ITD-mutant+leukemia+cells&doi=10.1038%2Fnm.4484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells</span></div><div class="casAuthors">Mathew, Nimitha R.; Baumgartner, Francis; Braun, Lukas; O'Sullivan, David; Thomas, Simone; Waterhouse, Miguel; Mueller, Tony A.; Hanke, Kathrin; Taromi, Sanaz; Apostolova, Petya; Illert, Anna L.; Melchinger, Wolfgang; Duquesne, Sandra; Schmitt-Graeff, Annette; Osswald, Lena; Yan, Kai-Li; Weber, Arnim; Tugues, Sonia; Spath, Sabine; Pfeifer, Dietmar; Follo, Marie; Claus, Rainer; Luebbert, Michael; Rummelt, Christoph; Bertz, Hartmut; Waesch, Ralph; Haag, Johanna; Schmidts, Andrea; Schultheiss, Michael; Bettinger, Dominik; Thimme, Robert; Ullrich, Evelyn; Tanriver, Yakup; Vuong, Giang Lam; Arnold, Renate; Hemmati, Philipp; Wolf, Dominik; Ditschkowski, Markus; Jilg, Cordula; Wilhelm, Konrad; Leiber, Christian; Gerull, Sabine; Halter, Joerg; Lengerke, Claudia; Pabst, Thomas; Schroeder, Thomas; Kobbe, Guido; Roesler, Wolf; Doostkam, Soroush; Meckel, Stephan; Stabla, Kathleen; Metzelder, Stephan K.; Halbach, Sebastian; Brummer, Tilman; Hu, Zehan; Dengjel, Joern; Hackanson, Bjoern; Schmid, Christoph; Holtick, Udo; Scheid, Christof; Spyridonidis, Alexandros; Stoelzel, Friedrich; Ordemann, Rainer; Mueller, Lutz P.; Sicre-de-Fontbrune, Flore; Ihorst, Gabriele; Kuball, Juergen; Ehlert, Jan E.; Feger, Daniel; Wagner, Eva-Maria; Cahn, Jean-Yves; Schnell, Jacqueline; Kuchenbauer, Florian; Bunjes, Donald; Chakraverty, Ronjon; Richardson, Simon; Gill, Saar; Kroeger, Nicolaus; Ayuk, Francis; Vago, Luca; Ciceri, Fabio; Mueller, Antonia M.; Kondo, Takeshi; Teshima, Takanori; Klaeger, Susan; Kuster, Bernhard; Kim, Dennis; Weisdorf, Daniel; van der Velden, Walter; Doerfel, Daniela; Bethge, Wolfgang; Hilgendorf, Inken; Hochhaus, Andreas; Andrieux, Geoffroy; Boerries, Melanie; Busch, Hauke; Magenau, John; Reddy, Pavan; Labopin, Myriam; Antin, Joseph H.; Henden, Andrea S.; Hill, Geoffrey R.; Kennedy, Glen A.; Bar, Merav; Sarma, Anita; McLornan, Donal; Mufti, Ghulam; Oran, Betul; Rezvani, Katayoun; Sha, Omid; Negrin, Robert S.; Nagler, Arnon; Prinz, Marco; Burchert, Andreas; Neubauer, Andreas; Beelen, Dietrich; MacKensen, Andreas; von Bubnoff, Nikolas; Herr, Wolfgang; Becher, Burkhard; Socie, Gerard; Caligiuri, Michael A.; Ruggiero, Eliana; Bonini, Chiara; Haecker, Georg; Duyster, Justus; Finke, Juergen; Pearce, Erika; Blazar, Bruce R.; Zeiser, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">282-291</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Individuals with acute myeloid leukemia (AML) harboring an internal tandem duplication (ITD) in the gene encoding Fms-related tyrosine kinase 3 (FLT3) who relapse after allogeneic hematopoietic cell transplantation (allo-HCT) have a 1-yr survival rate below 20%.  We obsd. that sorafenib, a multitargeted tyrosine kinase inhibitor, increased IL-15 prodn. by FLT3-ITD+ leukemia cells.  This synergized with the allogeneic CD8+ T cell response, leading to long-term survival in six mouse models of FLT3-ITD+ AML.  Sorafenib-related IL-15 prodn. caused an increase in CD8+CD107a+IFN-γ+ T cells with features of longevity (high levels of Bcl-2 and reduced PD-1 levels), which eradicated leukemia in secondary recipients.  Mechanistically, sorafenib reduced expression of the transcription factor ATF4, thereby blocking neg. regulation of interferon regulatory factor 7 (IRF7) activation, which enhanced IL-15 transcription.  Both IRF7 knockdown and ATF4 overexpression in leukemia cells antagonized sorafenib-induced IL-15 prodn. in vitro.  Human FLT3-ITD+ AML cells obtained from sorafenib responders following sorafenib therapy showed increased levels of IL-15, phosphorylated IRF7, and a transcriptionally active IRF7 chromatin state.  The mitochondrial spare respiratory capacity and glycolytic capacity of CD8+ T cells increased upon sorafenib treatment in sorafenib responders but not in nonresponders.  Our findings indicate that the synergism of T cells and sorafenib is mediated via reduced ATF4 expression, causing activation of the IRF7-IL-15 axis in leukemia cells and thereby leading to metabolic reprogramming of leukemia-reactive T cells in humans.  Therefore, sorafenib treatment has the potential to contribute to an immune-mediated cure of FLT3-ITD-mutant AML relapse, an otherwise fatal complication after allo-HCT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh28bOOpaxCbVg90H21EOLACvtfcHk0lhF1K17B4fzaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFCiu7k%253D&md5=33c82d882c54611ac8a7ffc53efe4197</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnm.4484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4484%26sid%3Dliteratum%253Aachs%26aulast%3DMathew%26aufirst%3DN.%2BR.%26aulast%3DBaumgartner%26aufirst%3DF.%26aulast%3DBraun%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DWaterhouse%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%2BA.%26aulast%3DHanke%26aufirst%3DK.%26aulast%3DTaromi%26aufirst%3DS.%26aulast%3DApostolova%26aufirst%3DP.%26aulast%3DIllert%26aufirst%3DA.%2BL.%26aulast%3DMelchinger%26aufirst%3DW.%26aulast%3DDuquesne%26aufirst%3DS.%26aulast%3DSchmitt-Graeff%26aufirst%3DA.%26aulast%3DOsswald%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DK.%2BL.%26aulast%3DWeber%26aufirst%3DA.%26aulast%3DTugues%26aufirst%3DS.%26aulast%3DSpath%26aufirst%3DS.%26aulast%3DPfeifer%26aufirst%3DD.%26aulast%3DFollo%26aufirst%3DM.%26aulast%3DClaus%26aufirst%3DR.%26aulast%3DL%25C3%25BCbbert%26aufirst%3DM.%26aulast%3DRummelt%26aufirst%3DC.%26aulast%3DBertz%26aufirst%3DH.%26aulast%3DW%25C3%25A4sch%26aufirst%3DR.%26aulast%3DHaag%26aufirst%3DJ.%26aulast%3DSchmidts%26aufirst%3DA.%26aulast%3DSchultheiss%26aufirst%3DM.%26aulast%3DBettinger%26aufirst%3DD.%26aulast%3DThimme%26aufirst%3DR.%26aulast%3DUllrich%26aufirst%3DE.%26aulast%3DTanriver%26aufirst%3DY.%26aulast%3DVuong%26aufirst%3DG.%2BL.%26aulast%3DArnold%26aufirst%3DR.%26aulast%3DHemmati%26aufirst%3DP.%26aulast%3DWolf%26aufirst%3DD.%26aulast%3DDitschkowski%26aufirst%3DM.%26aulast%3DJilg%26aufirst%3DC.%26aulast%3DWilhelm%26aufirst%3DK.%26aulast%3DLeiber%26aufirst%3DC.%26aulast%3DGerull%26aufirst%3DS.%26aulast%3DHalter%26aufirst%3DJ.%26aulast%3DLengerke%26aufirst%3DC.%26aulast%3DPabst%26aufirst%3DT.%26aulast%3DSchroeder%26aufirst%3DT.%26aulast%3DKobbe%26aufirst%3DG.%26aulast%3DR%25C3%25B6sler%26aufirst%3DW.%26aulast%3DDoostkam%26aufirst%3DS.%26aulast%3DMeckel%26aufirst%3DS.%26aulast%3DStabla%26aufirst%3DK.%26aulast%3DMetzelder%26aufirst%3DS.%2BK.%26aulast%3DHalbach%26aufirst%3DS.%26aulast%3DBrummer%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DDengjel%26aufirst%3DJ.%26aulast%3DHackanson%26aufirst%3DB.%26aulast%3DSchmid%26aufirst%3DC.%26aulast%3DHoltick%26aufirst%3DU.%26aulast%3DScheid%26aufirst%3DC.%26aulast%3DSpyridonidis%26aufirst%3DA.%26aulast%3DSt%25C3%25B6lzel%26aufirst%3DF.%26aulast%3DOrdemann%26aufirst%3DR.%26aulast%3DM%25C3%25BCller%26aufirst%3DL.%2BP.%26aulast%3DSicre-de-Fontbrune%26aufirst%3DF.%26aulast%3DIhorst%26aufirst%3DG.%26aulast%3DKuball%26aufirst%3DJ.%26aulast%3DEhlert%26aufirst%3DJ.%2BE.%26aulast%3DFeger%26aufirst%3DD.%26aulast%3DWagner%26aufirst%3DE.%2BM.%26aulast%3DCahn%26aufirst%3DJ.%2BY.%26aulast%3DSchnell%26aufirst%3DJ.%26aulast%3DKuchenbauer%26aufirst%3DF.%26aulast%3DBunjes%26aufirst%3DD.%26aulast%3DChakraverty%26aufirst%3DR.%26aulast%3DRichardson%26aufirst%3DS.%26aulast%3DGill%26aufirst%3DS.%26aulast%3DKr%25C3%25B6ger%26aufirst%3DN.%26aulast%3DAyuk%26aufirst%3DF.%26aulast%3DVago%26aufirst%3DL.%26aulast%3DCiceri%26aufirst%3DF.%26aulast%3DM%25C3%25BCller%26aufirst%3DA.%2BM.%26aulast%3DKondo%26aufirst%3DT.%26aulast%3DTeshima%26aufirst%3DT.%26aulast%3DKlaeger%26aufirst%3DS.%26aulast%3DKuster%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DD.%2BD.%2BH.%26aulast%3DWeisdorf%26aufirst%3DD.%26aulast%3Dvan%2Bder%2BVelden%26aufirst%3DW.%26aulast%3DD%25C3%25B6rfel%26aufirst%3DD.%26aulast%3DBethge%26aufirst%3DW.%26aulast%3DHilgendorf%26aufirst%3DI.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DAndrieux%26aufirst%3DG.%26aulast%3DB%25C3%25B6rries%26aufirst%3DM.%26aulast%3DBusch%26aufirst%3DH.%26aulast%3DMagenau%26aufirst%3DJ.%26aulast%3DReddy%26aufirst%3DP.%26aulast%3DLabopin%26aufirst%3DM.%26aulast%3DAntin%26aufirst%3DJ.%2BH.%26aulast%3DHenden%26aufirst%3DA.%2BS.%26aulast%3DHill%26aufirst%3DG.%2BR.%26aulast%3DKennedy%26aufirst%3DG.%2BA.%26aulast%3DBar%26aufirst%3DM.%26aulast%3DSarma%26aufirst%3DA.%26aulast%3DMcLornan%26aufirst%3DD.%26aulast%3DMufti%26aufirst%3DG.%26aulast%3DOran%26aufirst%3DB.%26aulast%3DRezvani%26aufirst%3DK.%26aulast%3DShah%26aufirst%3DO.%26aulast%3DNegrin%26aufirst%3DR.%2BS.%26aulast%3DNagler%26aufirst%3DA.%26aulast%3DPrinz%26aufirst%3DM.%26aulast%3DBurchert%26aufirst%3DA.%26aulast%3DNeubauer%26aufirst%3DA.%26aulast%3DBeelen%26aufirst%3DD.%26aulast%3DMackensen%26aufirst%3DA.%26aulast%3Dvon%2BBubnoff%26aufirst%3DN.%26aulast%3DHerr%26aufirst%3DW.%26aulast%3DBecher%26aufirst%3DB.%26aulast%3DSoci%25C3%25A9%26aufirst%3DG.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26aulast%3DRuggiero%26aufirst%3DE.%26aulast%3DBonini%26aufirst%3DC.%26aulast%3DH%25C3%25A4cker%26aufirst%3DG.%26aulast%3DDuyster%26aufirst%3DJ.%26aulast%3DFinke%26aufirst%3DJ.%26aulast%3DPearce%26aufirst%3DE.%26aulast%3DBlazar%26aufirst%3DB.%2BR.%26aulast%3DZeiser%26aufirst%3DR.%26atitle%3DSorafenib%2520promotes%2520graft-versus-leukemia%2520activity%2520in%2520mice%2520and%2520humans%2520through%2520IL-15%2520production%2520in%2520FLT3-ITD-mutant%2520leukemia%2520cells%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D282%26epage%3D291%26doi%3D10.1038%2Fnm.4484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamm, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, B. K.</span></span> <span> </span><span class="NLM_article-title">One-step cellular caspase-3/7 assay</span>. <i>Biotechniques</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1064</span>– <span class="NLM_lpage">1067</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2003&pages=1064-1067&author=R.+A.+Carrascoauthor=N.+B.+Stammauthor=B.+K.+Patel&title=One-step+cellular+caspase-3%2F7+assay"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarrasco%26aufirst%3DR.%2BA.%26aulast%3DStamm%26aufirst%3DN.%2BB.%26aulast%3DPatel%26aufirst%3DB.%2BK.%26atitle%3DOne-step%2520cellular%2520caspase-3%252F7%2520assay%26jtitle%3DBiotechniques%26date%3D2003%26volume%3D34%26spage%3D1064%26epage%3D1067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damm, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maple, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reboul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupyan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlgren, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaus, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerutti, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krilov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span> <span> </span><span class="NLM_article-title">OPLS3: A force field providing broad coverage of drug-like small molecules and proteins</span>. <i>J. Chem. Theory Comput.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">296</span>, <span class="refDoi"> DOI: 10.1021/acs.jctc.5b00864</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jctc.5b00864" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVCjtbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=281-296&author=E.+Harderauthor=W.+Dammauthor=J.+Mapleauthor=C.+Wuauthor=M.+Reboulauthor=J.+Y.+Xiangauthor=L.+Wangauthor=D.+Lupyanauthor=M.+K.+Dahlgrenauthor=J.+L.+Knightauthor=J.+W.+Kausauthor=D.+S.+Ceruttiauthor=G.+Krilovauthor=W.+L.+Jorgensenauthor=R.+Abelauthor=R.+A.+Friesner&title=OPLS3%3A+A+force+field+providing+broad+coverage+of+drug-like+small+molecules+and+proteins&doi=10.1021%2Facs.jctc.5b00864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins</span></div><div class="casAuthors">Harder, Edward; Damm, Wolfgang; Maple, Jon; Wu, Chuanjie; Reboul, Mark; Xiang, Jin Yu; Wang, Lingle; Lupyan, Dmitry; Dahlgren, Markus K.; Knight, Jennifer L.; Kaus, Joseph W.; Cerutti, David S.; Krilov, Goran; Jorgensen, William L.; Abel, Robert; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">281-296</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The parametrization and validation of the OPLS3 force field for small mols. and proteins are reported.  Enhancements with respect to the previous version (OPLS2.1) include the addn. of off-atom charge sites to represent halogen bonding and aryl nitrogen lone pairs as well as a complete refit of peptide dihedral parameters to better model the native structure of proteins.  To adequately cover medicinal chem. space, OPLS3 employs over an order of magnitude more ref. data and assocd. parameter types relative to other commonly used small mol. force fields (e.g., MMFF and OPLS_2005).  As a consequence, OPLS3 achieves a high level of accuracy across performance benchmarks that assess small mol. conformational propensities and solvation.  The newly fitted peptide dihedrals lead to significant improvements in the representation of secondary structure elements in simulated peptides and native structure stability over a no. of proteins.  Together, the improvements made to both the small mol. and protein force field lead to a high level of accuracy in predicting protein-ligand binding measured over a wide range of targets and ligands (less than 1 kcal/mol RMS error) representing a 30% improvement over earlier variants of the OPLS force field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY_jrOhcBRgrVg90H21EOLACvtfcHk0liIb5wXrx3tSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVCjtbfE&md5=42663f8cfa84b80a67132bbb13b9b7ce</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jctc.5b00864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jctc.5b00864%26sid%3Dliteratum%253Aachs%26aulast%3DHarder%26aufirst%3DE.%26aulast%3DDamm%26aufirst%3DW.%26aulast%3DMaple%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DReboul%26aufirst%3DM.%26aulast%3DXiang%26aufirst%3DJ.%2BY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLupyan%26aufirst%3DD.%26aulast%3DDahlgren%26aufirst%3DM.%2BK.%26aulast%3DKnight%26aufirst%3DJ.%2BL.%26aulast%3DKaus%26aufirst%3DJ.%2BW.%26aulast%3DCerutti%26aufirst%3DD.%2BS.%26aulast%3DKrilov%26aufirst%3DG.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DOPLS3%253A%2520A%2520force%2520field%2520providing%2520broad%2520coverage%2520of%2520drug-like%2520small%2520molecules%2520and%2520proteins%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2016%26volume%3D12%26spage%3D281%26epage%3D296%26doi%3D10.1021%2Facs.jctc.5b00864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halgren, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beard, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, J. L.</span></span> <span> </span><span class="NLM_article-title">Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1750</span>– <span class="NLM_lpage">1759</span>, <span class="refDoi"> DOI: 10.1021/jm030644s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030644s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFyit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1750-1759&author=T.+A.+Halgrenauthor=R.+B.+Murphyauthor=R.+A.+Friesnerauthor=H.+S.+Beardauthor=L.+L.+Fryeauthor=W.+T.+Pollardauthor=J.+L.+Banks&title=Glide%3A+a+new+approach+for+rapid%2C+accurate+docking+and+scoring.+2.+Enrichment+factors+in+database+screening&doi=10.1021%2Fjm030644s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening</span></div><div class="casAuthors">Halgren, Thomas A.; Murphy, Robert B.; Friesner, Richard A.; Beard, Hege S.; Frye, Leah L.; Pollard, W. Thomas; Banks, Jay L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1750-1759</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Glide's ability to identify active compds. in a database screen is characterized by applying Glide to a diverse set of nine protein receptors.  In many cases, two, or even three, protein sites are employed to probe the sensitivity of the results to the site geometry.  To make the database screens as realistic as possible, the screens use sets of "druglike" decoy ligands that have been selected to be representative of what we believe is likely to be found in the compd. collection of a pharmaceutical or biotechnol. company.  Results are presented for releases 1.8, 2.0, and 2.5 of Glide.  The comparisons show that av. measures for both "early" and "global" enrichment for Glide 2.5 are 3 times higher than for Glide 1.8 and more than 2 times higher than for Glide 2.0 because of better results for the least well-handled screens.  This improvement in enrichment stems largely from the better balance of the more widely parametrized GlideScore 2.5 function and the inclusion of terms that penalize ligand-protein interactions that violate established principles of phys. chem., particularly as it concerns the exposure to solvent of charged protein and ligand groups.  Comparisons to results for the thymidine kinase and estrogen receptors published by Rognan and co-workers (J. Med. Chem. 2000, 43, 4759-4767) show that Glide 2.5 performs better than GOLD 1.1, FlexX 1.8, or DOCK 4.01.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT2ptubbKbvLVg90H21EOLACvtfcHk0liIb5wXrx3tSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFyit78%253D&md5=33d68dd968e65626b449df61e44e37be</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm030644s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030644s%26sid%3Dliteratum%253Aachs%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DBeard%26aufirst%3DH.%2BS.%26aulast%3DFrye%26aufirst%3DL.%2BL.%26aulast%3DPollard%26aufirst%3DW.%2BT.%26aulast%3DBanks%26aufirst%3DJ.%2BL.%26atitle%3DGlide%253A%2520a%2520new%2520approach%2520for%2520rapid%252C%2520accurate%2520docking%2520and%2520scoring.%25202.%2520Enrichment%2520factors%2520in%2520database%2520screening%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1750%26epage%3D1759%26doi%3D10.1021%2Fjm030644s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 15 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Zhijie Wang, Jiongheng Cai, Jie Cheng, Wenqianzi Yang, Yifan Zhu, Hongmei Li, Tao Lu, Yadong Chen, <span class="NLM_string-name hlFld-ContribAuthor">Shuai Lu</span>. </span><span class="cited-content_cbyCitation_article-title">FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (6)
                                     , 2878-2900. <a href="https://doi.org/10.1021/acs.jmedchem.0c01851" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01851</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01851%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFLT3%252BInhibitors%252Bin%252BAcute%252BMyeloid%252BLeukemia%25253A%252BChallenges%252Band%252BRecent%252BDevelopments%252Bin%252BOvercoming%252BResistance%26aulast%3DWang%26aufirst%3DZhijie%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D23102020%26date%3D10032021%26volume%3D64%26issue%3D6%26spage%3D2878%26epage%3D2900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhouling Xie, Xiaoxiao Yang, Yajun Duan, Jihong Han, <span class="NLM_string-name hlFld-ContribAuthor">Chenzhong Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1283-1345. <a href="https://doi.org/10.1021/acs.jmedchem.0c01511" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01511%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BNononcologic%252BDiseases%26aulast%3DXie%26aufirst%3DZhouling%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29082020%26date%3D22012021%26volume%3D64%26issue%3D3%26spage%3D1283%26epage%3D1345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yue Zhong, Run-Ze Qiu, Shan-Liang Sun, Chao Zhao, Tian-Yuan Fan, Min Chen, Nian-Guang Li, <span class="NLM_string-name hlFld-ContribAuthor">Zhi-Hao Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (21)
                                     , 12403-12428. <a href="https://doi.org/10.1021/acs.jmedchem.0c00696" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00696</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00696&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00696%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BFms-like%252BTyrosine%252BKinase%252B3%252BInhibitors%25253A%252BAn%252BAttractive%252Band%252BEfficient%252BMethod%252Bfor%252Bthe%252BTreatment%252Bof%252BAcute%252BMyeloid%252BLeukemia%26aulast%3DZhong%26aufirst%3DYue%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26042020%26date%3D21072020%26date%3D13072020%26volume%3D63%26issue%3D21%26spage%3D12403%26epage%3D12428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tao Yang, Mengshi Hu, Wenyan Qi, Zhuang Yang, Minghai Tang, Jun He, Yong Chen, Peng Bai, Xue Yuan, Chufeng Zhang, Kongjun Liu, Yulin Lu, Mingli Xiang, <span class="NLM_string-name hlFld-ContribAuthor">Lijuan Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (22)
                                     , 10305-10320. <a href="https://doi.org/10.1021/acs.jmedchem.9b01348" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01348</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01348%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPotent%252Band%252BOrally%252BEffective%252BDual%252BJanus%252BKinase%252B2%25252FFLT3%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BAcute%252BMyelogenous%252BLeukemia%252Band%252BMyeloproliferative%252BNeoplasms%26aulast%3DYang%26aufirst%3DTao%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D15082019%26date%3D08112019%26date%3D31102019%26volume%3D62%26issue%3D22%26spage%3D10305%26epage%3D10320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xue Yuan, Yong Chen, Wanhua Zhang, Jun He, Lei Lei, Minghai Tang, Jiang Liu, Muzhou Li, Caixia Dou, Tao Yang, Linyu Yang, Shengyong Yang, Yuquan Wei, Aihua Peng, Ting Niu, Mingli Xiang, Haoyu Ye, <span class="NLM_string-name hlFld-ContribAuthor">Lijuan Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Pyrrolo[2,3-d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (8)
                                     , 4158-4173. <a href="https://doi.org/10.1021/acs.jmedchem.9b00223" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00223</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00223%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BPyrrolo%25255B2%25252C3-d%25255Dpyrimidine-Based%252BDerivatives%252Bas%252BPotent%252Band%252BOrally%252BEffective%252BFms-like%252BTyrosine%252BReceptor%252BKinase%252B3%252B%252528FLT3%252529%252BInhibitors%252Bfor%252BTreating%252BAcute%252BMyelogenous%252BLeukemia%26aulast%3DYuan%26aufirst%3DXue%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D02022019%26date%3D15042019%26date%3D02042019%26volume%3D62%26issue%3D8%26spage%3D4158%26epage%3D4173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mathias  Elsocht</span>, <span class="hlFld-ContribAuthor ">Philippe  Giron</span>, <span class="hlFld-ContribAuthor ">Laila  Maes</span>, <span class="hlFld-ContribAuthor ">Wim  Versées</span>, <span class="hlFld-ContribAuthor ">Gustavo J.  Gutierrez</span>, <span class="hlFld-ContribAuthor ">Jacques  De Grève</span>, <span class="hlFld-ContribAuthor ">Steven  Ballet</span>. </span><span class="cited-content_cbyCitation_article-title">Structure–Activity Relationship (SAR) Study of Spautin-1 to Entail the Discovery of Novel NEK4 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (2)
                                     , 635. <a href="https://doi.org/10.3390/ijms22020635" title="DOI URL">https://doi.org/10.3390/ijms22020635</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22020635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22020635%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DStructure%2525E2%252580%252593Activity%252BRelationship%252B%252528SAR%252529%252BStudy%252Bof%252BSpautin-1%252Bto%252BEntail%252Bthe%252BDiscovery%252Bof%252BNovel%252BNEK4%252BInhibitors%26aulast%3DElsocht%26aufirst%3DMathias%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D2%26spage%3D635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A  Špičáková</span>, <span class="hlFld-ContribAuthor ">P  Kraus</span>, <span class="hlFld-ContribAuthor ">T  Gucký</span>, <span class="hlFld-ContribAuthor ">V  Kryštof</span>, <span class="hlFld-ContribAuthor ">M  Strnad</span>, <span class="hlFld-ContribAuthor ">V  Bazgier</span>, <span class="hlFld-ContribAuthor ">M  Otyepka</span>, <span class="hlFld-ContribAuthor ">V  Kubíčková</span>, <span class="hlFld-ContribAuthor ">M  Poruba</span>, <span class="hlFld-ContribAuthor ">Z  Rácová</span>, <span class="hlFld-ContribAuthor ">I  Zapletalová</span>, <span class="hlFld-ContribAuthor ">P  Anzenbacher</span>. </span><span class="cited-content_cbyCitation_article-title">in vitro and in silico studies of interaction of synthetic 2,6,9-trisubstituted purine kinase inhibitors BPA-302, BP-21 and BP-117 with liver drug-metabolizing cytochromes P450. </span><span class="cited-content_cbyCitation_journal-name">Physiological Research</span><span> <strong>2020,</strong> <em> </em>, S627-S636. <a href="https://doi.org/10.33549/physiolres.934611" title="DOI URL">https://doi.org/10.33549/physiolres.934611</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.33549/physiolres.934611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.33549%2Fphysiolres.934611%26sid%3Dliteratum%253Aachs%26jtitle%3DPhysiological%2520Research%26atitle%3Din%252Bvitro%252Band%252Bin%252Bsilico%252Bstudies%252Bof%252Binteraction%252Bof%252Bsynthetic%252B2%25252C6%25252C9-trisubstituted%252Bpurine%252Bkinase%252Binhibitors%252BBPA-302%25252C%252BBP-21%252Band%252BBP-117%252Bwith%252Bliver%252Bdrug-metabolizing%252Bcytochromes%252BP450%26aulast%3D%25C5%25A0pi%25C4%258D%25C3%25A1kov%25C3%25A1%26aufirst%3DA%26date%3D2020%26date%3D2020%26spage%3DS627%26epage%3DS636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lexian  Tong</span>, <span class="hlFld-ContribAuthor ">Xuemei  Li</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>, <span class="hlFld-ContribAuthor ">Tao  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in FLT3 inhibitors for acute myeloid leukemia. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2020,</strong> <em>12 </em>
                                    (10)
                                     , 961-981. <a href="https://doi.org/10.4155/fmc-2019-0365" title="DOI URL">https://doi.org/10.4155/fmc-2019-0365</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2019-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2019-0365%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252BFLT3%252Binhibitors%252Bfor%252Bacute%252Bmyeloid%252Bleukemia%26aulast%3DTong%26aufirst%3DLexian%26date%3D2020%26volume%3D12%26issue%3D10%26spage%3D961%26epage%3D981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jean-Luc  Décout</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic 5-6 Systems—Purines. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,<a href="https://doi.org/10.1016/B978-0-12-409547-2.14915-7" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.14915-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.14915-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.14915-7%26sid%3Dliteratum%253Aachs%26atitle%3DBicyclic%252B5-6%252BSystems%2525E2%252580%252594Purines%26aulast%3DD%25C3%25A9cout%26aufirst%3DJean-Luc%26date%3D2020%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2020%26volume%3D42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jeanluc  Bertrand</span>, <span class="hlFld-ContribAuthor ">Hana  Dostálová</span>, <span class="hlFld-ContribAuthor ">Vladimir  Krystof</span>, <span class="hlFld-ContribAuthor ">Radek  Jorda</span>, <span class="hlFld-ContribAuthor ">Alejandro  Castro</span>, <span class="hlFld-ContribAuthor ">Jaime  Mella</span>, <span class="hlFld-ContribAuthor ">Christian  Espinosa-Bustos</span>, <span class="hlFld-ContribAuthor ">Ana  María Zarate</span>, <span class="hlFld-ContribAuthor ">Cristian O.  Salas</span>. </span><span class="cited-content_cbyCitation_article-title">New 2,6,9-trisubstituted purine derivatives as Bcr-Abl and Btk inhibitors and as promising agents against leukemia. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>94 </em>, 103361. <a href="https://doi.org/10.1016/j.bioorg.2019.103361" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103361</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103361%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DNew%252B2%25252C6%25252C9-trisubstituted%252Bpurine%252Bderivatives%252Bas%252BBcr-Abl%252Band%252BBtk%252Binhibitors%252Band%252Bas%252Bpromising%252Bagents%252Bagainst%252Bleukemia%26aulast%3DBertrand%26aufirst%3DJeanluc%26date%3D2020%26volume%3D94%26spage%3D103361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cristian  O. Salas</span>, <span class="hlFld-ContribAuthor ">Ana Maria  Zarate</span>, <span class="hlFld-ContribAuthor ">Vladimir  Kryštof</span>, <span class="hlFld-ContribAuthor ">Jaime  Mella</span>, <span class="hlFld-ContribAuthor ">Mario  Faundez</span>, <span class="hlFld-ContribAuthor ">Jose  Brea</span>, <span class="hlFld-ContribAuthor ">María Isabel  Loza</span>, <span class="hlFld-ContribAuthor ">Ivan  Brito</span>, <span class="hlFld-ContribAuthor ">Denisa  Hendrychová</span>, <span class="hlFld-ContribAuthor ">Radek  Jorda</span>, <span class="hlFld-ContribAuthor ">Alan R.  Cabrera</span>, <span class="hlFld-ContribAuthor ">Ricardo A.  Tapia</span>, <span class="hlFld-ContribAuthor ">Christian  Espinosa-Bustos</span>. </span><span class="cited-content_cbyCitation_article-title">Promising 2,6,9-Trisubstituted Purine Derivatives for Anticancer Compounds: Synthesis, 3D-QSAR, and Preliminary Biological Assays. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (1)
                                     , 161. <a href="https://doi.org/10.3390/ijms21010161" title="DOI URL">https://doi.org/10.3390/ijms21010161</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21010161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21010161%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DPromising%252B2%25252C6%25252C9-Trisubstituted%252BPurine%252BDerivatives%252Bfor%252BAnticancer%252BCompounds%25253A%252BSynthesis%25252C%252B3D-QSAR%25252C%252Band%252BPreliminary%252BBiological%252BAssays%26aulast%3DO.%2BSalas%26aufirst%3DCristian%26date%3D2020%26date%3D2019%26volume%3D21%26issue%3D1%26spage%3D161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyi  Jiang</span>, <span class="hlFld-ContribAuthor ">Ji  Yu</span>, <span class="hlFld-ContribAuthor ">Zhongxia  Zhou</span>, <span class="hlFld-ContribAuthor ">Jacob  Kongsted</span>, <span class="hlFld-ContribAuthor ">Yuning  Song</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Vasanthanathan  Poongavanam</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular design opportunities presented by solvent‐exposed regions of target proteins. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (6)
                                     , 2194-2238. <a href="https://doi.org/10.1002/med.21581" title="DOI URL">https://doi.org/10.1002/med.21581</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21581%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DMolecular%252Bdesign%252Bopportunities%252Bpresented%252Bby%252Bsolvent%2525E2%252580%252590exposed%252Bregions%252Bof%252Btarget%252Bproteins%26aulast%3DJiang%26aufirst%3DXiangyi%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D6%26spage%3D2194%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eva  Řezníčková</span>, <span class="hlFld-ContribAuthor ">Tomáš  Gucký</span>, <span class="hlFld-ContribAuthor ">Veronika  Kováčová</span>, <span class="hlFld-ContribAuthor ">Haresh  Ajani</span>, <span class="hlFld-ContribAuthor ">Radek  Jorda</span>, <span class="hlFld-ContribAuthor ">Vladimír  Kryštof</span>. </span><span class="cited-content_cbyCitation_article-title">Activity of 2,6,9-trisubstituted purines as potent PDGFRα kinase inhibitors with antileukaemic activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>182 </em>, 111663. <a href="https://doi.org/10.1016/j.ejmech.2019.111663" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111663</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111663%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DActivity%252Bof%252B2%25252C6%25252C9-trisubstituted%252Bpurines%252Bas%252Bpotent%252BPDGFR%2525CE%2525B1%252Bkinase%252Binhibitors%252Bwith%252Bantileukaemic%252Bactivity%26aulast%3D%25C5%2598ezn%25C3%25AD%25C4%258Dkov%25C3%25A1%26aufirst%3DEva%26date%3D2019%26volume%3D182%26spage%3D111663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">V. V.  Musiyak</span>, <span class="hlFld-ContribAuthor ">I. A.  Nizova</span>, <span class="hlFld-ContribAuthor ">T. V.  Matveeva</span>, <span class="hlFld-ContribAuthor ">G. L.  Levit</span>, <span class="hlFld-ContribAuthor ">V. P.  Krasnov</span>, <span class="hlFld-ContribAuthor ">V. N.  Charushin</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of New Purine Derivatives Containing α- and ω-Amino Acid Fragments. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>55 </em>
                                    (6)
                                     , 762-770. <a href="https://doi.org/10.1134/S1070428019060046" title="DOI URL">https://doi.org/10.1134/S1070428019060046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070428019060046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070428019060046%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252BNew%252BPurine%252BDerivatives%252BContaining%252B%2525CE%2525B1-%252Band%252B%2525CF%252589-Amino%252BAcid%252BFragments%26aulast%3DMusiyak%26aufirst%3DV.%2BV.%26date%3D2019%26date%3D2019%26volume%3D55%26issue%3D6%26spage%3D762%26epage%3D770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Baohui  Qi</span>, <span class="hlFld-ContribAuthor ">Xingwei  Xu</span>, <span class="hlFld-ContribAuthor ">Ying  Yang</span>, <span class="hlFld-ContribAuthor ">Yuting  Zhou</span>, <span class="hlFld-ContribAuthor ">Tao  Chen</span>, <span class="hlFld-ContribAuthor ">Guowei  Gong</span>, <span class="hlFld-ContribAuthor ">Xupeng  Yue</span>, <span class="hlFld-ContribAuthor ">Xin  Xu</span>, <span class="hlFld-ContribAuthor ">Liping  Hu</span>, <span class="hlFld-ContribAuthor ">Huan  He</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of thiazolidin-4-one urea analogues as novel multikinase inhibitors that potently inhibit FLT3 and VEGFR2. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (10)
                                     , 2127-2139. <a href="https://doi.org/10.1016/j.bmc.2019.03.049" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.03.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.03.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.03.049%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bthiazolidin-4-one%252Burea%252Banalogues%252Bas%252Bnovel%252Bmultikinase%252Binhibitors%252Bthat%252Bpotently%252Binhibit%252BFLT3%252Band%252BVEGFR2%26aulast%3DQi%26aufirst%3DBaohui%26date%3D2019%26volume%3D27%26issue%3D10%26spage%3D2127%26epage%3D2139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/medium/jm-2017-015295_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01529&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/medium/jm-2017-015295_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0005.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01529&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reaction conditions: (a) Appropriate secondary amine, K<sub>2</sub>CO<sub>3</sub>, ethanol, reflux; (b) H<sub>2</sub>/Pd–C 5%, rt, atmospheric pressure.</p></p></figure><figure data-id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/medium/jm-2017-015295_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0006.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01529&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reaction conditions: (a) Appropriate 4-substituted aniline or 6-substituted-pyridine-3-amine, DIPEA, <i>n</i>-propanol, 120 °C, 4–20 h, sealed tube; (b) appropriate primary or secondary amine, 1,2-ethandiol, 160 °C, 4–20 h, sealed tube.</p></p></figure><figure data-id="fig1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/medium/jm-2017-015295_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0001.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Docked binding pose of <b>7d</b> (orange sticks) in FLT3. The kinase (cyan cartoon) is modeled in active conformation, and the P-loop (green cartoon), helix-C (magenta), and activation loop (AL; yellow) are highlighted. FLT3 interacting residues are shown as sticks colored gray for carbon, blue for nitrogen, red for oxygen, yellow for sulfur, and white for hydrogen. Figure prepared with Maestro, Schrodinger, LLC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01529&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/medium/jm-2017-015295_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Effect of <b>7d</b> on FLT3 and some of its downstream signaling pathways. PCNA was used as a control for protein loading. Densitometric analysis is available from <a href="/doi/suppl/10.1021/acs.jmedchem.7b01529/suppl_file/jm7b01529_si_003.pdf" class="ext-link">Figure S2</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01529&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/medium/jm-2017-015295_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effect of <b>7d</b> on cell cycle (A) and apoptosis (B, C) in the MV4-11 and K562 cell lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01529&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/medium/jm-2017-015295_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>7d</b> induces sustained suppression of FLT3-ITD signaling in MV4-11 xenograft tumors. Subcutaneous mouse xenografts were treated with 10 mg/kg <b>7d</b> (A) or quizartinib (B), and the phosphorylation status of FLT3 and its downstream signaling molecules was analyzed by immunoblotting at the indicated times. GAPDH was used as a control for protein loading. Each line represents a separate animal.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01529/20180504/images/large/jm-2017-015295_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01529&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i87">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71432" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71432" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 30 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, N.</span></span> <span> </span><span class="NLM_article-title">Realizing the promise of cancer predisposition genes</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>505</i></span>,  <span class="NLM_fpage">302</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1038/nature12981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1038%2Fnature12981" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=505&publication_year=2014&pages=302-308&author=N.+Rahman&title=Realizing+the+promise+of+cancer+predisposition+genes&doi=10.1038%2Fnature12981"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnature12981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12981%26sid%3Dliteratum%253Aachs%26aulast%3DRahman%26aufirst%3DN.%26atitle%3DRealizing%2520the%2520promise%2520of%2520cancer%2520predisposition%2520genes%26jtitle%3DNature%26date%3D2014%26volume%3D505%26spage%3D302%26epage%3D308%26doi%3D10.1038%2Fnature12981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J.</span></span> <span> </span><span class="NLM_article-title">The roles of FLT3 in hematopoiesis and leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">1532</span>– <span class="NLM_lpage">1542</span>, <span class="refDoi"> DOI: 10.1182/blood-2002-02-0492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1182%2Fblood-2002-02-0492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=12176867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslyhsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2002&pages=1532-1542&author=D.+Gillilandauthor=J.+Griffin&title=The+roles+of+FLT3+in+hematopoiesis+and+leukemia&doi=10.1182%2Fblood-2002-02-0492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The roles of FLT3 in hematopoiesis and leukemia</span></div><div class="casAuthors">Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1532-1542</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">FLT3 is a receptor tyrosine kinase expressed by immature hematopoietic cells and is important for the normal development of stem cells and the immune system.  The ligand for FLT3 is expressed by marrow stromal cells and other cells and synergized with other growth factors to stimulate proliferation of stem cells, progenitor cells, dendritic cells, and natural killer cells.  Mutations of FLT3 have been detected in about 30% of patients with acute myelogenous leukemia and a small no. of patients with acute lymphocytic leukemia or myelodysplastic syndrome.  Patients with FLT3 mutations tend to have a poor prognosis.  The mutations most often involve small tandem duplications of amino acids within the juxtamembrane domain of the receptor and result in constitutive tyrosine kinase activity.  Expression of a mutant FLT3 receptor in murine marrow cells results in a lethal myeloproliferative syndrome and preliminary studies suggest that mutant FLT3 cooperates with other leukemia oncogenes to confer a more aggressive phenotype.  Taken together, these results suggest that FLT3 is an attractive therapeutic target for kinase inhibitors or other approaches for patients with mutations of this gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYQc2WkC8EQbVg90H21EOLACvtfcHk0lifW0obcrNLGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslyhsLc%253D&md5=f6d04b227f5c5baf5c22cfba6e693ff1</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1182%2Fblood-2002-02-0492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2002-02-0492%26sid%3Dliteratum%253Aachs%26aulast%3DGilliland%26aufirst%3DD.%26aulast%3DGriffin%26aufirst%3DJ.%26atitle%3DThe%2520roles%2520of%2520FLT3%2520in%2520hematopoiesis%2520and%2520leukemia%26jtitle%3DBlood%26date%3D2002%26volume%3D100%26spage%3D1532%26epage%3D1542%26doi%3D10.1182%2Fblood-2002-02-0492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabs, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civin, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span> <span> </span><span class="NLM_article-title">Localization of the human stem cell tyrosine kinase-1 gene (FLT3) to 13Q12-->Q13</span>. <i>Cytogenet. Cell Genet.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1159/000134046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1159%2F000134046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=7789184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADyaK2MXnsF2quro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1995&pages=255-257&author=C.+Carowauthor=E.+Kimauthor=A.+Hawkinsauthor=H.+Webbauthor=C.+Griffinauthor=E.+Jabsauthor=C.+I.+Civinauthor=D.+Small&title=Localization+of+the+human+stem+cell+tyrosine+kinase-1+gene+%28FLT3%29+to+13Q12%2D%2D%3EQ13&doi=10.1159%2F000134046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Localization of the human stem cell tyrosine kinase-1 gene (FLT3) to 13q12→q13</span></div><div class="casAuthors">Carow, C. E.; Kim, E.; Hawkins, A. L.; Webb, H. D.; Griffin, C. A.; Jabs, E. W.; Civin, C. I.; Small, D.</div><div class="citationInfo"><span class="NLM_cas:title">Cytogenetics and Cell Genetics</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">255-7</span>CODEN:
                <span class="NLM_cas:coden">CGCGBR</span>;
        ISSN:<span class="NLM_cas:issn">0301-0171</span>.
    
            (<span class="NLM_cas:orgname">Karger</span>)
        </div><div class="casAbstract">The authors have previously reported the cloning of stem cell tyrosine kinase-1 (STK-1, gene symbol FLT3), the human homolog of the mouse Flk2/Flt3 gene (Small et al., 1994).  This growth factor receptor is expressed in CD34+ human bone marrow (stem/progenitor) cells.  The authors have mapped the gene for STK-1 using PCR screening of a human-rodent somatic cell hybrid panel, and fluorescence in situ mol. hybridization (FISH) of STK-1 genomic probes to mitotic chromosomes of normal human lymphocytes.  The results of both analyses show that the gene for STK-1 (FLT3) localizes to chromosome 13q12→q13.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRJa_lpqYqSbVg90H21EOLACvtfcHk0lifW0obcrNLGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnsF2quro%253D&md5=200dafceeae2d055045e814f93f3106c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1159%2F000134046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000134046%26sid%3Dliteratum%253Aachs%26aulast%3DCarow%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DE.%26aulast%3DHawkins%26aufirst%3DA.%26aulast%3DWebb%26aufirst%3DH.%26aulast%3DGriffin%26aufirst%3DC.%26aulast%3DJabs%26aufirst%3DE.%26aulast%3DCivin%26aufirst%3DC.%2BI.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DLocalization%2520of%2520the%2520human%2520stem%2520cell%2520tyrosine%2520kinase-1%2520gene%2520%2528FLT3%2529%2520to%252013Q12--%253EQ13%26jtitle%3DCytogenet.%2520Cell%2520Genet.%26date%3D1995%26volume%3D70%26spage%3D255%26epage%3D257%26doi%3D10.1159%2F000134046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiike, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonoda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misawa, S.</span></span> <span> </span><span class="NLM_article-title">Internal tandem duplication of the flt3 gene found in acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1911</span>– <span class="NLM_lpage">1918</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=8946930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A280%3ADyaK2s7gt1Kqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1996&pages=1911-1918&author=M.+Nakaoauthor=S.+Yokotaauthor=T.+Iwaiauthor=H.+Kanekoauthor=S.+Horiikeauthor=K.+Kashimaauthor=Y.+Sonodaauthor=T.+Fujimotoauthor=S.+Misawa&title=Internal+tandem+duplication+of+the+flt3+gene+found+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Internal tandem duplication of the flt3 gene found in acute myeloid leukemia</span></div><div class="casAuthors">Nakao M; Yokota S; Iwai T; Kaneko H; Horiike S; Kashima K; Sonoda Y; Fujimoto T; Misawa S</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1911-8</span>
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    </div><div class="casAbstract">We analyzed mRNA expression of the flt3 gene in 30 patients with acute myeloid leukemia (AML) and 50 with acute lymphoblastic leukemia (ALL).  Using reverse transcriptase-polymerase chain reaction (RT-PCR), expression of flt3 was observed in 61 patients; 22 (73%) with AML and 39 (78%) with ALL.  Among these, five patients with AML (one M2, two M4, and two M5) showed unexpected longer transcripts with a primer combination which could amplify the transmembrane (TM) domain through the juxtamembrane (JM) domain.  For those patients who expressed flt3 mRNA, the extracellular domain of the flt3 gene was also examined by RT-PCR, but no length abnormality was seen in this region.  We further analyzed the TM domain through the second tyrosine kinase domain by genomic amplifications.  The five patients who showed aberrant flt3 transcripts exhibited abnormal longer PCR products in addition to the germline products at a region corresponding to the JM through the first TK (TK1) domains.  Sequence analyses of the abnormal RT-PCR products demonstrated that partial sequences were tandemly duplicated.  Because all these altered transcripts were in-frame, deduced protein products could be expected.  Sequence analyses of the genomic DNA revealed that three of the five patients showed a simple internal duplication within exon 11; one had an internal duplication (26 bp) with a 4-bp insertion; and in the fifth patient, a 136-bp sequence from the 3' part of exon 11 to intron 11 and the first 16-bp sequence of exon 12 were each duplicated with 1-bp insertion.  In order to confirm the tumor specificity of these alterations, DNA samples obtained at complete remission were also analyzed in the three patients harboring an flt3 duplication, but no abnormal PCR product other than germline was detected in any of the samples.  Our results suggest that an internal tandem duplication at the JM/TK1 domains of the flt3 gene is a somatic change detected preferentially in AML, possibly containing a monocytic component.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQL5G2hUkeODSA3UY9EwTNrfW6udTcc2eZQbaqLVMNR1bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s7gt1Kqsg%253D%253D&md5=da0c7f21e6c4daf68bd4b1ae38a92891</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNakao%26aufirst%3DM.%26aulast%3DYokota%26aufirst%3DS.%26aulast%3DIwai%26aufirst%3DT.%26aulast%3DKaneko%26aufirst%3DH.%26aulast%3DHoriike%26aufirst%3DS.%26aulast%3DKashima%26aufirst%3DK.%26aulast%3DSonoda%26aufirst%3DY.%26aulast%3DFujimoto%26aufirst%3DT.%26aulast%3DMisawa%26aufirst%3DS.%26atitle%3DInternal%2520tandem%2520duplication%2520of%2520the%2520flt3%2520gene%2520found%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D1996%26volume%3D10%26spage%3D1911%26epage%3D1918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stirewalt, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopecky, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meshinchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogosova-Agadjanyan, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linsley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slovak, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willman, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radich, J. P.</span></span> <span> </span><span class="NLM_article-title">Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">3724</span>– <span class="NLM_lpage">3726</span>, <span class="refDoi"> DOI: 10.1182/blood-2005-08-3453</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1182%2Fblood-2005-08-3453" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2006&pages=3724-3726&author=D.+L.+Stirewaltauthor=K.+J.+Kopeckyauthor=S.+Meshinchiauthor=J.+H.+Engelauthor=E.+L.+Pogosova-Agadjanyanauthor=J.+Linsleyauthor=M.+L.+Slovakauthor=C.+L.+Willmanauthor=J.+P.+Radich&title=Size+of+FLT3+internal+tandem+duplication+has+prognostic+significance+in+patients+with+acute+myeloid+leukemia&doi=10.1182%2Fblood-2005-08-3453"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-08-3453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-08-3453%26sid%3Dliteratum%253Aachs%26aulast%3DStirewalt%26aufirst%3DD.%2BL.%26aulast%3DKopecky%26aufirst%3DK.%2BJ.%26aulast%3DMeshinchi%26aufirst%3DS.%26aulast%3DEngel%26aufirst%3DJ.%2BH.%26aulast%3DPogosova-Agadjanyan%26aufirst%3DE.%2BL.%26aulast%3DLinsley%26aufirst%3DJ.%26aulast%3DSlovak%26aufirst%3DM.%2BL.%26aulast%3DWillman%26aufirst%3DC.%2BL.%26aulast%3DRadich%26aufirst%3DJ.%2BP.%26atitle%3DSize%2520of%2520FLT3%2520internal%2520tandem%2520duplication%2520has%2520prognostic%2520significance%2520in%2520patients%2520with%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2006%26volume%3D107%26spage%3D3724%26epage%3D3726%26doi%3D10.1182%2Fblood-2005-08-3453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pemmaraju, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span> <span> </span><span class="NLM_article-title">FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">3293</span>– <span class="NLM_lpage">3304</span>, <span class="refDoi"> DOI: 10.1002/cncr.25908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1002%2Fcncr.25908" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=3293-3304&author=N.+Pemmarajuauthor=H.+Kantarjianauthor=F.+Ravandiauthor=J.+Cortes&title=FLT3+inhibitors+in+the+treatment+of+acute+myeloid+leukemia%3A+the+start+of+an+era%3F&doi=10.1002%2Fcncr.25908"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fcncr.25908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.25908%26sid%3Dliteratum%253Aachs%26aulast%3DPemmaraju%26aufirst%3DN.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DFLT3%2520inhibitors%2520in%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%253A%2520the%2520start%2520of%2520an%2520era%253F%26jtitle%3DCancer%26date%3D2011%26volume%3D117%26spage%3D3293%26epage%3D3304%26doi%3D10.1002%2Fcncr.25908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wander, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fathi, A. T.</span></span> <span> </span><span class="NLM_article-title">The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond</span>. <i>Ther. Adv. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1177/2040620714532123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1177%2F2040620714532123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=24883179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1SlsrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=65-77&author=S.+A.+Wanderauthor=M.+J.+Levisauthor=A.+T.+Fathi&title=The+evolving+role+of+FLT3+inhibitors+in+acute+myeloid+leukemia%3A+quizartinib+and+beyond&doi=10.1177%2F2040620714532123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond</span></div><div class="casAuthors">Wander, Seth A.; Levis, Mark J.; Fathi, Amir T.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Hematology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">65-77</span>CODEN:
                <span class="NLM_cas:coden">TAHHAT</span>;
        ISSN:<span class="NLM_cas:issn">2040-6207</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Acute myeloid leukemia remains assocd. with poor outcomes despite advances in our understanding of the complicated mol. events driving leukemogenesis and malignant progression.  Those patients harboring mutations in the FLT3 receptor tyrosine kinase have a particularly poor prognosis; however, significant excitement has been generated by the emergence of a variety of targeted inhibitors capable of suppressing FLT3 signaling in vivo.  Here we will review results from preclin. studies and early clin. trials evaluating both first- and second-generation FLT3 inhibitors.  Early FLT3 inhibitors (including sunitinib, midostaurin, and lestaurtinib) demonstrated significant promise in preclin. models of FLT3 mutant AML.  Unfortunately, many of these compds. failed to achieve robust and sustained FLT3 inhibition in early clin. trials, at best resulting in only transient decreases in peripheral blast counts.  These results have prompted the development of second-generation FLT3 inhibitors, epitomized by the novel agent quizartinib.  These second-generation inhibitors have demonstrated enhanced FLT3 specificity and have been generally well tolerated in early clin. trials.  Several FLT3 inhibitors have reached phase III clin. trials, and a variety of phase I/II trials exploring a role for these novel compds. in conjunction with conventional chemotherapy or hematopoietic stem cell transplantation are ongoing.  Finally, mol. insights provided by FLT3 inhibitors have shed light upon the variety of mechanisms underlying the acquisition of resistance and have provided a rationale supporting the use of combinatorial regimens with other emerging targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdBjhHfJvx77Vg90H21EOLACvtfcHk0ljtddE6TkSpEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1SlsrjN&md5=8cd3430a461df381c6480d42d4d75c0e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1177%2F2040620714532123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2040620714532123%26sid%3Dliteratum%253Aachs%26aulast%3DWander%26aufirst%3DS.%2BA.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DFathi%26aufirst%3DA.%2BT.%26atitle%3DThe%2520evolving%2520role%2520of%2520FLT3%2520inhibitors%2520in%2520acute%2520myeloid%2520leukemia%253A%2520quizartinib%2520and%2520beyond%26jtitle%3DTher.%2520Adv.%2520Hematol.%26date%3D2014%26volume%3D5%26spage%3D65%26epage%3D77%26doi%3D10.1177%2F2040620714532123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pemmaraju, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreeff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span> <span> </span><span class="NLM_article-title">Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">943</span>– <span class="NLM_lpage">954</span>, <span class="refDoi"> DOI: 10.1517/13543784.2014.911839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1517%2F13543784.2014.911839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=24749672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1WitL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=943-954&author=N.+Pemmarajuauthor=H.+Kantarjianauthor=M.+Andreeffauthor=J.+Cortesauthor=F.+Ravandi&title=Investigational+FMS-like+tyrosine+kinase+3+inhibitors+in+treatment+of+acute+myeloid+leukemia&doi=10.1517%2F13543784.2014.911839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia</span></div><div class="casAuthors">Pemmaraju, Naveen; Kantarjian, Hagop; Andreeff, Michael; Cortes, Jorge; Ravandi, Farhad</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">943-954</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Outcomes for the majority of patients with acute myeloid leukemia (AML) remain poor.  Over the past decade, significant progress has been made in the understanding of the cytogenetic and mol. determinants of AML pathogenesis.  One such advance is the identification of recurring mutations in the FMS-like tyrosine kinase 3 gene (FLT3).  Currently, this marker, which appears in approx. one-third of all AML patients, not only signifies a poorer prognosis but also identifies an important target for therapy.  FLT3 inhibitors have now undergone clin. evaluation in Phase I, II and III clin. trials, as both single agents and in combination with chemotherapeutics.  Unfortunately, to date, none of the FLT3 inhibitors have gained FDA approval for the treatment of patients with AML.  Yet, several promising FLT3 inhibitors are being evaluated in all phases of drug development.  Areas covered: This review aims to highlight the agents furthest along in their development.  It also focuses on those FLT3 inhibitors that are being evaluated in combination with other anti-leukemia agents.  Expert opinion: The authors believe that the field of research for FLT3 inhibitors remains promising, despite the historically poor prognosis of this subgroup of patients with AML.  The most promising areas of research will likely be the elucidation of the mechanisms of resistance to FLT3 inhibitors, and development of potent FLT3 inhibitors alone or in combination with hypomethylating agents, cytotoxic chemotherapy or with other targeted agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzTT7YoH9KV7Vg90H21EOLACvtfcHk0ljtddE6TkSpEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1WitL8%253D&md5=b624124fc07e406fe1c802b2e6f6a94c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1517%2F13543784.2014.911839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2014.911839%26sid%3Dliteratum%253Aachs%26aulast%3DPemmaraju%26aufirst%3DN.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DAndreeff%26aufirst%3DM.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DRavandi%26aufirst%3DF.%26atitle%3DInvestigational%2520FMS-like%2520tyrosine%2520kinase%25203%2520inhibitors%2520in%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2014%26volume%3D23%26spage%3D943%26epage%3D954%26doi%3D10.1517%2F13543784.2014.911839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buaboonnam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orwick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janke, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inaba, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. D.</span></span> <span> </span><span class="NLM_article-title">Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">3607</span>– <span class="NLM_lpage">3615</span>, <span class="refDoi"> DOI: 10.1182/blood-2013-07-513044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1182%2Fblood-2013-07-513044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=24046014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVKjsL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=3607-3615&author=E.+I.+Zimmermanauthor=D.+C.+Turnerauthor=J.+Buaboonnamauthor=S.+Huauthor=S.+Orwickauthor=M.+S.+Robertsauthor=L.+J.+Jankeauthor=A.+Ramachandranauthor=C.+F.+Stewartauthor=H.+Inabaauthor=S.+D.+Baker&title=Crenolanib+is+active+against+models+of+drug-resistant+FLT3-ITD-positive+acute+myeloid+leukemia&doi=10.1182%2Fblood-2013-07-513044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia</span></div><div class="casAuthors">Zimmerman, Eric I.; Turner, David C.; Buaboonnam, Jassada; Hu, Shuiying; Orwick, Shelley; Roberts, Michael S.; Janke, Laura J.; Ramachandran, Abhijit; Stewart, Clinton F.; Inaba, Hiroto; Baker, Sharyn D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3607-3615</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">FLT3 kinase internal tandem duplication (ITD) mutations are common in acute myeloid leukemia (AML) and are assocd. with poor clin. outcomes.  Although initial responses to FLT3 tyrosine kinase inhibitors (TKIs) are obsd. in FLT3-ITD-pos. patients, subsequent relapse often occurs upon acquisition of secondary FLT3 kinase domain (KD) mutations, primarily at residues D835 and F691.  Using biochem. assays, we detd. that crenolanib, a novel TKI, demonstrates type I properties and is active against FLT3 contg. ITD and/or D835- or F691-activating mutations.  Potent activity was obsd. in FLT3-ITD-pos. AML cell lines.  Crenolanib delayed the outgrowth of MV4-11 cells in a xenograft mouse model, whereas in combination with the type II TKI sorafenib, a significant decrease in leukemic burden (P < .001) and prolonged survival (P < .01) was obsd. compared with either type I or II TKI alone.  Crenolanib was active against Ba/F3 cells harboring FLT3-ITD and secondary KD mutations and sorafenib-resistant MOLM-13 cells contg. FLT3-ITD/D835Y both in vitro and in vivo.  In addn., crenolanib inhibited drug-resistant AML primary blasts with FLT3-ITD and D835H/Y mutations.  These preclin. data demonstrate that crenolanib is effective against FLT3-ITD contg. secondary KD mutations, suggesting that crenolanib may be a useful therapeutic agent for TKI-naive and drug-resistant FLT3-ITD-pos. AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBQ8ZNZvhAw7Vg90H21EOLACvtfcHk0lihgfGNfbGeIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVKjsL%252FE&md5=5d4052c5b3d470a2a9d14104286271ce</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-07-513044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-07-513044%26sid%3Dliteratum%253Aachs%26aulast%3DZimmerman%26aufirst%3DE.%2BI.%26aulast%3DTurner%26aufirst%3DD.%2BC.%26aulast%3DBuaboonnam%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DS.%26aulast%3DOrwick%26aufirst%3DS.%26aulast%3DRoberts%26aufirst%3DM.%2BS.%26aulast%3DJanke%26aufirst%3DL.%2BJ.%26aulast%3DRamachandran%26aufirst%3DA.%26aulast%3DStewart%26aufirst%3DC.%2BF.%26aulast%3DInaba%26aufirst%3DH.%26aulast%3DBaker%26aufirst%3DS.%2BD.%26atitle%3DCrenolanib%2520is%2520active%2520against%2520models%2520of%2520drug-resistant%2520FLT3-ITD-positive%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26spage%3D3607%26epage%3D3615%26doi%3D10.1182%2Fblood-2013-07-513044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajkhowa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span> <span> </span><span class="NLM_article-title">Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">260</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-10-745133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1182%2Fblood-2016-10-745133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=27908881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosVKitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=257-260&author=L.+Y.+Leeauthor=D.+Hernandezauthor=T.+Rajkhowaauthor=S.+C.+Smithauthor=J.+R.+Ramanauthor=B.+Nguyenauthor=D.+Smallauthor=M.+Levis&title=Preclinical+studies+of+gilteritinib%2C+a+next-generation+FLT3+inhibitor&doi=10.1182%2Fblood-2016-10-745133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor</span></div><div class="casAuthors">Lee, Lauren Y.; Hernandez, Daniela; Rajkhowa, Trivikram; Smith, Samuel C.; Raman, Jayant Ranganathan; Nguyen, Bao; Small, Donald; Levis, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-260</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">This article describes about the activity of gilteritinib and compared it with 4 other FLT3 TKIs in clin. development: midostaurin, sorafenib, quizartinib, and crenolanib.  In this article, inhibitory activity of gilteritinib against different forms of FLT3 in leukemia cells are studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKpTUQzYy5lrVg90H21EOLACvtfcHk0lihgfGNfbGeIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosVKitL0%253D&md5=75429ea03b906ea92d24033613f0315b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-10-745133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-10-745133%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DL.%2BY.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DRajkhowa%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DS.%2BC.%26aulast%3DRaman%26aufirst%3DJ.%2BR.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DLevis%26aufirst%3DM.%26atitle%3DPreclinical%2520studies%2520of%2520gilteritinib%252C%2520a%2520next-generation%2520FLT3%2520inhibitor%26jtitle%3DBlood%26date%3D2017%26volume%3D129%26spage%3D257%26epage%3D260%26doi%3D10.1182%2Fblood-2016-10-745133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3)</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1007/s10822-012-9572-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1007%2Fs10822-012-9572-z" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=437-450&author=A.+Poulsenauthor=A.+Williamauthor=S.+Blanchardauthor=A.+Leeauthor=H.+Nagarajauthor=H.+Wangauthor=E.+Teoauthor=E.+Tanauthor=K.+C.+Gohauthor=B.+Dymock&title=Structure-based+design+of+oxygen-linked+macrocyclic+kinase+inhibitors%3A+discovery+of+SB1518+and+SB1578%2C+potent+inhibitors+of+Janus+kinase+2+%28JAK2%29+and+Fms-like+tyrosine+kinase-3+%28FLT3%29&doi=10.1007%2Fs10822-012-9572-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs10822-012-9572-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-012-9572-z%26sid%3Dliteratum%253Aachs%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DWilliam%26aufirst%3DA.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DTeo%26aufirst%3DE.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DDymock%26aufirst%3DB.%26atitle%3DStructure-based%2520design%2520of%2520oxygen-linked%2520macrocyclic%2520kinase%2520inhibitors%253A%2520discovery%2520of%2520SB1518%2520and%2520SB1578%252C%2520potent%2520inhibitors%2520of%2520Janus%2520kinase%25202%2520%2528JAK2%2529%2520and%2520Fms-like%2520tyrosine%2520kinase-3%2520%2528FLT3%2529%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2012%26volume%3D26%26spage%3D437%26epage%3D450%26doi%3D10.1007%2Fs10822-012-9572-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1038/leu.2011.218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1038%2Fleu.2011.218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=21860433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFGgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=236-243&author=K.+C.+Gohauthor=V.+Novotny-Diermayrauthor=S.+Hartauthor=L.+C.+Ongauthor=Y.+K.+Lohauthor=A.+Cheongauthor=Y.+C.+Tanauthor=C.+Huauthor=R.+Jayaramanauthor=A.+D.+Williamauthor=E.+T.+Sunauthor=B.+W.+Dymockauthor=K.+H.+Ongauthor=K.+Ethirajuluauthor=F.+Burrowsauthor=J.+M.+Wood&title=TG02%2C+a+novel+oral+multi-kinase+inhibitor+of+CDKs%2C+JAK2+and+FLT3+with+potent+anti-leukemic+properties&doi=10.1038%2Fleu.2011.218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties</span></div><div class="casAuthors">Goh, K. C.; Novotny-Diermayr, V.; Hart, S.; Ong, L. C.; Loh, Y. K.; Cheong, A.; Tan, Y. C.; Hu, C.; Jayaraman, R.; William, A. D.; Sun, E. T.; Dymock, B. W.; Ong, K. H.; Ethirajulu, K.; Burrows, F.; Wood, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-243</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3.  It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs.  TG02 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis.  Primary cultures of progenitor cells derived from acute myeloid leukemia (AML) and polycythemia vera patients are very sensitive to TG02.  Comparison with ref. inhibitors that block only one of the main targets of TG02 demonstrate the benefit of combined CDK and JAK2/FLT3 inhibition in cell lines as well as primary cells.  In vivo, TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling.  TG02 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60).  These data demonstrate that TG02 is active in various models of leukemia and provide a rationale for the ongoing clin. evaluation of TG02 in patients with advanced leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMelEE91r_BrVg90H21EOLACvtfcHk0lhXSxHmsYpawQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFGgtLc%253D&md5=30af7dc302f9c421924b5b0062e82655</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fleu.2011.218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2011.218%26sid%3Dliteratum%253Aachs%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DLoh%26aufirst%3DY.%2BK.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DOng%26aufirst%3DK.%2BH.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DBurrows%26aufirst%3DF.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DTG02%252C%2520a%2520novel%2520oral%2520multi-kinase%2520inhibitor%2520of%2520CDKs%252C%2520JAK2%2520and%2520FLT3%2520with%2520potent%2520anti-leukemic%2520properties%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26spage%3D236%26epage%3D243%26doi%3D10.1038%2Fleu.2011.218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragains, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coberly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenback, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksterowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alba, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quéva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickramasinghe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, K.</span></span> <span> </span><span class="NLM_article-title">Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">880</span>– <span class="NLM_lpage">889</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0858</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1158%2F1535-7163.MCT-13-0858" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=24526162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=880-889&author=K.+Keeganauthor=C.+Liauthor=Z.+Liauthor=J.+Maauthor=M.+Ragainsauthor=S.+Coberlyauthor=D.+Hollenbackauthor=J.+Eksterowiczauthor=L.+Liangauthor=M.+Weidnerauthor=J.+Huardauthor=X.+Wangauthor=G.+Albaauthor=J.+Orfauthor=M.+C.+Loauthor=S.+Zhaoauthor=R.+Ngoauthor=A.+Chenauthor=L.+Liuauthor=T.+Carlsonauthor=C.+Qu%C3%A9vaauthor=L.+R.+McGeeauthor=J.+Medinaauthor=A.+Kambauthor=D.+Wickramasingheauthor=K.+Dai&title=Preclinical+evaluation+of+AMG+925%2C+a+FLT3%2FCDK4+dual+kinase+inhibitor+for+treating+acute+myeloid+leukemia&doi=10.1158%2F1535-7163.MCT-13-0858"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia</span></div><div class="casAuthors">Keegan, Kathleen; Li, Cong; Li, Zhihong; Ma, Ji; Ragains, Mark; Coberly, Suzanne; Hollenback, David; Eksterowicz, John; Liang, Lingming; Weidner, Margaret; Huard, Justin; Wang, Xianghong; Alba, Grace; Orf, Jessica; Lo, Mei-Chu; Zhao, Sharon; Ngo, Rachel; Chen, Ada; Liu, Lily; Carlson, Timothy; Queva, Christophe; McGee, Lawrence R.; Medina, Julio; Kamb, Alexander; Wickramasinghe, Dineli; Dai, Kang</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">880-889</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) remains a serious unmet medical need.  Despite high remission rates with chemotherapy std.-of-care treatment, the disease eventually relapses in a major proportion of patients.  Activating Fms-like tyrosine kinase 3 (FLT3) mutations are found in approx. 30% of patients with AML.  Targeting FLT3 receptor tyrosine kinase has shown encouraging results in treating FLT3-mutated AML.  Responses, however, are not sustained and acquired resistance has been a clin. challenge.  Treatment options to overcome resistance are currently the focus of research.  We report here the preclin. evaluation of AMG 925, a potent, selective, and bioavailable FLT3/cyclin-dependent kinase 4 (CDK4) dual kinase inhibitor.  AMG 925 inhibited AML xenograft tumor growth by 96% to 99% without significant body wt. loss.  The antitumor activity of AMG 925 correlated with the inhibition of STAT5 and RB phosphorylation, the pharmacodynamic markers for inhibition of FLT3 and CDK4, resp.  In addn., AMG 925 was also found to inhibit FLT3 mutants (e.g., D835Y) that are resistant to the current FLT3 inhibitors (e.g., AC220 and sorafenib).  CDK4 is a cyclin D-dependent kinase that plays an essential central role in regulating cell proliferation in response to external growth signals.  A crit. role of the CDK4-RB pathway in cancer development has been well established.  CDK4-specific inhibitors are being developed for treating RB-pos. cancer.  AMG 925, which combines inhibition of two kinases essential for proliferation and survival of FLT3-mutated AML cells, may improve and prolong clin. responses.  Mol Cancer Ther; 13(4); 880-9. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI4p2uOyF0ObVg90H21EOLACvtfcHk0liGlM_r3gTmPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Gjurs%253D&md5=7343fdb82e66c9115c8b018a260aadde</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0858%26sid%3Dliteratum%253Aachs%26aulast%3DKeegan%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DRagains%26aufirst%3DM.%26aulast%3DCoberly%26aufirst%3DS.%26aulast%3DHollenback%26aufirst%3DD.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DWeidner%26aufirst%3DM.%26aulast%3DHuard%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DAlba%26aufirst%3DG.%26aulast%3DOrf%26aufirst%3DJ.%26aulast%3DLo%26aufirst%3DM.%2BC.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DNgo%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DCarlson%26aufirst%3DT.%26aulast%3DQu%25C3%25A9va%26aufirst%3DC.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%26aulast%3DKamb%26aufirst%3DA.%26aulast%3DWickramasinghe%26aufirst%3DD.%26aulast%3DDai%26aufirst%3DK.%26atitle%3DPreclinical%2520evaluation%2520of%2520AMG%2520925%252C%2520a%2520FLT3%252FCDK4%2520dual%2520kinase%2520inhibitor%2520for%2520treating%2520acute%2520myeloid%2520leukemia%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D880%26epage%3D889%26doi%3D10.1158%2F1535-7163.MCT-13-0858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksterowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribble, M. W.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alba, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connors, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeGraffenreid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deignan, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquette, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huard, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaizerman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lively, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMinn, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihalic, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattabiraman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piper, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Queva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragains, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suchomel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wanska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehn, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickramasinghe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3430</span>– <span class="NLM_lpage">3449</span>, <span class="refDoi"> DOI: 10.1021/jm500118j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500118j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3430-3449&author=Z.+Liauthor=X.+Wangauthor=J.+Eksterowiczauthor=M.+W.+Gribbleauthor=G.+Q.+Albaauthor=M.+Ayresauthor=T.+J.+Carlsonauthor=A.+Chenauthor=X.+Chenauthor=R.+Choauthor=R.+V.+Connorsauthor=M.+DeGraffenreidauthor=J.+T.+Deignanauthor=J.+Duquetteauthor=P.+Fanauthor=B.+Fisherauthor=J.+Fuauthor=J.+N.+Huardauthor=J.+Kaizermanauthor=K.+S.+Keeganauthor=C.+Liauthor=K.+Liauthor=Y.+Liauthor=L.+Liangauthor=W.+Liuauthor=S.+E.+Livelyauthor=M.+C.+Loauthor=J.+Maauthor=D.+L.+McMinnauthor=J.+T.+Mihalicauthor=K.+Modiauthor=R.+Ngoauthor=K.+Pattabiramanauthor=D.+E.+Piperauthor=C.+Quevaauthor=M.+L.+Ragainsauthor=J.+Suchomelauthor=S.+Thibaultauthor=N.+Walkerauthor=X.+Wangauthor=Z.+Wangauthor=M.+Wanskaauthor=P.+M.+Wehnauthor=M.+F.+Weidnerauthor=A.+J.+Zhangauthor=X.+Zhaoauthor=A.+Kambauthor=D.+Wickramasingheauthor=K.+Daiauthor=L.+R.+McGeeauthor=J.+C.+Medina&title=Discovery+of+AMG+925%2C+a+FLT3+and+CDK4+dual+kinase+inhibitor+with+preferential+affinity+for+the+activated+state+of+FLT3&doi=10.1021%2Fjm500118j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3</span></div><div class="casAuthors">Li, Zhihong; Wang, Xianghong; Eksterowicz, John; Gribble, Michael W.; Alba, Grace Q.; Ayres, Merrill; Carlson, Timothy J.; Chen, Ada; Chen, Xiaoqi; Cho, Robert; Connors, Richard V.; DeGraffenreid, Michael; Deignan, Jeffrey T.; Duquette, Jason; Fan, Pingchen; Fisher, Benjamin; Fu, Jiasheng; Huard, Justin N.; Kaizerman, Jacob; Keegan, Kathleen S.; Li, Cong; Li, Kexue; Li, Yunxiao; Liang, Lingming; Liu, Wen; Lively, Sarah E.; Lo, Mei-Chu; Ma, Ji; McMinn, Dustin L.; Mihalic, Jeffrey T.; Modi, Kriti; Ngo, Rachel; Pattabiraman, Kanaka; Piper, Derek E.; Queva, Christophe; Ragains, Mark L.; Suchomel, Julia; Thibault, Steve; Walker, Nigel; Wang, Xiaodong; Wang, Zhulun; Wanska, Malgorzata; Wehn, Paul M.; Weidner, Margaret F.; Zhang, Alex J.; Zhao, Xiaoning; Kamb, Alexander; Wickramasinghe, Dineli; Dai, Kang; McGee, Lawrence R.; Medina, Julio C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3430-3449</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors describe the structural optimization of a lead compd. that exhibits dual inhibitory activities against FLT3 and CDK4.  A series of pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidine derivs. was synthesized, and SAR anal., using cell-based assays, led to the discovery of AMG 925 (I), a potent and orally bioavailable dual inhibitor of CDK4 and FLT3, including many FLT3 mutants reported to date.  Compd. I inhibits the proliferation of a panel of human tumor cell lines including Colo205 (Rb+) and U937 (FLT3WT) and induced cell death in MOLM13 (FLT3ITD) and even in MOLM13 (FLT3ITD, D835Y), which exhibits resistance to a no. of FLT3 inhibitors currently under clin. development.  At well-tolerated doses, compd. I leads to significant growth inhibition of MOLM13 xenografts in nude mice, and the activity correlates with inhibition of STAT5 and Rb phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcJdjH0aU8KrVg90H21EOLACvtfcHk0lhaKEU22_1dJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D&md5=4047a6ea068dbde57896da520fbdf0d3</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm500118j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500118j%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DGribble%26aufirst%3DM.%2BW.%26aulast%3DAlba%26aufirst%3DG.%2BQ.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DCarlson%26aufirst%3DT.%2BJ.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCho%26aufirst%3DR.%26aulast%3DConnors%26aufirst%3DR.%2BV.%26aulast%3DDeGraffenreid%26aufirst%3DM.%26aulast%3DDeignan%26aufirst%3DJ.%2BT.%26aulast%3DDuquette%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DHuard%26aufirst%3DJ.%2BN.%26aulast%3DKaizerman%26aufirst%3DJ.%26aulast%3DKeegan%26aufirst%3DK.%2BS.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLively%26aufirst%3DS.%2BE.%26aulast%3DLo%26aufirst%3DM.%2BC.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DMcMinn%26aufirst%3DD.%2BL.%26aulast%3DMihalic%26aufirst%3DJ.%2BT.%26aulast%3DModi%26aufirst%3DK.%26aulast%3DNgo%26aufirst%3DR.%26aulast%3DPattabiraman%26aufirst%3DK.%26aulast%3DPiper%26aufirst%3DD.%2BE.%26aulast%3DQueva%26aufirst%3DC.%26aulast%3DRagains%26aufirst%3DM.%2BL.%26aulast%3DSuchomel%26aufirst%3DJ.%26aulast%3DThibault%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWanska%26aufirst%3DM.%26aulast%3DWehn%26aufirst%3DP.%2BM.%26aulast%3DWeidner%26aufirst%3DM.%2BF.%26aulast%3DZhang%26aufirst%3DA.%2BJ.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DKamb%26aufirst%3DA.%26aulast%3DWickramasinghe%26aufirst%3DD.%26aulast%3DDai%26aufirst%3DK.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520of%2520AMG%2520925%252C%2520a%2520FLT3%2520and%2520CDK4%2520dual%2520kinase%2520inhibitor%2520with%2520preferential%2520affinity%2520for%2520the%2520activated%2520state%2520of%2520FLT3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3430%26epage%3D3449%26doi%3D10.1021%2Fjm500118j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gucký, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zatloukal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazgier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Řezníčková, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Béres, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryštof, V.</span></span> <span> </span><span class="NLM_article-title">A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">6234</span>– <span class="NLM_lpage">6247</span>, <span class="refDoi"> DOI: 10.1021/jm4006884</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4006884" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6234-6247&author=T.+Guck%C3%BDauthor=R.+Jordaauthor=M.+Zatloukalauthor=V.+Bazgierauthor=K.+Berkaauthor=E.+%C5%98ezn%C3%AD%C4%8Dkov%C3%A1author=T.+B%C3%A9resauthor=M.+Strnadauthor=V.+Kry%C5%A1tof&title=A+novel+series+of+highly+potent+2%2C6%2C9-trisubstituted+purine+cyclin-dependent+kinase+inhibitors&doi=10.1021%2Fjm4006884"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm4006884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4006884%26sid%3Dliteratum%253Aachs%26aulast%3DGuck%25C3%25BD%26aufirst%3DT.%26aulast%3DJorda%26aufirst%3DR.%26aulast%3DZatloukal%26aufirst%3DM.%26aulast%3DBazgier%26aufirst%3DV.%26aulast%3DBerka%26aufirst%3DK.%26aulast%3D%25C5%2598ezn%25C3%25AD%25C4%258Dkov%25C3%25A1%26aufirst%3DE.%26aulast%3DB%25C3%25A9res%26aufirst%3DT.%26aulast%3DStrnad%26aufirst%3DM.%26aulast%3DKry%25C5%25A1tof%26aufirst%3DV.%26atitle%3DA%2520novel%2520series%2520of%2520highly%2520potent%25202%252C6%252C9-trisubstituted%2520purine%2520cyclin-dependent%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6234%26epage%3D6247%26doi%3D10.1021%2Fjm4006884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zatloukal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gucky, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reznickova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pospisil, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malinkova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamcova, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystof, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.06.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1016%2Fj.ejmech.2012.06.036" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2013&pages=61-72&author=M.+Zatloukalauthor=R.+Jordaauthor=T.+Guckyauthor=E.+Reznickovaauthor=J.+Vollerauthor=T.+Pospisilauthor=V.+Malinkovaauthor=H.+Adamcovaauthor=V.+Krystofauthor=M.+Strnad&title=Synthesis+and+in+vitro+biological+evaluation+of+2%2C6%2C9-trisubstituted+purines+targeting+multiple+cyclin-dependent+kinases&doi=10.1016%2Fj.ejmech.2012.06.036"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.06.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.06.036%26sid%3Dliteratum%253Aachs%26aulast%3DZatloukal%26aufirst%3DM.%26aulast%3DJorda%26aufirst%3DR.%26aulast%3DGucky%26aufirst%3DT.%26aulast%3DReznickova%26aufirst%3DE.%26aulast%3DVoller%26aufirst%3DJ.%26aulast%3DPospisil%26aufirst%3DT.%26aulast%3DMalinkova%26aufirst%3DV.%26aulast%3DAdamcova%26aufirst%3DH.%26aulast%3DKrystof%26aufirst%3DV.%26aulast%3DStrnad%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520in%2520vitro%2520biological%2520evaluation%2520of%25202%252C6%252C9-trisubstituted%2520purines%2520targeting%2520multiple%2520cyclin-dependent%2520kinases%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D61%26spage%3D61%26epage%3D72%26doi%3D10.1016%2Fj.ejmech.2012.06.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sengupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhmedov, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span> <span> </span><span class="NLM_article-title">Mitsunobu coupling of nucleobases and alcohols: an efficient, practical synthesis for novel nonsugar carbon nucleosides</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">5012</span>– <span class="NLM_lpage">5015</span>, <span class="refDoi"> DOI: 10.1021/jo070515+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo070515%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=5012-5015&author=W.+Luauthor=S.+Senguptaauthor=J.+L.+Petersenauthor=N.+G.+Akhmedovauthor=X.+Shi&title=Mitsunobu+coupling+of+nucleobases+and+alcohols%3A+an+efficient%2C+practical+synthesis+for+novel+nonsugar+carbon+nucleosides&doi=10.1021%2Fjo070515%2B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjo070515%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo070515%252B%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DW.%26aulast%3DSengupta%26aufirst%3DS.%26aulast%3DPetersen%26aufirst%3DJ.%2BL.%26aulast%3DAkhmedov%26aufirst%3DN.%2BG.%26aulast%3DShi%26aufirst%3DX.%26atitle%3DMitsunobu%2520coupling%2520of%2520nucleobases%2520and%2520alcohols%253A%2520an%2520efficient%252C%2520practical%2520synthesis%2520for%2520novel%2520nonsugar%2520carbon%2520nucleosides%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2007%26volume%3D72%26spage%3D5012%26epage%3D5015%26doi%3D10.1021%2Fjo070515%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, N.
G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Browne, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drysdale, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foloppe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geoffrey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matassova, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roughley, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoepfer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scriven, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmonite, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surgenor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brough, P.</span></span> <span> </span><span class="NLM_article-title">Targeting conserved water molecules: design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">6770</span>– <span class="NLM_lpage">6789</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2012.08.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1016%2Fj.bmc.2012.08.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=23018093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVSltrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=6770-6789&author=N.%0AG.+Daviesauthor=H.+Browneauthor=B.+Davisauthor=M.+J.+Drysdaleauthor=N.+Foloppeauthor=S.+Geoffreyauthor=B.+Gibbonsauthor=T.+Hartauthor=R.+Hubbardauthor=M.+R.+Jensenauthor=H.+Mansellauthor=A.+Masseyauthor=N.+Matassovaauthor=J.+D.+Mooreauthor=J.+Murrayauthor=R.+Prattauthor=S.+Rayauthor=A.+Robertsonauthor=S.+D.+Roughleyauthor=J.+Schoepferauthor=K.+Scrivenauthor=H.+Simmoniteauthor=S.+Stokesauthor=A.+Surgenorauthor=P.+Webbauthor=M.+Woodauthor=L.+Wrightauthor=P.+Brough&title=Targeting+conserved+water+molecules%3A+design+of+4-aryl-5-cyanopyrrolo%5B2%2C3-d%5Dpyrimidine+Hsp90+inhibitors+using+fragment-based+screening+and+structure-based+optimization&doi=10.1016%2Fj.bmc.2012.08.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting conserved water molecules: Design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization</span></div><div class="casAuthors">Davies, Nicholas G. M.; Browne, Helen; Davis, Ben; Drysdale, Martin J.; Foloppe, Nicolas; Geoffrey, Stephanie; Gibbons, Ben; Hart, Terance; Hubbard, Roderick; Jensen, Michael Rugaard; Mansell, Howard; Massey, Andrew; Matassova, Natalia; Moore, Jonathan D.; Murray, James; Pratt, Robert; Ray, Stuart; Robertson, Alan; Roughley, Stephen D.; Schoepfer, Joseph; Scriven, Kirsten; Simmonite, Heather; Stokes, Stephen; Surgenor, Allan; Webb, Paul; Wood, Mike; Wright, Lisa; Brough, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6770-6789</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Inhibitors of the Hsp90 mol. chaperone are showing promise as anti-cancer agents.  Here the authors describe a series of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine ATP competitive Hsp90 inhibitors that were identified following structure-driven optimization of purine hits revealed by NMR based screening of a proprietary fragment library.  Ligand-Hsp90 x-ray structures combined with mol. modeling led to the rational displacement of a conserved water mol. leading to enhanced affinity for Hsp90 as measured by fluorescence polarization, isothermal titrn. calorimetry and surface plasmon resonance assays.  This displacement was achieved with a nitrile group, presenting an example of efficient gain in binding affinity with minimal increase in mol. wt.  Some compds. in this chem. series inhibit the proliferation of human cancer cell lines in vitro and cause depletion of oncogenic Hsp90 client proteins and concomitant elevation of the co-chaperone Hsp70.  In addn., one compd. was demonstrated to be orally bioavailable in the mouse.  This work demonstrates the power of structure-based design for the rapid evolution of potent Hsp90 inhibitors and the importance of considering conserved water mols. in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMAwVhZUzKD7Vg90H21EOLACvtfcHk0lj7NN8yKItqBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVSltrvN&md5=69c85da95d07bd488f07eaf503c978f4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.08.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.08.050%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DN.%2BG.%26aulast%3DBrowne%26aufirst%3DH.%26aulast%3DDavis%26aufirst%3DB.%26aulast%3DDrysdale%26aufirst%3DM.%2BJ.%26aulast%3DFoloppe%26aufirst%3DN.%26aulast%3DGeoffrey%26aufirst%3DS.%26aulast%3DGibbons%26aufirst%3DB.%26aulast%3DHart%26aufirst%3DT.%26aulast%3DHubbard%26aufirst%3DR.%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DMansell%26aufirst%3DH.%26aulast%3DMassey%26aufirst%3DA.%26aulast%3DMatassova%26aufirst%3DN.%26aulast%3DMoore%26aufirst%3DJ.%2BD.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DPratt%26aufirst%3DR.%26aulast%3DRay%26aufirst%3DS.%26aulast%3DRobertson%26aufirst%3DA.%26aulast%3DRoughley%26aufirst%3DS.%2BD.%26aulast%3DSchoepfer%26aufirst%3DJ.%26aulast%3DScriven%26aufirst%3DK.%26aulast%3DSimmonite%26aufirst%3DH.%26aulast%3DStokes%26aufirst%3DS.%26aulast%3DSurgenor%26aufirst%3DA.%26aulast%3DWebb%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DWright%26aufirst%3DL.%26aulast%3DBrough%26aufirst%3DP.%26atitle%3DTargeting%2520conserved%2520water%2520molecules%253A%2520design%2520of%25204-aryl-5-cyanopyrrolo%255B2%252C3-d%255Dpyrimidine%2520Hsp90%2520inhibitors%2520using%2520fragment-based%2520screening%2520and%2520structure-based%2520optimization%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D6770%26epage%3D6789%26doi%3D10.1016%2Fj.bmc.2012.08.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zorn, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimura, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barros, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220)</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e0121177</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0121177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1371%2Fjournal.pone.0121177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=25837374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Gmsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0121177&author=J.+A.+Zornauthor=Q.+Wangauthor=E.+Fujimuraauthor=T.+Barrosauthor=J.+Kuriyan&title=Crystal+structure+of+the+FLT3+kinase+domain+bound+to+the+inhibitor+Quizartinib+%28AC220%29&doi=10.1371%2Fjournal.pone.0121177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the FLT3 kinase domain bound to the inhibitor quizartinib (AC220)</span></div><div class="casAuthors">Zorn, Julie A.; Wang, Qi; Fujimura, Eric; Barros, Tiago; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e0121177/1-e0121177/15</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">More than 30% of acute myeloid leukemia (AML) patients possess activating mutations in the receptor tyrosine kinase FMS-like tyrosine kinase 3 or FLT3.  A small-mol. inhibitor of FLT3 (known as quizartinib or AC220) that is currently in clin. trials appears promising for the treatment of AML.  Here, we report the co-crystal structure of the kinase domain of FLT3 in complex with quizartinib.  FLT3 with quizartinib bound adopts an "Abl-like"inactive conformation with the activation loop stabilized in the "DFG-out"orientation and folded back onto the kinase domain.  This conformation is similar to that obsd. for the uncomplexed intracellular domain of FLT3 as well as for related receptor tyrosine kinases, except for a localized induced fit in the activation loop.  The co-crystal structure reveals the interactions between quizartinib and the active site of FLT3 that are key for achieving its high potency against both wild-type FLT3 as well as a FLT3 variant obsd. in many AML patients.  This co-complex further provides a structural rationale for quizartinib-resistance mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOXAklBbZKP7Vg90H21EOLACvtfcHk0lj7NN8yKItqBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Gmsr%252FM&md5=d3c23bf8a8e242dd35e20e6e9b2de924</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0121177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0121177%26sid%3Dliteratum%253Aachs%26aulast%3DZorn%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DFujimura%26aufirst%3DE.%26aulast%3DBarros%26aufirst%3DT.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520FLT3%2520kinase%2520domain%2520bound%2520to%2520the%2520inhibitor%2520Quizartinib%2520%2528AC220%2529%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0121177%26doi%3D10.1371%2Fjournal.pone.0121177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasater, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCreery, M. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damon, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perl, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeschke, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogan, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. P.</span></span> <span> </span><span class="NLM_article-title">Crenolanib is a selective type I pan-FLT3 inhibitor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">5319</span>– <span class="NLM_lpage">5324</span>, <span class="refDoi"> DOI: 10.1073/pnas.1320661111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1073%2Fpnas.1320661111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=24623852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1Snsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=5319-5324&author=C.+C.+Smithauthor=E.+A.+Lasaterauthor=K.+C.+Linauthor=Q.+Wangauthor=M.+Q.+McCreeryauthor=W.+K.+Stewartauthor=L.+E.+Damonauthor=A.+E.+Perlauthor=G.+R.+Jeschkeauthor=M.+Sugitaauthor=M.+Carrollauthor=S.+C.+Koganauthor=J.+Kuriyanauthor=N.+P.+Shah&title=Crenolanib+is+a+selective+type+I+pan-FLT3+inhibitor&doi=10.1073%2Fpnas.1320661111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Crenolanib is a selective type I pan-FLT3 inhibitor</span></div><div class="casAuthors">Smith, Catherine Choy; Lasater, Elisabeth A.; Lin, Kimberly C.; Wang, Qi; McCreery, Melissa Quino; Stewart, Whitney K.; Damon, Lauren E.; Perl, Alexander E.; Jeschke, Grace R.; Sugita, Mayumi; Carroll, Martin; Kogan, Scott C.; Kuriyan, John; Shah, Neil P.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5319-5324</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Tyrosine kinase inhibitors (TKIs) represent transformative therapies for several malignancies.  Two crit. features necessary for maximizing TKI tolerability and response duration are kinase selectivity and invulnerability to resistance-conferring kinase domain (KD) mutations in the intended target.  No prior TKI has demonstrated both of these properties.  Aiming to maximize selectivity, medicinal chemists have largely sought to create TKIs that bind to an inactive (type II) kinase conformation.  The investigational type I TKI crenolanib is a potent inhibitor of Fms tyrosine kinase-3 (FLT3) internal tandem duplication, a validated therapeutic target in human acute myeloid leukemia (AML), as well as all secondary KD mutants previously shown to confer resistance to the first highly active FLT3 TKI quizartinib.  Moreover, crenolanib is highly selective for FLT3 relative to the closely related protein tyrosine kinase KIT, demonstrating that simultaneous FLT3/KIT inhibition, a prominent feature of other clin. active FLT3 TKIs, is not required for AML cell cytotoxicity in vitro and may contribute to undesirable toxicity in patients.  A satn. mutagenesis screen of FLT3-internal tandem duplication failed to recover any resistant colonies in the presence of a crenolanib concn. well below what has been safely achieved in humans, suggesting that crenolanib has the potential to suppress KD mutation-mediated clin. resistance.  Crenolanib represents the first TKI to exhibit both kinase selectivity and invulnerability to resistance-conferring KD mutations, which is unexpected of a type I inhibitor.  Crenolanib has significant promise for achieving deep and durable responses in FLT3-mutant AML, and may have a profound impact upon future medicinal chem. efforts in oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwxReAanOwB7Vg90H21EOLACvtfcHk0lhiefCad91uMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1Snsbw%253D&md5=955f1f242a1690247ae239050e2a8a8f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1320661111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1320661111%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DLasater%26aufirst%3DE.%2BA.%26aulast%3DLin%26aufirst%3DK.%2BC.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DMcCreery%26aufirst%3DM.%2BQ.%26aulast%3DStewart%26aufirst%3DW.%2BK.%26aulast%3DDamon%26aufirst%3DL.%2BE.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26aulast%3DJeschke%26aufirst%3DG.%2BR.%26aulast%3DSugita%26aufirst%3DM.%26aulast%3DCarroll%26aufirst%3DM.%26aulast%3DKogan%26aufirst%3DS.%2BC.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DN.%2BP.%26atitle%3DCrenolanib%2520is%2520a%2520selective%2520type%2520I%2520pan-FLT3%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D5319%26epage%3D5324%26doi%3D10.1073%2Fpnas.1320661111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stecula, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. P.</span></span> <span> </span><span class="NLM_article-title">FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2390</span>– <span class="NLM_lpage">2392</span>, <span class="refDoi"> DOI: 10.1038/leu.2015.165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1038%2Fleu.2015.165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=26108694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Wrtb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=2390-2392&author=C.+C.+Smithauthor=K.+Linauthor=A.+Steculaauthor=A.+Saliauthor=N.+P.+Shah&title=FLT3+D835+mutations+confer+differential+resistance+to+type+II+FLT3+inhibitors&doi=10.1038%2Fleu.2015.165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors</span></div><div class="casAuthors">Smith, C. C.; Lin, K.; Stecula, A.; Sali, A.; Shah, N. P.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2390-2392</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activating mutations in FLT3 occur in ∼30% of adult acute myeloid leukemia, primarily consisting of internal tandem duplication (ITD) mutations (∼25%) and point mutations in the tyrosine kinase domain (∼5%), commonly at the activation loop residue D835.  Secondary kinase domain mutations in FLT3-ITD, particularly at the D835 residue are frequently assocd. with acquired clin. resistance to effective FLT3 tyrosine kinase inhibitors (TKIs).  Mol. docking studies have suggested that D835 mutations primarily confer resistance by stabilizing an active Asp-Phe-Gly in ('DFG-in') kinase conformation unfavorable to the binding of type II FLT3 TKIs, which target a 'DFG-out' inactive conformation.  We profiled the activity of active type II FLT3 TKIs against D835 kinase domain mutants that have been clin. detected to date.  We found that type II inhibitors (quizartinib, sorafenib, ponatinib and PLX3397) retain activity against specific D835 substitutions.  Modeling studies suggest that bulky hydrophobic substitutions (D835Y/V/I/F) at this residue are particularly resistant, whereas mutations that preserve interactions between D835 and S838 are relatively sensitive (D835E/N).  All mutants retain sensitivity to the type I inhibitor crenolanib.  These results suggest that patients with relatively sensitive D835 mutations should be included in clin. trials of type II FLT3 TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQhZ7jQYhBcbVg90H21EOLACvtfcHk0lhiefCad91uMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Wrtb%252FJ&md5=f6de44ca15604b8429a5dab811fe8eeb</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.165%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DStecula%26aufirst%3DA.%26aulast%3DSali%26aufirst%3DA.%26aulast%3DShah%26aufirst%3DN.%2BP.%26atitle%3DFLT3%2520D835%2520mutations%2520confer%2520differential%2520resistance%2520to%2520type%2520II%2520FLT3%2520inhibitors%26jtitle%3DLeukemia%26date%3D2015%26volume%3D29%26spage%3D2390%26epage%3D2392%26doi%3D10.1038%2Fleu.2015.165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawardane, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belli, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratz, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprankle, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, S. S.</span></span> <span> </span><span class="NLM_article-title">AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">2984</span>– <span class="NLM_lpage">2992</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-05-222034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1182%2Fblood-2009-05-222034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=19654408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht12qurzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=2984-2992&author=P.+P.+Zarrinkarauthor=R.+N.+Gunawardaneauthor=M.+D.+Cramerauthor=M.+F.+Gardnerauthor=D.+Brighamauthor=B.+Belliauthor=M.+W.+Karamanauthor=K.+W.+Pratzauthor=G.+Pallaresauthor=Q.+Chaoauthor=K.+G.+Sprankleauthor=H.+K.+Patelauthor=M.+Levisauthor=R.+C.+Armstrongauthor=J.+Jamesauthor=S.+S.+Bhagwat&title=AC220+is+a+uniquely+potent+and+selective+inhibitor+of+FLT3+for+the+treatment+of+acute+myeloid+leukemia+%28AML%29&doi=10.1182%2Fblood-2009-05-222034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)</span></div><div class="casAuthors">Zarrinkar, Patrick P.; Gunawardane, Ruwanthi N.; Cramer, Merryl D.; Gardner, Michael F.; Brigham, Daniel; Belli, Barbara; Karaman, Mazen W.; Pratz, Keith W.; Pallares, Gabriel; Chao, Qi; Sprankle, Kelly G.; Patel, Hitesh K.; Levis, Mark; Armstrong, Robert C.; James, Joyce; Bhagwat, Shripad S.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2984-2992</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Activating mutations in the receptor tyrosine kinase FLT3 are present in up to approx. 30% of acute myeloid leukemia (AML) patients, implicating FLT3 as a driver of the disease and therefore as a target for therapy.  We report the characterization of AC220, a second-generation FLT3 inhibitor, and a comparison of AC220 with the first-generation FLT3 inhibitors CEP-701, MLN-518, PKC-412, sorafenib, and sunitinib.  AC220 exhibits low nanomolar potency in biochem. and cellular assays and exceptional kinase selectivity, and in animal models is efficacious at doses as low as 1 mg/kg given orally once daily.  The data reveal that the combination of excellent potency, selectivity, and pharmacokinetic properties is unique to AC220, which therefore is the first drug candidate with a profile that matches the characteristics desirable for a clin. FLT3 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_RzDr7kzxsLVg90H21EOLACvtfcHk0lixGp_XGgptHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht12qurzN&md5=4f8368a7b2eab9d1234ef36e01f5f260</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-05-222034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-05-222034%26sid%3Dliteratum%253Aachs%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DBelli%26aufirst%3DB.%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DPratz%26aufirst%3DK.%2BW.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DBhagwat%26aufirst%3DS.%2BS.%26atitle%3DAC220%2520is%2520a%2520uniquely%2520potent%2520and%2520selective%2520inhibitor%2520of%2520FLT3%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D2984%26epage%3D2992%26doi%3D10.1182%2Fblood-2009-05-222034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gunawardane, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepomuceno, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooks, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricono, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belli, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, R. C.</span></span> <span> </span><span class="NLM_article-title">Transient exposure to quizartinib mediates sustained inhibition of FLT3 signaling while specifically inducing apoptosis in FLT3-activated leukemia cells</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">447</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1158%2F1535-7163.MCT-12-0305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=23412931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC3sXls12qsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=438-447&author=R.+N.+Gunawardaneauthor=R.+R.+Nepomucenoauthor=A.+M.+Rooksauthor=J.+P.+Huntauthor=J.+M.+Riconoauthor=B.+Belliauthor=R.+C.+Armstrong&title=Transient+exposure+to+quizartinib+mediates+sustained+inhibition+of+FLT3+signaling+while+specifically+inducing+apoptosis+in+FLT3-activated+leukemia+cells&doi=10.1158%2F1535-7163.MCT-12-0305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Transient Exposure to Quizartinib Mediates Sustained Inhibition of FLT3 Signaling while Specifically Inducing Apoptosis in FLT3-Activated Leukemia Cells</span></div><div class="casAuthors">Gunawardane, Ruwanthi N.; Nepomuceno, Ronald R.; Rooks, Allison M.; Hunt, Jeremy P.; Ricono, Jill M.; Belli, Barbara; Armstrong, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">438-447</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Fms-like tyrosine kinase 3 (FLT3) is implicated in the pathogenesis of acute myeloid leukemia (AML).  FLT3-activating internal tandem duplication (ITD) mutations are found in approx. 30% of patients with AML and are assocd. with poor outcome in this patient population.  Quizartinib (AC220) has previously been shown to be a potent and selective FLT3 inhibitor.  In the current study, we expand on previous observations by showing that quizartinib potently inhibits the phosphorylation of FLT3 and downstream signaling mols. independent of FLT3 genotype, yet induces loss of viability only in cells expressing constitutively activated FLT3.  We further show that transient exposure to quizartinib, whether in vitro or in vivo, leads to prolonged inhibition of FLT3 signaling, induction of apoptosis, and drastic redns. in tumor vol. and pharmacodynamic endpoints.  In vitro expts. suggest that these prolonged effects are mediated by slow binding kinetics that provide for durable inhibition of the kinase following drug removal/clearance.  Together these data suggest quizartinib, with its unique combination of selectivity and potent/sustained inhibition of FLT3, may provide a safe and effective treatment against FLT3-driven leukemia.  Mol Cancer Ther; 12(4); 438-47. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS9XnwyldyrrVg90H21EOLACvtfcHk0lixGp_XGgptHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXls12qsrc%253D&md5=7943cbb662d1e010628ffac4437da6c1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0305%26sid%3Dliteratum%253Aachs%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DNepomuceno%26aufirst%3DR.%2BR.%26aulast%3DRooks%26aufirst%3DA.%2BM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DRicono%26aufirst%3DJ.%2BM.%26aulast%3DBelli%26aufirst%3DB.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26atitle%3DTransient%2520exposure%2520to%2520quizartinib%2520mediates%2520sustained%2520inhibition%2520of%2520FLT3%2520signaling%2520while%2520specifically%2520inducing%2520apoptosis%2520in%2520FLT3-activated%2520leukemia%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D438%26epage%3D447%26doi%3D10.1158%2F1535-7163.MCT-12-0305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kampa-Schittenhelm, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akmut, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schittenhelm, M. M.</span></span> <span> </span><span class="NLM_article-title">Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">19</span>, <span class="refDoi"> DOI: 10.1186/1476-4598-12-19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1186%2F1476-4598-12-19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=23497317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotFCms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=19&author=K.+M.+Kampa-Schittenhelmauthor=M.+C.+Heinrichauthor=F.+Akmutauthor=H.+D%C3%B6hnerauthor=K.+D%C3%B6hnerauthor=M.+M.+Schittenhelm&title=Quizartinib+%28AC220%29+is+a+potent+second+generation+class+III+tyrosine+kinase+inhibitor+that+displays+a+distinct+inhibition+profile+against+mutant-FLT3%2C+-PDGFRA+and+-KIT+isoforms&doi=10.1186%2F1476-4598-12-19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms</span></div><div class="casAuthors">Kampa-Schittenhelm, Kerstin Maria; Heinrich, Michael Charles; Akmut, Figen; Doehner, Hartmut; Doehner, Konstanze; Schittenhelm, Marcus Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">19</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Activating mutations of class III receptor tyrosine kinases (RTK) FLT3, PDGFR and KIT are assocd. with multiple human neoplasms including hematol. malignancies, for example: systemic mast cell disorders (KIT), non-CML myeloproliferative neoplasms (PDGFR) and subsets of acute leukemias (FLT3 and KIT).  First generation tyrosine kinase inhibitors (TKI) are rapidly being integrated into routine cancer care.  However, the expanding spectrum of TK-mutations, bioavailability issues and the emerging problem of primary or secondary TKI-therapy resistance have lead to the search for novel second generation TKIs to improve target potency and to overcome resistant clones.  Quizartinib was recently demonstrated to be a selective FLT3 inhibitor with excellent pharmacokinetics and promising in vivo activity in a phase II study for FLT3 ITD + AML patients.  In vitro kinase assays have suggested that in addn. to FLT3, quizartinib also targets related class III RTK isoforms.  Methods: Various FLT3 or KIT leukemia cell lines and native blasts were used to det. the antiproliferative and proapoptotic efficacy of quizartinib.  To better compare differences between the mutant kinase isoforms, we generated an isogenic BaF3 cell line expressing different FLT3, KIT or BCR/ABL isoforms.  Using immunoblotting, we examd. the effects of quizartinib on activation of mutant KIT or FLT3 isoforms.  Results: Kinase inhibition of (mutant) KIT , PDGFR and FLT3 isoforms by quizartinib leads to potent inhibition of cellular proliferation and induction of apoptosis in in vitro leukemia models as well as in native leukemia blasts treated ex vivo.  However, the sensitivity patterns vary widely depending on the underlying (mutant)-kinase isoform, with some isoforms being relatively insensitive to this agent (e.g. FLT3 D835V and KIT codon D816 mutations).  Evaluation of sensitivities in an isogenic cellular background confirms a direct assocn. with the underlying mutant-TK isoform - which is further validated by immunoblotting expts. demonstrating kinase inhibition consistent with the cellular sensitivity/resistance to quizartinib.  Conclusion: Quizartinib is a potent second-generation class III receptor TK-inhibitor - but specific, mutation restricted spectrum of activity may require mutation screening prior to therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzNdFVikwovbVg90H21EOLACvtfcHk0ljwgwWto7GJ-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotFCms78%253D&md5=592fee7ae105d731fdf0390745932ada</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-12-19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-12-19%26sid%3Dliteratum%253Aachs%26aulast%3DKampa-Schittenhelm%26aufirst%3DK.%2BM.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DAkmut%26aufirst%3DF.%26aulast%3DD%25C3%25B6hner%26aufirst%3DH.%26aulast%3DD%25C3%25B6hner%26aufirst%3DK.%26aulast%3DSchittenhelm%26aufirst%3DM.%2BM.%26atitle%3DQuizartinib%2520%2528AC220%2529%2520is%2520a%2520potent%2520second%2520generation%2520class%2520III%2520tyrosine%2520kinase%2520inhibitor%2520that%2520displays%2520a%2520distinct%2520inhibition%2520profile%2520against%2520mutant-FLT3%252C%2520-PDGFRA%2520and%2520-KIT%2520isoforms%26jtitle%3DMol.%2520Cancer%26date%3D2013%26volume%3D12%26spage%3D19%26doi%3D10.1186%2F1476-4598-12-19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruner, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, A. C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratz, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratilas, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, D.</span></span> <span> </span><span class="NLM_article-title">Signaling adaptation to TKI treatment reactivates ERK signaling in FLT3/ITD leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">33</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=33&author=J.+K.+Brunerauthor=L.+Liauthor=H.+S.+Maauthor=A.+C.+R.+Qinauthor=M.+J.+Levisauthor=K.+W.+Pratzauthor=C.+A.+Pratilasauthor=D.+Small&title=Signaling+adaptation+to+TKI+treatment+reactivates+ERK+signaling+in+FLT3%2FITD+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBruner%26aufirst%3DJ.%2BK.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DH.%2BS.%26aulast%3DQin%26aufirst%3DA.%2BC.%2BR.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DPratz%26aufirst%3DK.%2BW.%26aulast%3DPratilas%26aufirst%3DC.%2BA.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DSignaling%2520adaptation%2520to%2520TKI%2520treatment%2520reactivates%2520ERK%2520signaling%2520in%2520FLT3%252FITD%2520leukemia%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26spage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. D.</span></span> <span> </span><span class="NLM_article-title">Technique for assessment of leukocyte adherence to human umbilical vein endothelial cell monolayers</span>. <i>J. Pharmacol. Toxicol. Methods</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/1056-8719(94)90056-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1016%2F1056-8719%2894%2990056-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=7532469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADyaK2MXitFensro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1994&pages=73-77&author=P.+E.+McGregorauthor=D.+K.+Agrawalauthor=J.+D.+Edwards&title=Technique+for+assessment+of+leukocyte+adherence+to+human+umbilical+vein+endothelial+cell+monolayers&doi=10.1016%2F1056-8719%2894%2990056-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Technique for assessment of leukocyte adherence to human umbilical vein endothelial cell monolayers</span></div><div class="casAuthors">McGregor, Patrick E.; Agrawal, Devendra K.; Edwards, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">73-7</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The interaction between endothelial cells and immune/inflammatory cells plays an important role in the pathogenesis of vascular diseases.  Inflammatory cells also activate endothelial cells and release both proliferative and cytotoxic mediators.  In order to exam. the interaction between leukocytes and endothelial cells and the effect of various drugs, we established the methodol. for isolating and culturing the endothelial cells from human umbilical vein.  Endothelial cells were harvested by using 0.1% collagenase within 48 h of collecting the cord.  Cells were grown to confluency in 96-well plates in Medium 199 contg. 20% fetal calf serum, endothelial cell growth supplement, heparin, and antibiotics.  Using this method, we obtained a confluent layer of the cells in all the 96 wells within 48 h.  We then examd. the effect of peptides, endothelin-1, substance P, and neurokinin-A on the adherence of human blood neutrophils (purity and viability > 98%) to endothelial monolayers.  All the peptides enhanced (p < 0.05) the adherence of neutrophils to endothelial cells in a time-dependent manner.  This method of endothelial cell culturing is reliable, reproducible, and effective in evaluating the role of various mediators and drugs on the adherence of various white blood cells to endothelium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFJIlJ5a1oLbVg90H21EOLACvtfcHk0ljn09Spty8Mbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXitFensro%253D&md5=6e65f5298d5d3d65c8e2209b51a8fb82</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2F1056-8719%2894%2990056-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F1056-8719%252894%252990056-6%26sid%3Dliteratum%253Aachs%26aulast%3DMcGregor%26aufirst%3DP.%2BE.%26aulast%3DAgrawal%26aufirst%3DD.%2BK.%26aulast%3DEdwards%26aufirst%3DJ.%2BD.%26atitle%3DTechnique%2520for%2520assessment%2520of%2520leukocyte%2520adherence%2520to%2520human%2520umbilical%2520vein%2520endothelial%2520cell%2520monolayers%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D1994%26volume%3D32%26spage%3D73%26epage%3D77%26doi%3D10.1016%2F1056-8719%2894%2990056-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgartner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Sullivan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterhouse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taromi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apostolova, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illert, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchinger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquesne, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt-Graeff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osswald, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tugues, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeifer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Follo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lübbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rummelt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wäsch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haag, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidts, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultheiss, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettinger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thimme, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanriver, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuong, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmati, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ditschkowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jilg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leiber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerull, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengerke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pabst, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobbe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rösler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doostkam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meckel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stabla, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzelder, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halbach, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dengjel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackanson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtick, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheid, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spyridonidis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stölzel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ordemann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicre-de-Fontbrune, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihorst, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuball, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehlert, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cahn, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuchenbauer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunjes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraverty, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kröger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayuk, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vago, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaeger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuster, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisdorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Velden, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dörfel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethge, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilgendorf, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochhaus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrieux, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Börries, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magenau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labopin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henden, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLornan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mufti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezvani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negrin, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burchert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beelen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackensen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Bubnoff, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herr, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Socié, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligiuri, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggiero, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Häcker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duyster, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blazar, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeiser, R.</span></span> <span> </span><span class="NLM_article-title">Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">282</span>– <span class="NLM_lpage">291</span>, <span class="refDoi"> DOI: 10.1038/nm.4484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=10.1038%2Fnm.4484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=29431743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFCiu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=282-291&author=N.+R.+Mathewauthor=F.+Baumgartnerauthor=L.+Braunauthor=D.+O%E2%80%99Sullivanauthor=S.+Thomasauthor=M.+Waterhouseauthor=T.+A.+M%C3%BCllerauthor=K.+Hankeauthor=S.+Taromiauthor=P.+Apostolovaauthor=A.+L.+Illertauthor=W.+Melchingerauthor=S.+Duquesneauthor=A.+Schmitt-Graeffauthor=L.+Osswaldauthor=K.+L.+Yanauthor=A.+Weberauthor=S.+Tuguesauthor=S.+Spathauthor=D.+Pfeiferauthor=M.+Folloauthor=R.+Clausauthor=M.+L%C3%BCbbertauthor=C.+Rummeltauthor=H.+Bertzauthor=R.+W%C3%A4schauthor=J.+Haagauthor=A.+Schmidtsauthor=M.+Schultheissauthor=D.+Bettingerauthor=R.+Thimmeauthor=E.+Ullrichauthor=Y.+Tanriverauthor=G.+L.+Vuongauthor=R.+Arnoldauthor=P.+Hemmatiauthor=D.+Wolfauthor=M.+Ditschkowskiauthor=C.+Jilgauthor=K.+Wilhelmauthor=C.+Leiberauthor=S.+Gerullauthor=J.+Halterauthor=C.+Lengerkeauthor=T.+Pabstauthor=T.+Schroederauthor=G.+Kobbeauthor=W.+R%C3%B6slerauthor=S.+Doostkamauthor=S.+Meckelauthor=K.+Stablaauthor=S.+K.+Metzelderauthor=S.+Halbachauthor=T.+Brummerauthor=Z.+Huauthor=J.+Dengjelauthor=B.+Hackansonauthor=C.+Schmidauthor=U.+Holtickauthor=C.+Scheidauthor=A.+Spyridonidisauthor=F.+St%C3%B6lzelauthor=R.+Ordemannauthor=L.+P.+M%C3%BCllerauthor=F.+Sicre-de-Fontbruneauthor=G.+Ihorstauthor=J.+Kuballauthor=J.+E.+Ehlertauthor=D.+Fegerauthor=E.+M.+Wagnerauthor=J.+Y.+Cahnauthor=J.+Schnellauthor=F.+Kuchenbauerauthor=D.+Bunjesauthor=R.+Chakravertyauthor=S.+Richardsonauthor=S.+Gillauthor=N.+Kr%C3%B6gerauthor=F.+Ayukauthor=L.+Vagoauthor=F.+Ciceriauthor=A.+M.+M%C3%BCllerauthor=T.+Kondoauthor=T.+Teshimaauthor=S.+Klaegerauthor=B.+Kusterauthor=D.+D.+H.+Kimauthor=D.+Weisdorfauthor=W.+van+der+Veldenauthor=D.+D%C3%B6rfelauthor=W.+Bethgeauthor=I.+Hilgendorfauthor=A.+Hochhausauthor=G.+Andrieuxauthor=M.+B%C3%B6rriesauthor=H.+Buschauthor=J.+Magenauauthor=P.+Reddyauthor=M.+Labopinauthor=J.+H.+Antinauthor=A.+S.+Hendenauthor=G.+R.+Hillauthor=G.+A.+Kennedyauthor=M.+Barauthor=A.+Sarmaauthor=D.+McLornanauthor=G.+Muftiauthor=B.+Oranauthor=K.+Rezvaniauthor=O.+Shahauthor=R.+S.+Negrinauthor=A.+Naglerauthor=M.+Prinzauthor=A.+Burchertauthor=A.+Neubauerauthor=D.+Beelenauthor=A.+Mackensenauthor=N.+von+Bubnoffauthor=W.+Herrauthor=B.+Becherauthor=G.+Soci%C3%A9author=M.+A.+Caligiuriauthor=E.+Ruggieroauthor=C.+Boniniauthor=G.+H%C3%A4ckerauthor=J.+Duysterauthor=J.+Finkeauthor=E.+Pearceauthor=B.+R.+Blazarauthor=R.+Zeiser&title=Sorafenib+promotes+graft-versus-leukemia+activity+in+mice+and+humans+through+IL-15+production+in+FLT3-ITD-mutant+leukemia+cells&doi=10.1038%2Fnm.4484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells</span></div><div class="casAuthors">Mathew, Nimitha R.; Baumgartner, Francis; Braun, Lukas; O'Sullivan, David; Thomas, Simone; Waterhouse, Miguel; Mueller, Tony A.; Hanke, Kathrin; Taromi, Sanaz; Apostolova, Petya; Illert, Anna L.; Melchinger, Wolfgang; Duquesne, Sandra; Schmitt-Graeff, Annette; Osswald, Lena; Yan, Kai-Li; Weber, Arnim; Tugues, Sonia; Spath, Sabine; Pfeifer, Dietmar; Follo, Marie; Claus, Rainer; Luebbert, Michael; Rummelt, Christoph; Bertz, Hartmut; Waesch, Ralph; Haag, Johanna; Schmidts, Andrea; Schultheiss, Michael; Bettinger, Dominik; Thimme, Robert; Ullrich, Evelyn; Tanriver, Yakup; Vuong, Giang Lam; Arnold, Renate; Hemmati, Philipp; Wolf, Dominik; Ditschkowski, Markus; Jilg, Cordula; Wilhelm, Konrad; Leiber, Christian; Gerull, Sabine; Halter, Joerg; Lengerke, Claudia; Pabst, Thomas; Schroeder, Thomas; Kobbe, Guido; Roesler, Wolf; Doostkam, Soroush; Meckel, Stephan; Stabla, Kathleen; Metzelder, Stephan K.; Halbach, Sebastian; Brummer, Tilman; Hu, Zehan; Dengjel, Joern; Hackanson, Bjoern; Schmid, Christoph; Holtick, Udo; Scheid, Christof; Spyridonidis, Alexandros; Stoelzel, Friedrich; Ordemann, Rainer; Mueller, Lutz P.; Sicre-de-Fontbrune, Flore; Ihorst, Gabriele; Kuball, Juergen; Ehlert, Jan E.; Feger, Daniel; Wagner, Eva-Maria; Cahn, Jean-Yves; Schnell, Jacqueline; Kuchenbauer, Florian; Bunjes, Donald; Chakraverty, Ronjon; Richardson, Simon; Gill, Saar; Kroeger, Nicolaus; Ayuk, Francis; Vago, Luca; Ciceri, Fabio; Mueller, Antonia M.; Kondo, Takeshi; Teshima, Takanori; Klaeger, Susan; Kuster, Bernhard; Kim, Dennis; Weisdorf, Daniel; van der Velden, Walter; Doerfel, Daniela; Bethge, Wolfgang; Hilgendorf, Inken; Hochhaus, Andreas; Andrieux, Geoffroy; Boerries, Melanie; Busch, Hauke; Magenau, John; Reddy, Pavan; Labopin, Myriam; Antin, Joseph H.; Henden, Andrea S.; Hill, Geoffrey R.; Kennedy, Glen A.; Bar, Merav; Sarma, Anita; McLornan, Donal; Mufti, Ghulam; Oran, Betul; Rezvani, Katayoun; Sha, Omid; Negrin, Robert S.; Nagler, Arnon; Prinz, Marco; Burchert, Andreas; Neubauer, Andreas; Beelen, Dietrich; MacKensen, Andreas; von Bubnoff, Nikolas; Herr, Wolfgang; Becher, Burkhard; Socie, Gerard; Caligiuri, Michael A.; Ruggiero, Eliana; Bonini, Chiara; Haecker, Georg; Duyster, Justus; Finke, Juergen; Pearce, Erika; Blazar, Bruce R.; Zeiser, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">282-291</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Individuals with acute myeloid leukemia (AML) harboring an internal tandem duplication (ITD) in the gene encoding Fms-related tyrosine kinase 3 (FLT3) who relapse after allogeneic hematopoietic cell transplantation (allo-HCT) have a 1-yr survival rate below 20%.  We obsd. that sorafenib, a multitargeted tyrosine kinase inhibitor, increased IL-15 prodn. by FLT3-ITD+ leukemia cells.  This synergized with the allogeneic CD8+ T cell response, leading to long-term survival in six mouse models of FLT3-ITD+ AML.  Sorafenib-related IL-15 prodn. caused an increase in CD8+CD107a+IFN-γ+ T cells with features of longevity (high levels of Bcl-2 and reduced PD-1 levels), which eradicated leukemia in secondary recipients.  Mechanistically, sorafenib reduced expression of the transcription factor ATF4, thereby blocking neg. regulation of interferon regulatory factor 7 (IRF7) activation, which enhanced IL-15 transcription.  Both IRF7 knockdown and ATF4 overexpression in leukemia cells antagonized sorafenib-induced IL-15 prodn. in vitro.  Human FLT3-ITD+ AML cells obtained from sorafenib responders following sorafenib therapy showed increased levels of IL-15, phosphorylated IRF7, and a transcriptionally active IRF7 chromatin state.  The mitochondrial spare respiratory capacity and glycolytic capacity of CD8+ T cells increased upon sorafenib treatment in sorafenib responders but not in nonresponders.  Our findings indicate that the synergism of T cells and sorafenib is mediated via reduced ATF4 expression, causing activation of the IRF7-IL-15 axis in leukemia cells and thereby leading to metabolic reprogramming of leukemia-reactive T cells in humans.  Therefore, sorafenib treatment has the potential to contribute to an immune-mediated cure of FLT3-ITD-mutant AML relapse, an otherwise fatal complication after allo-HCT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh28bOOpaxCbVg90H21EOLACvtfcHk0lj_VH9AnPWMKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFCiu7k%253D&md5=33c82d882c54611ac8a7ffc53efe4197</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnm.4484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4484%26sid%3Dliteratum%253Aachs%26aulast%3DMathew%26aufirst%3DN.%2BR.%26aulast%3DBaumgartner%26aufirst%3DF.%26aulast%3DBraun%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DWaterhouse%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%2BA.%26aulast%3DHanke%26aufirst%3DK.%26aulast%3DTaromi%26aufirst%3DS.%26aulast%3DApostolova%26aufirst%3DP.%26aulast%3DIllert%26aufirst%3DA.%2BL.%26aulast%3DMelchinger%26aufirst%3DW.%26aulast%3DDuquesne%26aufirst%3DS.%26aulast%3DSchmitt-Graeff%26aufirst%3DA.%26aulast%3DOsswald%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DK.%2BL.%26aulast%3DWeber%26aufirst%3DA.%26aulast%3DTugues%26aufirst%3DS.%26aulast%3DSpath%26aufirst%3DS.%26aulast%3DPfeifer%26aufirst%3DD.%26aulast%3DFollo%26aufirst%3DM.%26aulast%3DClaus%26aufirst%3DR.%26aulast%3DL%25C3%25BCbbert%26aufirst%3DM.%26aulast%3DRummelt%26aufirst%3DC.%26aulast%3DBertz%26aufirst%3DH.%26aulast%3DW%25C3%25A4sch%26aufirst%3DR.%26aulast%3DHaag%26aufirst%3DJ.%26aulast%3DSchmidts%26aufirst%3DA.%26aulast%3DSchultheiss%26aufirst%3DM.%26aulast%3DBettinger%26aufirst%3DD.%26aulast%3DThimme%26aufirst%3DR.%26aulast%3DUllrich%26aufirst%3DE.%26aulast%3DTanriver%26aufirst%3DY.%26aulast%3DVuong%26aufirst%3DG.%2BL.%26aulast%3DArnold%26aufirst%3DR.%26aulast%3DHemmati%26aufirst%3DP.%26aulast%3DWolf%26aufirst%3DD.%26aulast%3DDitschkowski%26aufirst%3DM.%26aulast%3DJilg%26aufirst%3DC.%26aulast%3DWilhelm%26aufirst%3DK.%26aulast%3DLeiber%26aufirst%3DC.%26aulast%3DGerull%26aufirst%3DS.%26aulast%3DHalter%26aufirst%3DJ.%26aulast%3DLengerke%26aufirst%3DC.%26aulast%3DPabst%26aufirst%3DT.%26aulast%3DSchroeder%26aufirst%3DT.%26aulast%3DKobbe%26aufirst%3DG.%26aulast%3DR%25C3%25B6sler%26aufirst%3DW.%26aulast%3DDoostkam%26aufirst%3DS.%26aulast%3DMeckel%26aufirst%3DS.%26aulast%3DStabla%26aufirst%3DK.%26aulast%3DMetzelder%26aufirst%3DS.%2BK.%26aulast%3DHalbach%26aufirst%3DS.%26aulast%3DBrummer%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DDengjel%26aufirst%3DJ.%26aulast%3DHackanson%26aufirst%3DB.%26aulast%3DSchmid%26aufirst%3DC.%26aulast%3DHoltick%26aufirst%3DU.%26aulast%3DScheid%26aufirst%3DC.%26aulast%3DSpyridonidis%26aufirst%3DA.%26aulast%3DSt%25C3%25B6lzel%26aufirst%3DF.%26aulast%3DOrdemann%26aufirst%3DR.%26aulast%3DM%25C3%25BCller%26aufirst%3DL.%2BP.%26aulast%3DSicre-de-Fontbrune%26aufirst%3DF.%26aulast%3DIhorst%26aufirst%3DG.%26aulast%3DKuball%26aufirst%3DJ.%26aulast%3DEhlert%26aufirst%3DJ.%2BE.%26aulast%3DFeger%26aufirst%3DD.%26aulast%3DWagner%26aufirst%3DE.%2BM.%26aulast%3DCahn%26aufirst%3DJ.%2BY.%26aulast%3DSchnell%26aufirst%3DJ.%26aulast%3DKuchenbauer%26aufirst%3DF.%26aulast%3DBunjes%26aufirst%3DD.%26aulast%3DChakraverty%26aufirst%3DR.%26aulast%3DRichardson%26aufirst%3DS.%26aulast%3DGill%26aufirst%3DS.%26aulast%3DKr%25C3%25B6ger%26aufirst%3DN.%26aulast%3DAyuk%26aufirst%3DF.%26aulast%3DVago%26aufirst%3DL.%26aulast%3DCiceri%26aufirst%3DF.%26aulast%3DM%25C3%25BCller%26aufirst%3DA.%2BM.%26aulast%3DKondo%26aufirst%3DT.%26aulast%3DTeshima%26aufirst%3DT.%26aulast%3DKlaeger%26aufirst%3DS.%26aulast%3DKuster%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DD.%2BD.%2BH.%26aulast%3DWeisdorf%26aufirst%3DD.%26aulast%3Dvan%2Bder%2BVelden%26aufirst%3DW.%26aulast%3DD%25C3%25B6rfel%26aufirst%3DD.%26aulast%3DBethge%26aufirst%3DW.%26aulast%3DHilgendorf%26aufirst%3DI.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DAndrieux%26aufirst%3DG.%26aulast%3DB%25C3%25B6rries%26aufirst%3DM.%26aulast%3DBusch%26aufirst%3DH.%26aulast%3DMagenau%26aufirst%3DJ.%26aulast%3DReddy%26aufirst%3DP.%26aulast%3DLabopin%26aufirst%3DM.%26aulast%3DAntin%26aufirst%3DJ.%2BH.%26aulast%3DHenden%26aufirst%3DA.%2BS.%26aulast%3DHill%26aufirst%3DG.%2BR.%26aulast%3DKennedy%26aufirst%3DG.%2BA.%26aulast%3DBar%26aufirst%3DM.%26aulast%3DSarma%26aufirst%3DA.%26aulast%3DMcLornan%26aufirst%3DD.%26aulast%3DMufti%26aufirst%3DG.%26aulast%3DOran%26aufirst%3DB.%26aulast%3DRezvani%26aufirst%3DK.%26aulast%3DShah%26aufirst%3DO.%26aulast%3DNegrin%26aufirst%3DR.%2BS.%26aulast%3DNagler%26aufirst%3DA.%26aulast%3DPrinz%26aufirst%3DM.%26aulast%3DBurchert%26aufirst%3DA.%26aulast%3DNeubauer%26aufirst%3DA.%26aulast%3DBeelen%26aufirst%3DD.%26aulast%3DMackensen%26aufirst%3DA.%26aulast%3Dvon%2BBubnoff%26aufirst%3DN.%26aulast%3DHerr%26aufirst%3DW.%26aulast%3DBecher%26aufirst%3DB.%26aulast%3DSoci%25C3%25A9%26aufirst%3DG.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26aulast%3DRuggiero%26aufirst%3DE.%26aulast%3DBonini%26aufirst%3DC.%26aulast%3DH%25C3%25A4cker%26aufirst%3DG.%26aulast%3DDuyster%26aufirst%3DJ.%26aulast%3DFinke%26aufirst%3DJ.%26aulast%3DPearce%26aufirst%3DE.%26aulast%3DBlazar%26aufirst%3DB.%2BR.%26aulast%3DZeiser%26aufirst%3DR.%26atitle%3DSorafenib%2520promotes%2520graft-versus-leukemia%2520activity%2520in%2520mice%2520and%2520humans%2520through%2520IL-15%2520production%2520in%2520FLT3-ITD-mutant%2520leukemia%2520cells%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D282%26epage%3D291%26doi%3D10.1038%2Fnm.4484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamm, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, B. K.</span></span> <span> </span><span class="NLM_article-title">One-step cellular caspase-3/7 assay</span>. <i>Biotechniques</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1064</span>– <span class="NLM_lpage">1067</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2003&pages=1064-1067&author=R.+A.+Carrascoauthor=N.+B.+Stammauthor=B.+K.+Patel&title=One-step+cellular+caspase-3%2F7+assay"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarrasco%26aufirst%3DR.%2BA.%26aulast%3DStamm%26aufirst%3DN.%2BB.%26aulast%3DPatel%26aufirst%3DB.%2BK.%26atitle%3DOne-step%2520cellular%2520caspase-3%252F7%2520assay%26jtitle%3DBiotechniques%26date%3D2003%26volume%3D34%26spage%3D1064%26epage%3D1067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damm, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maple, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reboul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupyan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlgren, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaus, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerutti, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krilov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span> <span> </span><span class="NLM_article-title">OPLS3: A force field providing broad coverage of drug-like small molecules and proteins</span>. <i>J. Chem. Theory Comput.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">296</span>, <span class="refDoi"> DOI: 10.1021/acs.jctc.5b00864</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jctc.5b00864" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVCjtbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=281-296&author=E.+Harderauthor=W.+Dammauthor=J.+Mapleauthor=C.+Wuauthor=M.+Reboulauthor=J.+Y.+Xiangauthor=L.+Wangauthor=D.+Lupyanauthor=M.+K.+Dahlgrenauthor=J.+L.+Knightauthor=J.+W.+Kausauthor=D.+S.+Ceruttiauthor=G.+Krilovauthor=W.+L.+Jorgensenauthor=R.+Abelauthor=R.+A.+Friesner&title=OPLS3%3A+A+force+field+providing+broad+coverage+of+drug-like+small+molecules+and+proteins&doi=10.1021%2Facs.jctc.5b00864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins</span></div><div class="casAuthors">Harder, Edward; Damm, Wolfgang; Maple, Jon; Wu, Chuanjie; Reboul, Mark; Xiang, Jin Yu; Wang, Lingle; Lupyan, Dmitry; Dahlgren, Markus K.; Knight, Jennifer L.; Kaus, Joseph W.; Cerutti, David S.; Krilov, Goran; Jorgensen, William L.; Abel, Robert; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">281-296</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The parametrization and validation of the OPLS3 force field for small mols. and proteins are reported.  Enhancements with respect to the previous version (OPLS2.1) include the addn. of off-atom charge sites to represent halogen bonding and aryl nitrogen lone pairs as well as a complete refit of peptide dihedral parameters to better model the native structure of proteins.  To adequately cover medicinal chem. space, OPLS3 employs over an order of magnitude more ref. data and assocd. parameter types relative to other commonly used small mol. force fields (e.g., MMFF and OPLS_2005).  As a consequence, OPLS3 achieves a high level of accuracy across performance benchmarks that assess small mol. conformational propensities and solvation.  The newly fitted peptide dihedrals lead to significant improvements in the representation of secondary structure elements in simulated peptides and native structure stability over a no. of proteins.  Together, the improvements made to both the small mol. and protein force field lead to a high level of accuracy in predicting protein-ligand binding measured over a wide range of targets and ligands (less than 1 kcal/mol RMS error) representing a 30% improvement over earlier variants of the OPLS force field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY_jrOhcBRgrVg90H21EOLACvtfcHk0liQJFpIqRR3Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVCjtbfE&md5=42663f8cfa84b80a67132bbb13b9b7ce</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jctc.5b00864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jctc.5b00864%26sid%3Dliteratum%253Aachs%26aulast%3DHarder%26aufirst%3DE.%26aulast%3DDamm%26aufirst%3DW.%26aulast%3DMaple%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DReboul%26aufirst%3DM.%26aulast%3DXiang%26aufirst%3DJ.%2BY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLupyan%26aufirst%3DD.%26aulast%3DDahlgren%26aufirst%3DM.%2BK.%26aulast%3DKnight%26aufirst%3DJ.%2BL.%26aulast%3DKaus%26aufirst%3DJ.%2BW.%26aulast%3DCerutti%26aufirst%3DD.%2BS.%26aulast%3DKrilov%26aufirst%3DG.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DOPLS3%253A%2520A%2520force%2520field%2520providing%2520broad%2520coverage%2520of%2520drug-like%2520small%2520molecules%2520and%2520proteins%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2016%26volume%3D12%26spage%3D281%26epage%3D296%26doi%3D10.1021%2Facs.jctc.5b00864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halgren, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beard, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, J. L.</span></span> <span> </span><span class="NLM_article-title">Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1750</span>– <span class="NLM_lpage">1759</span>, <span class="refDoi"> DOI: 10.1021/jm030644s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030644s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFyit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1750-1759&author=T.+A.+Halgrenauthor=R.+B.+Murphyauthor=R.+A.+Friesnerauthor=H.+S.+Beardauthor=L.+L.+Fryeauthor=W.+T.+Pollardauthor=J.+L.+Banks&title=Glide%3A+a+new+approach+for+rapid%2C+accurate+docking+and+scoring.+2.+Enrichment+factors+in+database+screening&doi=10.1021%2Fjm030644s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening</span></div><div class="casAuthors">Halgren, Thomas A.; Murphy, Robert B.; Friesner, Richard A.; Beard, Hege S.; Frye, Leah L.; Pollard, W. Thomas; Banks, Jay L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1750-1759</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Glide's ability to identify active compds. in a database screen is characterized by applying Glide to a diverse set of nine protein receptors.  In many cases, two, or even three, protein sites are employed to probe the sensitivity of the results to the site geometry.  To make the database screens as realistic as possible, the screens use sets of "druglike" decoy ligands that have been selected to be representative of what we believe is likely to be found in the compd. collection of a pharmaceutical or biotechnol. company.  Results are presented for releases 1.8, 2.0, and 2.5 of Glide.  The comparisons show that av. measures for both "early" and "global" enrichment for Glide 2.5 are 3 times higher than for Glide 1.8 and more than 2 times higher than for Glide 2.0 because of better results for the least well-handled screens.  This improvement in enrichment stems largely from the better balance of the more widely parametrized GlideScore 2.5 function and the inclusion of terms that penalize ligand-protein interactions that violate established principles of phys. chem., particularly as it concerns the exposure to solvent of charged protein and ligand groups.  Comparisons to results for the thymidine kinase and estrogen receptors published by Rognan and co-workers (J. Med. Chem. 2000, 43, 4759-4767) show that Glide 2.5 performs better than GOLD 1.1, FlexX 1.8, or DOCK 4.01.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT2ptubbKbvLVg90H21EOLACvtfcHk0ljMdJiawJM6nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFyit78%253D&md5=33d68dd968e65626b449df61e44e37be</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm030644s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030644s%26sid%3Dliteratum%253Aachs%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DBeard%26aufirst%3DH.%2BS.%26aulast%3DFrye%26aufirst%3DL.%2BL.%26aulast%3DPollard%26aufirst%3DW.%2BT.%26aulast%3DBanks%26aufirst%3DJ.%2BL.%26atitle%3DGlide%253A%2520a%2520new%2520approach%2520for%2520rapid%252C%2520accurate%2520docking%2520and%2520scoring.%25202.%2520Enrichment%2520factors%2520in%2520database%2520screening%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1750%26epage%3D1759%26doi%3D10.1021%2Fjm030644s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB','PDB','1RJB'); return false;">PDB: 1RJB</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG','PDB','1PKG'); return false;">PDB: 1PKG</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i83"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01529">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_16731"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b01529">10.1021/acs.jmedchem.7b01529</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">FLT3 model with docked lead compound <b>7d</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01529/suppl_file/jm7b01529_si_001.pdb">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01529/suppl_file/jm7b01529_si_002.csv">CSV</a>)</p></li><li><p class="inline">Mean and SD values of enzyme–inhibitory and antiproliferative activities of novel compounds, preliminary kinase selectivity profile of <b>7d</b>, control experiments with quizartinib (FLT3 and its downstream signaling pathway inhibition, cell cycle in the MV4-11 cell line), quantification of phosphorylation levels in cell lysates and tumor tissue harvested from xenografts, NMR spectra of prepared compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01529/suppl_file/jm7b01529_si_003.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01529/suppl_file/jm7b01529_si_001.pdb">jm7b01529_si_001.pdb (201.02 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01529/suppl_file/jm7b01529_si_002.csv">jm7b01529_si_002.csv (2.7 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01529/suppl_file/jm7b01529_si_003.pdf">jm7b01529_si_003.pdf (13.61 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01529&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01529%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-9%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01529" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66798064db8a2290","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
